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Abstract 
 
The lack of safe and efficient gene- delivery methods has been constantly a limiting obstacle to 
human gene therapy. Viral vectors have been superior in delivering exogenous DNA or RNA 
into a foreign cell due to their ability to integrate and generate their genetic material within a 
cell. However, their immunogenicity and the unfortunate deaths came as a consequence to these 
trials and shifted gears toward a safer realm. Histones are able to complex and compact DNA 
inside the nucleus. In the same manner, cationic polymers, lipids and gemini surfactants are able 
to complex DNA. Tremendous efforts have been made to enhance gene delivery with cationic 
moieties, such efforts are development of more compounds, and investigation of structure-
activity correlation to improve transfection. Gemini surfactants are made of two surfactant 
monomers which are connected at the head group area with a spacer linker. They are able to 
compact and complex DNA efficiently and they can be synthesized at the bench top, with 
relatively low cost. 
Two series of dissymmetric gemini surfactants, pyrene-based surfactants, pyr-3-n (n= 8, 12, 14, 
16, and 18), and 12-3-n surfactants with n= 14, 16, and 18 were rationally designed and 
synthesized. Due to the bulky nature of pyrene ring and the increased hydrophobicity due to its 
presence, these surfactants exhibited lower values of critical micelle concentrations (CMC) with 
early onset of micellization compared to their symmetric m-3-m gemini surfactants. The 
dissymmetry with increased hydrophobicity with increasing the alkyl tail in 12-3-n surfactants 
caused dramatic reductions in CMC values. These dissymmetric surfactants have higher 
aggregation abilities due to increased intermolecular hydrophobic interactions within the 
micelle. Both of the groups showed higher degrees of micelle ionization, which is advantageous 
to gene delivery applications. This is mainly due to the easier access of anions to the surfactants 
iv 
 
within the micelle in order to reduce the electrostatic repulsion caused by the ammonium head 
groups.   
The lack of understanding of how DNA influences the arrangement of vector components during 
the complexation of DNA, as well as their interaction with biological membranes is still a major 
barrier hindering the transfection abilities of non-viral vectors. Hence in this work we 
characterized the arrangement of the gemini surfactants and phospholipids that make up the 
transfection vector (both in the presence and absence of DNA) as well as the effect of these 
components on model biological membranes using Brewster’s Angle Microscopy (BAM).  
Two model membrane systems were characterized, DPPC/Cholesterol and POPC/Cholesterol. 
The first monolayer system exhibited a rigid solid phase at the biological surface pressure 
threshold (30-35mN/m). The latter is more flexible due to the presence of unsaturation within 
the POPC alkyl chains, which makes it more fluid than the first system. In this study, in the 
presence or absence of DNA, structural arrangement within the gemini surfactant alone or within 
the vector components led to interactions with the model membranes, hence affecting its fluidity. 
All the gemini-DNA complexes from both groups caused the membranes to become more fluid, 
thus internalization of the vector may become possible.  
Further characterization of the nanoparticles (polyplexes) formed by formulating the GS and the 
DNA into aqueous solution was conducted through the measurement of the particle size and the 
zeta potential to determine the stability of the complexes at higher charge ratio. Smaller particles 
were formed at higher charge ratios with net positive charge, indicating the complete and 
successful complexation of DNA with the gemini surfactants. These nanoparticles were tested 
in the presence or absence of DOPE in MG-63 bone cancer cells, and HEK-293 kidney cells. 
Unfortunately, Pyrene-3-n surfactants transfection results obtained from flow cytometer were 
not useful due to the interference of the pyrene emission peak with the GFP signal. However, the 
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pyrenyl surfactants were tested by ELISA in COS-7 cell lines, and showed poor transfection, 
with the highest protein expression was that of pyrene-3-8, which gave better results than the 
positive control itself (Lipofectamine plus). This can be attributed to the loose packing of the 
DNA which was shown in the physical characterization results (the zeta potential= <30mV) and 
the average size was below 200 nm at 1:10 and 1:5 ratios. The 12-3-n transfection complexes 
showed high toxicity imparted by these dissymmetric gemini surfactants, with relatively good 
transfection results were shown by 12-3-16 in the presence of DOPE and in its absence. DOPE`s 
presence did not improve the transfection and it increased the overall toxicity of the complex 
with a significance of 0.985.  
Over all, the level of the in vitro transfection observed by ELISA assay for the pyr-3-m gemini 
surfactants proved to be generally poor, with the exception of pyr-3-8, which showed remarkable 
transfection ability with protein expression of 8000pg and 15000pg after 48 h, and 72 h 
incubation periods, respectively. In addition to that, low toxicity was observed for all of the pyr-
3-m surfactant complexes. These two surfactants (pyr-3-8 and 12-3-16) have emerged as 
promising candidates for non-viral gene delivery in different cell lines.  
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Chapter 1: Introduction 
 
1.1 Gene therapy 
 
     Toward the end of the twentieth century, geneticists managed to sequence the entire human 
genome.1 With this seminal tool, scientists and researchers have been able to elucidate the nature 
and the histology of diseases, and link them to precise genes. With this breakthrough researchers 
realized obstacles and hurdles to curing these genetic diseases or cancers of malignant nature. 
Further investigation led to the idea of possibly introducing a foreign piece of DNA into cells.2 
This simple concept is known as gene therapy and it includes the introduction of an exogenous 
gene, by means of viral or non-viral vectors or, to produce a desirable result. This result can 
correct an existing defect through the translation of a missing protein, or by repressing or 
inhibiting an existing function, thus eliminating the disease.3 The first trial goes back to 1970 
when Rogers & colleagues, introduced the shope papilloma virus that encodes arginase, which 
is an enzyme that degrades arginine to orinithine in patients with hyperargininemia, a rare genetic 
disease. Despite the lack of safety measures, the introduced gene segment led to the desired 
outcome without the development of adverse effects.4 This study, however, proved to be 
unsuccessful later. However, in 1999, a gene therapy clinical trial to treat Jesse Gelsinger, a 
patient with ornithine transcarbamylase deficiency, led to the death of a youth after a  severe 
immune response caused by the injected adenoviral vector.5 This tragedy led to a substantial 
setback in the field. However, in the new millennium, with the advancement in the field of gene 
therapy, it became possible to use it to treat people and improve their life.  
To develop a gene therapy, several parameters should be considered, including the likelihood of 
a disease to be treated by gene therapy, the successful choice of a particular gene, regulatory 
signals, upstream or downstream effectors, the ability of a particular cell to be transfected, 
whether this cell is active or not, the delivery vehicle, and the route of administration.6  A crucial  
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factor to the success of gene therapy is the means by which DNA is delivered to a nucleus in 
order to be expressed and to exert the desired action. However, this can be a difficult process 
because of the bulky nature of the DNA or the stability of RNA. In addition, the hydrophobic 
nature of cell membranes act as barriers to most foreign materials.7 
1.2 Gene delivery  
 
Deoxy ribonucleic acid (DNA) is the genetic material that is passed down from one generation 
to the next. DNA is contained within the nucleus of the cells and it is made of nucleotide units, 
which are composed of a nucleobase, a sugar, and a phosphate. According to the variations in 
the nucleobases, which are adenine, thiamine, cytosine, and guanine (A,T,C,G), trillions of 
combinations are possible, and it is from this code that essential compounds are made in the 
body.8 Peptides, proteins, enzymes and receptors are the result of the precise sequence of DNA 
base-pairing between the DNA nucleotides. All these proteins are required to function normally. 
If there is an incorrect pairing or a full sequence deletion, dramatic health consequences can 
ensue ranging from hair loss to life threatening conditions such as cyctic fibrosis and certain 
forms of cancer9. These errors happen at the level of the genomic material and are called 
mutations. These mutations can occur either  naturally or be caused by chemical damage by UV 
light (photochemical damage) or  exposure to certain types of pesticides.10,11 The need for a 
strategy or a treatment for inherited diseases as well as acquired disorders led to the development 
of gene therapy, which requires gene delivery vehicles that can be used specifically to deliver a 
segment of DNA, absent or deficient. Several methods are being utilized to introduce genetic 
material to cells, whether in vitro or ex vitro. These range from physical methods 
(electroporation, heat gun or high pressure) for delivery of DNA not complexed by chemical or 
biological components, to biological methods (mainly viruses), and chemical methods (cationic 
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lipids, polymers, dendrimers, and gemini surfactants), each of which will be described in details 
below: 
1.2.1Naked DNA delivery 
 
Plasmid DNA is a large polymer that cannot cross cell membranes freely. In order to facilitate 
its passage, assisted methods of delivery are required. DNA has been introduced to various cells 
by means of different physical methods that generally operate on the principle of creating a hole 
in cell membranes through which DNA can pass and gain access to the interior of the cell. This 
concept of injecting DNA was first introduced by Wolff et al.12 in 1990. He injected a reporter 
gene into mouse muscle and its expression. This technique delivers a transgene by causing 
transient membrane damage.13 A  ̏heat gun ̋ has been used to transfer genes to skin, mucosa and 
exposed tissues within a limited area.14 In this technique, DNA is deposited on the surface of 
gold nanoparticles, which are then fired out of the gun by pressurized gas and expelled onto 
targeted cells. The heat gun method is able to bypass physical barriers including cell membranes, 
but has a number of limitations. For example, the nanoparticles only manage to penetrate few 
millimeters into the target tissues.  In addition, the size of the delivered DNA is limited by the 
size of the gold nanoparticles, and inconsistencies of the coated nanoparticles may interfere with 
the release of the DNA, and the delivery efficacy. However, delivery of DNA was made possible 
to a wide range of cell types and cell environments using this technique. Delivery of naked DNA 
has also been introduced to cells by application of either electrical or magnetic field to a specific 
area. This method has more potential than the heat gun and direct injection, as it has demonstrated 
to increase gene expression by several orders of magnitude compared to heat gun efficacy.15 
Electroporation is an example of applying an electric potential to increase gene or drug delivery. 
Electroporation involves applying an electrical pulse to permeate the cell membrane, whether in 
vitro or ex vivo.16 This technique involves the insertion of two electrodes with a space 
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(approximately ~1cm) between them. Applying an electric pulse temporarily disrupts the 
structure of the cell membrane, and allows the DNA to actually permeate into cells. Successful 
gene delivery using electroporation both, in in vitro and in vivo studies has been reported by a 
number of groups. Titomirov et al.17 placed surface electrodes to deliver a plasmid coded for a 
reporter gene into new-born mouse skin. A transient and long term transfection of isolated and 
cultured cells were reported.  Hansson et al.18 also demonstrated increased transient expression 
of DNA in an isolated lung tissue in ex vivo setting. They treated  lung muscles with 
hyaluronidase prior to electroporation and injection of the DNA, which enhanced the transfection 
significantly because of the ability of hyaluronidase to relax the muscles, which improved 
distribution of the plasmid in the tissue.19 Although electroporation was applied and used in 
numerous delivery studies, both in vitro and in vivo, it still has major drawbacks. First, its 
effective range is limited to approximately 1cm. Second, in some organs, electroporation requires 
a surgical procedure to insert the electrodes. Third, high voltages are required. Moreover, 
irreversible damage (cell death) was seen as a result of thermal heating.20 With all these 
drawbacks, it is very difficult to apply such an invasive method into humans.  
1.2.2. Viral Vectors 
 
Viruses have evolved to become highly efficient in the delivery of exogenous nucleic acids 
(DNA, RNA) to various tissues.21 Researchers have created mutated viruses that retain their 
ability to deliver genetic materials to cells/organisms, but without the subsequent 
pathogenicity.22 Currently, viral vectors are used in more than 70% of human gene delivery 
clinical trials (see Figure 1.1), mainly because of their efficiency in delivering genes to numerous 
cell lines23. In addition, there are commercially available gene therapy products of viral origins, 
GendicineTM, OncorineTM, and GlyberaTM.  Gendicine is recombinant Human Ad-p53 Injection, 
trademarked as Gendicine and developed independently by Sibiono successfully obtained a Drug 
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license. At the beginning of 2004, Production Approval and GMP Certification were obtained 
from the China State Food & Drug Administration (SFDA). Gendicine is a gene therapy drug 
that has been approved to treat head and neck squamous cell carcinoma (HNSCC)24. Oncorine 
which is also used to treat head and neck sarcoma is another oncolytic viral based gene 
therapeutic. These two drugs are mainly composed of replication-incompetent recombinant Ad5-
p53 virus particles, which are based on adenovirus serotype 5 and human wild-type p53 tumor 
suppressor gene, a key housekeeping gene, coding human wild-type p53 protein. These two 
medications have been approved by the China state food and drug administration, but has not 
been approved in neither Europe nor North America. However, Glybera is a gene therapy that is 
designed to restore the LPL enzyme activity required to enable the processing, or clearance, of 
fat-carrying chylomicron particles formed in the intestine after a fat-containing meal. This drug 
consists of an engineered copy of the human LPL gene packaged with a tissue-specific promoter 
in a non-replicating AAV1 vector, which has a particular affinity for muscle cells. The latter 
product has been approved by the European Medicines agency (EMA), but not by the Food and 
drug agency (FDA) in America. The presence of three different drugs that might be deemed safe 
and are the result of viral gene therapy holds a promise of better and more options of treatments 
in the near future.25 In the following section, we discuss some of the viruses that have been used 
in gene delivery and gene therapy application: 
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Figure1.1 Gene therapy vectors in clinical trials up to 201326 
 
1.2.2.1 Retroviruses 
 
Retroviruses are small RNA viruses that replicate through a DNA intermediary through specific 
interactions between the viral envelope and a specific cell receptor. Once internalized by the cell, 
the RNA is reverse-transcribed into double stranded-DNA (dsDNA). Retroviral DNA has the 
ability to integrate into the host DNA, which makes it a sustainable source for the expression of 
an exogenous DNA for the life of the cell. However, in order for this integration to happen, 
mitosis is required, which limits the use of these vectors to cells capable of division. Some of the 
cells that can be used for this kind of application are rapidly-dividing hepatocytes following 
partial hepatectomy and tumor cells.27 
1.2.2.2 Adenoviruses 
 
Adenoviruses are double-stranded linear DNA viruses of approximately 30-35kb in length. 28 
Adenovirus binds to integrin protein via its penton-base protein and unlike retroviruses, 
adenoviruses can infect non-dividing cells, an advantage over retroviruses. Defective 
adenoviruses are used for gene delivery applications by removing the E1gene, however, this 
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appears to affect the level of expression. Also, use of adenoviral gene products often stimulates 
the immune response, resulting in loss of gene expression 1-2 weeks after the injection.29  The 
diminishing activity can be explained by the depletion of CD-4 CTL and/ or NK cells. In one 
study, Leopold et al.30 covalently linked a fluorophore adenoviral vector to be able to track the 
gene transfer to A549 human epithelial lung cell line using a fluorescence microscopy. Cy3-Ad 
vector was co-administered with FITC-dextran to A549 cells and the vector was only co-
localized when endosome-acidification was blocked by bafilomycin A1, which suggests that Ad 
vectors rapidly escaped the endosomes, without evidence of endosome-endosome fusion. The 
event of endosome-endosome infusion is important to deliver the cargo from outside of the cell 
to the inside of it. Moreover, through this mechanism, the endocytosed gene delivery or drug 
delivery vector is capable of being internalized and protected31.  Adenoviral and retroviral 
vectors are associated with numerous clinical trials.  
Due to their reported immunogenicity, third class of viruses is now being used, which is the 
adeno-associated viruses (AAV). AAV is a single stranded DNA virus that causes no current 
pathology in humans.32 A retroviral vector based gene therapy used to treat X-linked severe 
combined immunodeficiency (X-SCID) disease was a successful application of gene therapy 
(several patients cured of the disorder) until an unfortunate outcome happened when several 
children developed leukemia as a result of insertion mutation , which led to the suspension of 
the clinical trial with a setback that affected the entire field.33 Safety concerns, after the reported 
deaths, led to the development of other possible vectors. 
1.2.3. Non-viral vectors 
 
A fundamental engineering challenge to gene therapy is the development of a safe and efficient 
delivery vehicle for guaranteed gene expression.34 Viral vectors are far advanced in this field due 
to their ability to utilize the host replicating machinery to integrate and replicate its own DNA 
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or RNA. However, pre-immune responses are triggered with viruses and they can be oncogenic 
as well. Furthermore, they have limited DNA capacity, and working with viruses is quite 
expensive.35 Beside the physical methods mentioned above, chemical methods involving the 
formulation of DNA into condensed particles by using cationic lipids, cationic polymers and 
cationic surfactants are the most frequently studied methods (see Figure 1.1).36 DNA binds 
electrostatically to the cationic components of the particle, which compacts the DNA in order to 
protect it from the degradation by various endonucleases in the body. Unlike viral vectors, non-
viral vectors are less immunogenic and less toxic, with no limitation of the DNA cargo. Also, 
these compounds are less costly. Some of these non-viral vectors can be easily synthesized at the 
bench top and stored for a long time according to good manufacturing practice (GMP) methods.37  
However, non-viral vectors are less effective than viral vectors and for that, a series of measures 
should be taken into consideration when designing them. 
1.2.3.1 Barriers to non-viral gene delivery 
 
Entrapment of the genetic materials into a nanoparticle is important because DNA is susceptible 
to degradation by endonucleases present in the extracellular space.38 Zwitterionic lipids have 
been  used in gene delivery studies and shown to form stable nanoparticles, which is an indication 
of a longer half-life of the DNA in the blood stream in in vivo study.39 However, aggregation of 
the polyplex or the lipoplex by interacting with serum proteins occurs. Also, high salt 
concentration increases the recognition of the polyplex by the immune systems, which leads to 
its clearance by the reticuloendothelial system (RES) .40 Vector unpacking is assumed to be an 
important step in releasing DNA and gene expression. In a lipoplex, it has been proposed that 
fusion occurs between the cationic lipid of the lipoplex and the endosomal membrane lipids, 
hence, facilitating endosomal escape and DNA release.41 The most critical and the probably the 
success-limiting step in gene delivery using a non-viral vector is the passage through the nuclear 
9 
 
membrane.42 The nuclear envelope consists of two nuclear membranes and an underlying nuclear 
lamina and nuclear pore complex. The critical function of the nuclear membranes is to act as 
barriers that separate the nucleus from the cytoplasm, and the nuclear pores are the sole channel 
through which small polar molecules and macromolecules are able to travel, which signifies the 
importance of the size of the cargo and the ultimate release of the DNA from the nanoparticles.43 
An illustration of the physical barriers facing the non-viral vectors in gene therapy are 
summarized in Figure 1.2. 
 
Figure 1.2 Barriers to successful delivery of nucleic acid using non-viral vectors. Non-viral 
vectors can be used to carry DNA, mRNA, and short double- stranded RNA. These vectors need 
to prevent rapid clearance and degradation by serum endonucleases. Also, they need to avoid 
aggregation and eventual clearance by RES. This can happen by using polyethylene glycol 
(PEG) or other compounds. These vectors are required to mediate cell entry and endosomal 
escape of the cargo38. (Adapted from Reference 30) 
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1.2.3.2 Cationic Polymers 
 
Cationic polymers bind DNA electrostatically to condense the genetic material to a few 10-100 
nanometers in diameter. These complexes are often called polyplexes. Polymers can be off-shelf 
polymers or polymers designed specifically for gene delivery. These polymers are often 
comprised of DNA binding moieties; including primary, secondary, tertiary and quaternary 
amines. The polymers themselves can be either linear, branched, or dendritic in nature and due 
to the flexibility of polymers` chemistry, different functional groups can be introduced to 
improve gene delivery while maintaining biocompatibility and stability of the formulation.44 
1.2.3.2.1 Polylysine (PLL)  
 
Polylysine is one of the off-shelf polymers that has been extensively used for gene delivery and 
helped to establish basic understanding of the mechanisms by which a polymer-DNA complex 
can be internalized, can escape the endosomal compartment, and can release the DNA from the 
polyplex. Polylysine itself showed very poor transfection results, both, in vitro and in vivo. When 
at physiological pH, PLL amine groups tend to be positively charged and therefore, they have 
low capacity for endosomal buffering and lysis.45 Addition of an endosmolytic agent such as, 
chloroquine to polylysine gave moderate transfection results and conjugation of different ligands 
like asialo-orosomucoid glycoprotein to target the asialoglycoprotein receptor in mouse 
hepatocytes led to an increase in the transfection, as reported, in in vivo and in vitro studies46.  
 1.2.3.2.2 Polyethylenimine (PEI) 
 
PEI mediates gene delivery efficiently in the absence of an exogenous endosomolytic agent 
(lyses endosome). PEI-polyplexes have been used to target different cell types by ligand 
conjugation, using galactose47, mannose48, transferrin49 and antibodies.50 PEI has been 
successfully tested in gene delivery in vivo in different tissues including, the central nervous 
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system (CNS), the kidney51 and tumors.52 PEI is a highly efficient transfection agent due to its 
ability to efficiently escape from the endosome using the proton sponge mechanism.53 The only 
drawback of the PEI is its relatively high toxicity. 
 
Figure 1.3 The proton sponge hypothesis. influx of H+ and Cl- ions into the endosome , which 
leads to swelling of the endosome, drop in its pH, and finally its rupture53 
 
The proton sponge mechanism (see Figure 1.3) can be described as follows: at physiological pH, 
amine groups within the cationic polymers, like PEI, are not fully charged, but are increasingly 
protonated in the endosome due to low pH. The low pH in the endosome is brought about by the 
ATPase enzyme which transports proton from the cytosol into the endosome. The accumulation 
of protons in the endosome is balanced by a high influx of chloride ions, which increases the 
osmotic pressure causing the rupture of the endosome. This process causes the release of the 
polyplex into the cytosol of the cell54. 
1.2.3.2.3 Membrane-disruptive peptides and Polymers 
 
Endosomal escape is a crucial barrier to efficient gene delivery.34 Some of the viruses have 
evolved specific acidic peptides in their protein coat, which can become protonated at acidic 
pHs, enabling them to fuse with the endosomal membrane and carry the cargo all the way to the 
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nucleus for gene translation, and protein expression. Isolating these peptides sequences from 
viruses and utilizing them for gene delivery is not plausible due to the potential for development 
of an immune response toward viral components.55 This has led to increased interest in synthetic 
pH-responsive peptides. Stayton et al.56 synthesized hydrophilic acid-responsive polymers that 
become hydrophobic once protonated within the acidic environment of the endosome. This 
change in the nature of the polymers causes these polymers to partition into, and ultimately 
disrupt, the endosomal membrane. Another approach to the design of pH- responsive membrane-
disruptive polymers was successfully attempted by Murthy et al.57, by introducing acid-
degradable bonds, either in the polymer backbone or in the pendant groups. The research group 
used  encrypted polymers (graft terpopolymers), which consist of a hydrophobic membrane- 
disruptive backbone onto which hydrophilic polyethylene glycol (PEG) chains were grafted 
through an acetal linkage (acid-degradable linker). This polymer was used to deliver rhodamine-
labelled oligonucleotides into the cytoplasm of hepatocytes. Two new polymer derivatives 
(polymers E2 and E3) were synthesized. E2 contained lactose moiety for targeting and PEG-
FITC to increase half-life of the vector conjugated to it. On the other hand, E3 contained a 
pendant hexalysine moiety to complex the oligonucleotide. The fluorescence microscopy results 
showed that the polymers were able to directly escape the endosome and to efficiently deliver 
the oligonucleotides into the hepatic cytoplasm. 
1.2.3.2.4 Cyclodextrin-containing polymers 
 
Cyclodextrins (CDs) are cup-shaped molecules comprised of six, seven, or eight units of glucose, 
called α, β, or γ cyclodextrins, respectively. Due to the orientation of the glucose rings, the 
exterior of the cup is hydrophilic and the interior is hydrophobic, giving rise to the ability to form 
inclusion complexes with small, hydrophobic guest molecules. CDs are water soluble, 
biocompatible, and FDA approved compounds.44 A linear cationic β-cyclodextrin-based 
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polymers (βCDPs) were synthesized by the condensation of a diamino cyclodextrin monomer 
with a diimidate comonomer. The resulting polymers were complexed with DNA to form 
polyplexes, which were able to transfect baby hamster kidney cells (BHK-21). The addition of 
β-cyclodextrin to the polymer backbone significantly lowered the toxicity associated with the 
polymer while retaining the efficiency of the polymer as a non-viral gene delivery vector, making 
CDPs a promising agent for in vitro and possibly for in vivo studies.58 
1.2.3.2.5 Chitosan 
 
Chitosan is a natural, biodegradable polycationic polysaccharide with low toxicity. These 
properties make it an attractive gene and drug carrier due to its high positive charge density.59 
Chitosan is obtained by an alkaline deacetylation of chitin. Chitin is a polysaccharide found in 
the exoskeleton of crustaceans and insects60, and is a copolymer of N-acetyl-D-glucosamine and 
D-glucosamine. It enhances the transport of drugs across the cell membranes due to its cationic 
nature, which provides strong electrostatic interactions with mucus, negatively charged mucosal 
surfaces, and macromolecules such as DNA.61,62 When binding DNA, chitosan forms spherical 
structures with a mean size of 100 nm. The smaller the size of the produced nanoparticle, the 
easier its passage across the cell membrane through either endocytosis or pinocytosis. This can 
ultimately increases the transfection efficiency.63 Chitosan is easily modified in order to increase 
cell specificity in in vitro studies. Examples of these modifications are listed in sections 
1.2.3.2.4.1 to 3, below: 
1.2.3.2.5.1Lactosylation 
 
Chitosan was chemically modified by coupling lactose in order to target cells expressing a 
galactose- binding membrane lectin. Lactosylation did not improve the transfection in Human 
epithelial adenocarcinoma cell line (HeLa cells) and did not transfect Human hepatocarcinoma 
(Hep G2) nor mouse liver epithelial cells (BNL CL2 cells), either in the presence or absence of 
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chloroquine. This was attributed to decreased zeta potential of the polyplexes after the 
lactosylation64. However, Hashimoto, et al. showed that 8% lac- substitution on chitosan as a 
non-viral gene delivery vector improved transfection efficiency in hepatocytes expressing 
asialogycoprotein receptors.65 
1.2.3.2.5.2 Galactosylation 
 
Chitosan was modified by galactosylation and polyethanol glycol (PEG) was grafted on the 
chitosan to generate GCP chitosan then was complexed with DNA and was used as a non-viral 
vector in the Hep G2 cell line. However, the transfection efficiency of GCP/DNA complex was 
very low despite the small particle sizes produced at various charge ratios (N+/P-). The charge 
ratio is detrimental to the complexation and compaction process, as well as to the internalization 
process. An overall positive net charge is required to interact with the cell membranes. This 
mainly was the result of the interaction of the polyplexes with plasma proteins, which lead to the 
dissociation of the complexes66.  
1.2.3.2.5.3 Quaternization of oligomeric chitosan  
 
To increase the transfection rate of chitosan as a vector, chitosan oligomers were quaternized by 
trimethylation, producing trimethylated chitosan oligomers (TMO). This process is based on 
reductive methylation using methyl iodide in an alkaline environment67. The TMO polycations 
were complexed with DNA and tested for transfection efficiency in two cell lines: COS-1 (a 
green African monkey cells that resemble fibroblasts in humans), and Caco-2 (Colorectal 
adenocarcinoma cells). The transfection efficiency of the chitoplex was comparable to the 
positive standard in this study; DOTAP (1,2-dioleoyl-3trimethylammonium-propane) (see Table 
1.1) in COS-1 in the absence of fetal calf serum (FCS). In the presence of FCS, the chitoplex`s 
transfection results remained the same, whereas the DOTAP-DNA decreased. In Caco-2 cells, 
both DOTAP-DNA and the chitoplex had lower transfection efficiencies compared to those 
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observed with the COS-1 cell line, however, the chitoplex was superior in transfecting Caco-2 
as compared to DOTAP-DNA.  
 
Table 1.1 Structure of common studied cationic polymers 
Generic name                          Chemical name                           Chemical structure                   
PEI                                        Polyethylenimine                          
PLL                                  Poly(L-lysine)                           
CD                                  Cyclodextrin                                                
        
Chitosan                                                                                              
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1.2.4 Cationic Lipids 
 
Cationic lipids are amphiphilic molecules that consist of a hydrophilic head group, which may 
be cationic quaternary ammonium, amine, amino acids or peptides, guanidium, or heterocyclic 
functional groups68, attached via a linker region (which can be any number of functional groups) 
to typically two hydrocarbon chains or cholesterol derivatives, which makes up the hydrophobic 
component of the amphiphilic lipids. Like any amphiphile in solution, lipids form various 
structural phases, including micellar, lamellar, cubic and inverted hexagonal phases.69 A 
liposome is a minute spherical sac of phospholipid molecules enclosing a water droplet, to carry 
drugs or other substances into the tissues, and it has been investigated for over 20 years as a 
DNA vectors for gene therapy purposes, however the mechanisms by which they transfect cells 
are not fully understood. It is generally known that the success or failure of a liposomal based 
vector can depend on various physiochemical characteristics of the liposome/DNA complex.70 
These properties include the size of the lipoplex, the structure it can take in suspension, 
fusogenicity71, and the charge can play a role in transfection efficiency. One of the earliest 
seminal works on the use of liposomal based vectors was conducted by Felgner and coworkers72 
in 1987. They demonstrated the ability of a cationic liposome with a glycerol backbone lipid 
called 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) to deliver DNA in 
mouse L cells.  As the knowledge surrounding liposomal based vectors advanced, endocytosis 
has been identified as the leading pathway into internalization of the non-viral vector. The 
limiting factor for gene delivery is the eventual formation fusion with a lysosome, however, 
different structural modifications to the already existing compounds have been applied, most 
successful of which is pH –dependent gene delivery systems. The pH-sensitive delivery vectors 
function by acceleration of the acidification of the endosomal compartment by introducing acid-
sensitive linkage like the one in DC-Cholesterol.73 The acidic medium of the 
endosome/lysosome, helped to cleave PEGylated-lipids, which were initially used to extend the 
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half-life of a drug or a gene delivery. At neutral pH, PEG carries out its function, and once it is 
exposed to mild acidic pH, it is cleaved in order to avoid its clustering through the interaction 
with serum proteins.74 
Cationic lipids are usually employed as a non-viral vector as part of a liposome. The negatively 
charged DNA is neutralized by an excess of positively charged cationic lipids in order to complex 
and compact the DNA to ensure the protection of the cargo from the endonucleases degradation. 
Liposomes have been associated with increased toxicity and this is caused by the high positive 
charge on the liposome.75 The most commonly used charge ratios are 2:1, 5:1, and 10:1; however, 
there still does not appear to be any correlations between charge ratio and transfection efficiency 
that would apply across all cationic systems. Instead, the optimal charge ratio, while always 
greater than 1:1, is dependent on the chemical structure of the cationic component in the vector 
system.76 The higher the charge ratio, the more toxic the liposome. Additionally, high charge 
ratio (giving rise to high surface charge) may lead to increased interaction with serum proteins 
resulting in neutralization of the vector. This process leads to increases in the particle size and 
precipitation of the whole complex, causing toxicity.77 This toxicity can be monitored or 
controlled either by reducing the charge ratio or utilizing the toxicity to be cell-specific.  These 
liposomes can be used alone and in conjunction with other component to increase the stability 
of the non-viral vector together with increase of the transfection, and at the same time, reduce 
the toxicity or render the toxicity cell-specific. Cationic lipids can be categorized according to 
their hydrophobic tails, their head groups and the nature of the linker, and the impact of variations 
in these groups will be reviewed, below:  
1.2.4.1  Hydrophobic chains 
 
There are two major classes of functional groups that form the hydrophobic region of the cationic 
lipids, namely, aliphatic and cholesterol derivatives.78 Single-tailed aliphatic cationic lipids are 
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more toxic and less efficient carriers than their double-tailed counterparts as reported by 
Pinnaduwage et al. .79 They tested and compared cetyl triethylammonium bromide (CTAB) in 
L929 mouse fibroblasts and reported higher toxicity and less efficiency than that of 1, 2-di-O-
octadecenyl-3-trimethylammonium propane (DOTMA). However, Tang et al.80 synthesized a 
new cationic single-tail lipids-oleoyl ornithinate (OLON), and 6-lauroxylhexyl ornithinate 
(LHON) by introducing a biodegradable ester linkage to the OLON.  The cytotoxicity of LHON 
was lower than that of 1, 2-dioleoyl-3-trimethyl ammonium propane (DOTAP) or OLON. The 
transfection efficiency of the liposome composed of OLON/DOPE with DNA was 10 times 
higher than that of double-tailed 1`,2`-dioleyl-sn-glycero-3`-succinyl-1, 6-hexanediol ornithine 
conjugate (DOGSHDO) with an ornithine head group, DOTAP with an amine head group, and 
CTAB with quaternary head group and single tail. Cationic amphiphile with steroid backbones 
are more potent protein kinase C (PKC) inhibitors than the aliphatic chain analogues. Changing 
the structure from sterol to alkyl chain affects the pKa of the amine group, regardless of whether 
it is tertiary or quaternary, and this renders the compound uncharged in the PKC assay, which is 
a safe, reliable method to measure the phosphorylated form of this enzyme (inhibited state). 
However, with the steroid derivatives, the toxicity is higher.81  
1.2.4.2 Hydrophilic head groups 
 
The cytotoxicity of a cationic vector stems from its hydrophilic group, which usually consists of 
a primary, secondary, or tertiary amine, or quaternary ammonium group.82 Guanidino and 
imidazole groups have also been tested.83 Ilies et al.84 synthesized pyridinium based compounds, 
with the primary compound named 1-(2.3-dioleoyloxypropyl)-2, 4, 6-trimethyl pyridinium lipid 
having a pyridinium group as its head group instead of amine or quaternary ammonium groups. 
These compounds were tested and compared to DOTAP as the standard transfection agent in 
different cancer cell lines. These compounds were mixed with different helper lipids, including 
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cholesterol, and the findings are that at 1:1 ratio with cholesterol, these pyridinium compounds 
showed superior transfection than that of DOTAP, specifically in the human lung 
adenocarcinoma (NCI-H23). Yingyong et al85. synthesized three libraries of guanidinium-based 
transfecting agents and found that the library with two head groups and one tail were the most 
effective having less toxicity in comparison to the common detergents with quaternary 
ammonium head groups. 
1.2.4.3 Linker bonds 
 
Most of the linker bonds in synthesized lipids are ether, ester or amide bond. Compounds with 
ether linker have better transfection efficiency, but are too stable to biodegraded thus, causing 
toxicity. Cationic lipids such as DOTAP with ester bonds in the linker region are biodegradable 
and showed less cytotoxicity in cultured cells; however, they are also liable to decompose in the 
circulation system.86 Recently, carbamate-linked lipids have been synthesized, and these have 
shown lower toxicity and most likely due to the nature of the carbamate linker being labile to 
acid hydrolysis in a mild acidic medium and stable in a neutral pH. This assists a fast and safe 
release of the DNA cargo from the non-vial vector in the late endosome/lysosome 
compartment.87 
1.2.4.4 Helper Lipids 
 
Neutral lipids have often been added as a component of cationic liposomes used for DNA 
transfection. These are usually added to modifiy liposome properties in order to increase the 
transfection. Three neutral lipids have been repeatedly mentioned in the literature and they have 
been extensively incorporated in various liposome systems. These are 1,2-
dioleoylphosphatidylethanolamine (DOPE), 1,2-dioleoylphosphatidylcholine (DOPC) and 
cholesterol.78 DOPE is by far the most efficient helper lipid for in vitro gene transfection.88 It 
has been postulated, based on in vitro studies, that DOPE may facilitate cytoplasmic delivery via 
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membrane fusion once positively charged DNA-liposome complexes are bound to the cell 
membrane.89 DOPE helps to stabilize cationic liposomes and induce morphology transitions 
(from vesicle to inverted hexagonal or cubic structures), and this transition is speculated to 
facilitate the release of the lipoplexes from the late endosome/lysosome compartment through 
either fusion or destabilization of the endosomal membrane.90 Contrary to this, Friend et al91. did 
not obtain any evidence that supports92 the fusion theory when they used DOTMA/DOPE  
liposome to transfer DNA segment.91 Hong et al. intravenously injected two different 
formulations of liposomes using dimethyldioctadecylammonium bromide (DDAB) as the 
cationic lipid, once with luciferase and DOPE and, once with Luciferase and cholesterol. In their 
study, cholesterol sustained the transfection efficiency and not DOPE. On the contrary, when 
cholesterol was replaced by DOPE, DOPE attenuated the in vivo transfection. Despite these two 
studies, we cannot preclude the role of DOPE in non-viral gene delivery. In an in vivo mouse 
study, Cholesterol and DOPE were used in formulations as helper lipids together with different 
lipids, specifically DDAB, DOTAP, and 1,2-di-O-octadecenyl-3-trimethylammonium propane 
(DOTMA), complexed plasmid DNA. DOTAP-Chol formulations showed 50 times greater 
expression in mice lungs as compared to DDAB system. The DOTMA-DOPE formulation 
showed an additional 50 times greater expression than the DOTAP-Chol formulation  (Table 1.2 
structures of common cationic and helper lipids in gene therapy).93  
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Table 1.2 Structure of common cationic and helper lipids used in gene delivery 
DOTAP 
 
 
DOTMA                          
 
 
 
Cholesterol-DC                           
 
1.3 Gemini surfactants 
 
Gemini surfactants are bis-surfactants that have attracted increasing attention in both industry 
and academia due to their unique ̋ twin ̏ or dimeric structure which gives rise to some very 
advantageous surfactant properties.  Similar to any surfactant, they can be utilized in multiple 
applications including in soil remediation, soap and pigments industry, drug entrapment, and 
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recently,  in gene delivery.34 Menger94 was the first person to use the term Gemini to describe 
this group of amphiphilic compounds in 1991.These unique compounds are usually composed 
of two monomeric surfactant units that linked by a spacer, at or near, the head group area (see 
Figure 1.4). The spacer can be short, made up of two or three methylene units, or can be long, 
made up of ten or more methylene units. Also, spacers can be either hydrophilic or hydrophobic 
(depending upon chemical structure) and they can contain functional groups (added for specific 
and controlled purposes), i.e. pH- sensitive amine groups that trigger changes in the aggregate 
properties.95  The application of cationic gemini surfactants to gene delivery is the focus of this 
project, replacing cationic lipids as a non-viral vector in gene delivery and gene therapy studies.  
 
 
Figure 1.4 Chemical structure of N,N`-bis (dimethylalkyl)-alkane-diammonium-bromide (m-s-
m) gemini surfactants. In this example R=CmH2m+1 the alkyl tails connected to the quaternary 
ammonium head groups, which themselves are connected by spacer group of s methylene units 
in length 
 
Some of the unique properties of gemini surfactants possess include: their ability to form 
aggregates of various morphologies in aqueous solutions, which makes them effective tool for 
drug entrapment and gene delivery applications.96 Their  low critical micelle concentrations 
(CMCs), is generally two to three- fold lower than the conventional surfactants97, in particular, 
both of these properties are important to the application for gene delivery98, where differences in 
aggregate morphology are known to impact DNA delivery and low CMC values correspond to 
lower surfactant concentration in a given formulation, potentially decreasing any toxic effects.34  
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1.3.1 Structural variations in Gemini surfactants 
 
As introduced above, gemini surfactants are synthetic amphiphilic compounds made up of two 
monovalent surfactants. This molecular structure contributes to GSs peculiar physicochemical 
properties including their low CMC, or their diverse aggregate morphologies in solutions.  The 
covalent constraint of the spacer between the head groups is partially responsible for these 
unusual surfactant properties, which can in effect be tuned by varying the length, flexibility and 
extent of hydrophobicity/hydrophilicity of the spacer.99 In addition to the variations within the 
spacer group, variations in the length and the nature of the alkyl tails of the surfactants are also 
easily made, allowing the formulator impact a variety of possible applications including: 
producing biocompatible and biodegradable surfactants for gene delivery and/or drug delivery 
applications, or increasing the wetting ability, or promoting emulsification of oil in water, or 
enhancing the dispersion of solids, or increasing the solubilisation power of dyes by controlling 
the structural properties.100 The impact of various structural changes in the gemini surfactant 
structure are briefly reviewed in the sections below: 
1.3.1.1 Variations in the alkyl tail 
 
The physiochemical properties of gemini surfactants can be manipulated by changing the nature 
and the length of the alkyl tails. As for conventional surfactants, the CMC values for gemini 
surfactants decrease with an increase in the alkyl tail length96, with the magnitude of decrease in 
the CMC values in gemini surfactants being greater than the corresponding monomeric 
ones.101,102 Gemini surfactants can induce various biological activities, including; the inhibition 
of bacterial activity103, and drug and gene delivery.104  
The most well- studied family of GSs are the N,N-bis[(dimethyl alkyl)-α,ω-alkanediammonium 
dibromide], known as m-s-m gemini surfactants, where m is the carbon chain of the alkyl tails 
and s is the number of carbon atoms in the polymethylene spacer.96 Asymmetry and branching 
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were also introduced in gemini surfactants at the tail level. Wang et al.105 synthesized phytanyl-
3-n and phytanyl-7NH-n gemini surfactants (see Figure 1.5) to evaluate the effect of  branching 
in the alkyl tail (specifically an increase in hydrophobicity) on the transfection efficiency. In 
vitro studies showed superior transfection efficiency for phytanyl substituted surfactants 
compared to that of the symmetrical counterpart (16-3-16). The increased transfection efficiency 
was attributed to higher degrees of micellization (α) of the phytanyl surfactants and their ability 
to form vesicles in the absence of DNA, and transition into inverted hexagonal structures in the 
presence of DNA (Inverted hexagonal structure was associated with DOPE in the literature, 
enabling the fusion with the endosomal membrane, resulting in the escape of the complex from 
the endosomal compartment).106  The inverted hexagonal structure was confirmed by SAX 
studies. The latter structure has been related to better transfection data in several studies.106 The 
same inverted hexagonal morphology was tied to DOPE in earlier gemini 
surfactants/DNA/DOPE formulation in gene delivery studies.107 Higher (α) values are associated 
with greater dissociation of counter-ions from the micelles, which would promote the interaction 
of the micelle with DNA, forming stronger polyplexes, and therefore enhancing transfection 
efficiency.108  
 
 
Figure 1.5 Chemical structure of phytanyl-3-n. Where n =1-bromododecane, 1-
bromohexadecane, or 1-bromooctadecane 
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Dissymmetric gemini surfactants where hexylpyrene replaces one of the typical alkyl tails were 
synthesized with varying polymethylene spacer length groups, specifically propyl (s =3), and 
hexyl (s = 6) .109 The incorporation of the bulky pyrene moiety in these surfactants significantly 
impacted the micellization properties. CMC values of pyrenyl surfactants were significantly 
lower than their symmetric counterparts (m-s-m), and these surfactants were prone to form not 
only micellar aggregates, but also pre-micellar aggregates. The presence of these aggregates was 
favored in pyr-6-12. These compounds have the ability to serve as emissive components in DNA-
gemini lipoplex/polyplex in DNA trafficking, in gene delivery and gene therapy applications.109 
This potential can help identify the key parameters to help overcome the barriers in non-viral 
gene delivery methods. One of the means is to track the pyrene moiety in in vitro study using 
fluorescence techniques.  
The nature of the tail groups within gemini surfactants can have has several effects on the 
physical-chemical behavior of the compounds. An important effect is the introduction of 
different degrees of unsaturation, which brings about gel-liquid crystalline transition within 
vesicles formed in these compounds. In a bilayer-forming phospholipids, the longer the tail the 
higher the transition temperature, when the saturated tails are replaced with unsaturated tails 
(oleyl tails C18:1 as an example), the transition temperature decreases considerably. The 
presence of the oleyl tail can induce the formation of different favorable aggregates at lower 
temperatures.110  
In a study by Cardoso et al.,111 they investigated the ability of different bis-quaternary 
ammonium gemini surfactants with different alkyl chain lengths to transfect  human epithelial 
cervical carcinoma cell line (HeLa cells) with two different system: binary system with only 
DNA/GS, and ternary one with DNA/GS/ DOPE/Chol (2:1mol). Different charge ratios of N+/P- 
were investigated with a fixed ratio of helper lipids.111 The physio-chemical properties of these 
two systems at different charge ratios were investigated and showed the presence of diverse 
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aggregate sizes ranging from 140-3000nm in the absence of the helper lipids, and 170-2100nm 
in the presence of helper lipids. However, the polydispersity and contained more than one 
aggregates, which made the particle size range very wide. This might have stemmed from the 
nature of the GS-DOPE antagonistic interaction in solution, which drives the gemini surfactant 
to interact with the DNA, and the DOPE not to interact with the nanoparticle, shielding it. This 
shielding effect might cause the appearance of one peak representing the DOPE average size112. 
However, do to the hydrodynamic nature of the solution, sometimes, two peaks can be 
recognized, which ultimately gives the average size of the nanoparticle. These aggregates ranged 
from giant vesicles to small size vesicles and irregular shape aggregates. The in vitro studies 
showed that complexes with larger sizes are often better in transfection than smaller ones, 
attributed to the tendency of larger particles to sediment over the adherent cultured cells, thus 
increasing the contact area between the complexes and the cellular surfaces, hence, facilitating 
internalization. Larger complexes are also able to carry more DNA, which together with the 
presence of helper lipids contributes to higher transfection levels.  The ability of gemini 
surfactants to adopt different morphologies in solution has been linked to improved transfection 
in non-viral gene delivery systems, specifically with certain aggregate structures, such as, 
inverted hexagonal and cubic structures.107 In the current study by Cardoso et al., gemini 
surfactants with longer alkyl tails, 14-2-14, and 16-2-16 exhibited richer phase behavior 
irrelevant of the concentration range utilized, this phase behavior was not witnessed in 12-2-12 
surfactant in the video-enhanced light microscopy (VELM) micrographs. This provides support 
for the lower transfection efficiency observed when using the binary system of 12-2-12/DNA. 
In the absence of helper lipids, the above system displayed a low transfection efficiency of 6.6% 
of cells transfected. This transfection efficiency of the 12-2-12 surfactant increased dramatically 
upon the addition of the helper lipid up to 45.7%, this efficient transfection might have been 
caused by the induction of higher morphology structures induced by DOPE and the reduction of 
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serum interactions due to the presence of cholesterol in the helper lipid system. 14-2-14 and 16-
2-16 displayed 14.4% and 31.1% transfection efficiency in the absence of helper lipid, and 
44.2%, and 53.9% in its presence, respectively.  In the case of 16-2-16/DNA/helper lipid system, 
according to the VELM micrographs, there are two distinctive phases formed; lamellar and 
hexagonal, and both were compacted in a multi lamellar sandwich structure, giving rise to 
superior transfection efficiency.113 These suggest a strong influence of the alkyl tail length on 
transfection efficiency, with general observation that the longer the alkyl tail, the better the 
transfection.    
In summary, the literature reviews demonstrates that complexes containing gemini surfactants 
with longer alkyl tail lengths (m ≥ 14, 16, 18), or with unsaturation (oleyl), or branching 
(phytanyl) exhibit increased in vitro transfection relative to those with shorter tail lengths (m ≤ 
10, 12). 
1.3.1.2 Variations in the head groups 
 
The density and nature of the head group has been shown to influence gene transfection 
efficiency.114 The simplicity of varying the structure of these gemini surfactants led organic 
chemists to synthesize different surfactants by introducing biodegradable and biocompatible 
head groups, such as; sugars. Quaternary ammoniums were replaced by reduced sugars, such as 
glucose, and mannose connected to tertiary amines or amides with a polymethylene spacer.115 
The presence of either glucose or mannose116 in the head group area provides a biocompatible 
vector, which will extend the half-life of the vehicle in the circulation in Chinese hamster ovarian 
cells (CHO) .116 These sugars in the head group can lead to different hydration degrees and result 
in the formation of different aggregates (This impacts the head group area, and as a consequence, 
results in different morphologies) .117 Also, the presence of the tertiary amines can lead to a pH-
dependent aggregation behavior as a result of the protonation of the amines. At a lower pH, the 
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presence of the amine and the amide can assist in the escape of the vector from the late 
endosomal/lysosomal compartment and the possible release of the DNA cargo.115 The 
protonation effect is not a possibility with the amide linkage. 
Amino acids are also employed in the structure of the gemini surfactants to increase the 
biocompatibility. Cardoso et al.118 investigated the ability of six members of a new family of 
serine- derived GSs (Figure 1.6) to safely mediate gene delivery and gene transfection. They 
conducted a comparative study based on: i) the influence of the length of the alkyl tail in three 
different series depending on the spacer linker: amine, amide; and ester, and ii) the effect of the 
nature of the linker spacer on the transfection. The effect of both the alkyl tail and the spacer 
were evaluated in a plain surfactant/DNA complexes, and on surfactant/DNA/ helper lipid 
systems with DOPE/Cholesterol (2:1) as the helper lipid system. All the serine surfactants having 
amine linkers mediated gene transfection, however, no trend with respect to the length of the 
alkyl tail on transfection was observed. (16Ser)2N5 was the least efficient, which contrasts the 
already existing findings in the bis-quaternary ammonium gemini surfactants with hexadecyl 
tail, which showed the highest transfection efficiency.111  In addition, the presence of serine in 
the alkyl tail adds to the complexity of the gemini surfactants and can impact the physio-chemical 
parameters quite differently, and hence, affect the transfection (The size of the complexes ranged 
from 163nm to 3µm, with an increase in the size promoted by the addition of the helper lipid at 
different charge ratios. The zeta potential was also impacted by the addition of the DNA to the 
GS and with longer alkyl tails, the overall charge remained positive even in the presence of the 
DNa). The lowest toxicity in the amine series was observed at an (8:1) charge ratio, following 
the sequence (18Ser)2N5> (14Ser)2N5 > (16Ser)2N5. (16Ser)2N5 was shown to exert the highest 
toxicity and lowest efficiency in the transfection study. The helper lipid system employed in this 
study increased the transfection efficiency throughout the amine series. DOPE confers on the 
system the ability to escape lysosomal degradation through the formation of different aggregates, 
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and the cholesterol due to its biocompatibility. In addition, it is less prone to interact with serum 
proteins.119 However, helper lipids induced cytotoxicity in the case of complexes prepared with 
(18Ser)2N5. 
 
Figure. 1.6 Serine derived gemini surfactants, A) amine series designated as (nSer)2Nm, B) 
amide series (12Ser)2CON5, and C) ester series (12Ser)2COO
- 
 
One of the best available commercial transfection agent is lipifectamine™ 2000 (Invitrogen) 
and  it is a cationic lipid 2,3-dioleyloxy-N-[2-(spermine carobxamide) ethyl]-n,n-dimethyl-1-
propyl ammoinim choloride (DOSPA) with five quaternary ammonium head groups.120  
Head group area plays a huge role in the condensation of DNA, and thus, in protecting it from 
the effect of endonucleases once internalized. 
1.3. 1.3 Variations in the spacer group 
 
Properties of dimeric surfactants can differ greatly from those of conventional surfactants. This 
has been related to the distribution of distances between head groups in micelles formed by these 
two types of surfactants.99 For conventional surfactants, this distribution goes through a 
maximum at a thermodynamic equilibrium distance dT ≈ 0.7–0.9 nm, for dimeric surfactants the 
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distribution is bimodal, with a first maximum at a thermodynamic distance dT and another 
narrower maximum at a distance ds which corresponds to the length of the spacer.
121 This length 
is determined by the bond lengths and bond angles between the atoms in the spacer group. The 
bimodal distribution of head group distances and the effect of the chemical link between head 
groups on the packing of surfactant alkyl tails in the micelle core are strongly affects the 
curvature of the surfactants and thus the micelle shape and properties of the solution. The effect 
of the changes in the spacer group was investigated by transmission electronic microscopy at 
cryogenic temperatures (cryo-TEM) for 12-s-12 dimeric surfactants with different spacer length 
(4≤s≥12) .122 This study showed that 12-2-12 formed thread-like micelles at 2wt%, and 12-3-12 
showed spheroidal micelles at 7wt% in solution. DTAB, a monomeric form of both 12-2-12, and 
12-3-12, showed only spherical micelles irrelevant of the concentration and the ionic strength. 
The solution of 12-4-12, 12-8-12, and 12-12-12 exhibited densely packed spheroidal micelles at 
5-7wt% and vesicles were formed in solutions of 12-16-12 and 12-20-12.99  This demonstrates 
the effect of the s and the role it plays in determining the structure of the micelles formed. 
The shape of aggregates formed by a gemini surfactant is influenced by its molecular structure. 
A theory used to predict the shape of micellar aggregates is that of the packing parameter (also 
known as the surfactant parameter, S, or the critical parameter , CPP), defined as: 123 
 
                                                        P=v/la˳                                                         (1.1) 
 
where v is the volume of the alkyl tails, l is the length of alkyl chains, and a0 is the surface area 
occupied by the head group. The types of aggregate shapes predicted for certain ranges of P values are 
summarized in Table 1.3.  As can be seen by the equation above, the packing parameter is 
impacted directly by the length and the volume of the alkyl tails and the head group area; 
although for traditional surfactants the head group area remains essentially constant.  In dimeric 
surfactants, the spacer contributes significantly to the packing parameter, primarily by changing 
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the head group area. The effect of the spacer is difficult to generalize in simple terms. A large 
hydrophobic spacer will mainly contribute to the value of v and on the other hand, a small rigid 
spacer directly contributes to the effective head group area, allowing smaller head groups for the 
same effects and in both cases allow for spherical micelles to form. Since the number of different 
possible gemini surfactants is large, all types of association structures can form and they have to 
be investigated individually.124 
 
Table 1.3 Packing parameter and expected aggregates structures125 
P  Aggregates` shapes 
  
General surfactant type  
<0.33  Spherical micelles  Single-chain surfactants 
with relatively large head 
groups  
 
0.33-0.5  Cylindrical or rod-shaped 
 micelles  
Surfactants with relatively 
small head group 
  
0.5-1.0  Vesicles or flexible bilayer 
 structure  
Double-chain surfactants 
with large head groups and 
flexible chains  
 
1.0  Planar bilayer structures  Double-chain surfactants 
with small head groups or 
rigid chains  
 
>1.0  Inverted micelles  Double-chain surfactants 
with small head groups, very 
bulky chains  
 
The effect of the length of the spacer on the ability of the gemini surfactant to compact DNA 
was investigated by Karlsson et al.124 in the 12-s-12 series. In their study, shorter spacers (s =2,3) 
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showed the most efficient compaction of DNA and this is likely due to the spacing between the 
positive charges, which is small and keeps the surfactant acting like a divalent cation, thus 
interacts preferably with the negatively charged phosphate backbone. Larger values of s 
represent a more flexible spacer that can change its conformation to reduce the hydrocarbon-
H2O interaction; however, this will restrict the surfactant conformation and will result in entropy 
loss that has to be compensated for in order to compact the DNA. This happens through the 
association of the spacer within the hydrophobic core, thus reducing the coil- coexistence border. 
This happens only if the spacer is large enough to self-associate with the tails (s≥10). 
Intermediate spacers will be the least efficient in compacting DNA because it is not flexible 
enough to self-associate into the core. Despite the different effects of the spacer on the 
compaction of the DNA, the presence of coil-globular coexistence continue to persist regardless 
of the concentration. 
This implies that the nature and/ or the length of the spacer group in the head group area of a 
gemini surfactant has been shown to play a significant role in gene delivery and transfection. 
Wettig et al.126 investigated the introduction of tertiary (N-CH3), and secondary (-NH) amine 
groups in the spacer group of the gemini surfactant and the impact these modifications had on 
transfection activity. When these gemini surfactants were complexed with DNA alone, they 
showed little to no transfection, with the exception of the secondary amine substituted 12-7NH-
12 (1,9-bis(dodecyl)-1,1,9,9-tetramethyl-5-imino-1,9-nonanediammonium dibromide) which 
showed little transfection activity. The addition of DOPE resulted in a significant increase in 
transfection efficiency, in agreement with the previous studies of incorporating DOPE as part of 
non-viral delivery systems. DOPE helps to stabilize the cationic liposome and it also induces 
morphology transitions. These transitions are speculated to facilitate the release of DNA from 
the complex through either fusion or destabilization of the endosomal membrane.127,127b This  
study, gemini surfactants containing substitution, with either tertiary (N-CH3) or secondary 
33 
 
amine (-NH) in the spacer resulted in an increase in transfection efficiency. The highest level of 
transfection in COS-7 cells was achieved for the system containing the 12-7NH-12 gemini 
surfactants with an efficiency of 6.7 ± 0.5ng luciferase/2x104 cells, comparable to the positive 
control (Lipofectamine plus®). Also, cell viability of the tertiary gemini surfactants  1,5-
bis(dodecyl)-1,1,3,5,5-pentamethyl-3-aza-1,5-pentanediammonium dibromide (12-5N-12), 1,9-
bis(dodecyl)-1,15,9,9-pentamethyl-5-aza-1,9 nonanediammonium dibromide(12-7N-12), 1,10-
bis(dodecyl)-1,1,4,7,10,10 hexamethyl-5-diaza-1,1-dodacanediammonium dibromide (12-8N-
12) were comparable to that of lipofectamine plus® (80%) and lower cell viability was reported 
for the secondary amine gemini surfactants with cell viability of 70%.12-7N-12, and 12-8N-12  
exhibited the highest and the lowest transfection efficiencies, respectively. This probably 
resulted from an increase in the steric hindrance presented in the 12-8N-12, which compromised 
its ability to bind to the DNA and to form aggregates. The equilibrium distance between the 
nitrogen centers were compared to the distance between the phosphate groups in the DNA, which 
is equivalent to 6.5Å and 7.1Å.128 It has been estimated from a polyamine-DNA study that a 
spacing of 4.9Å129 between two nitrogen centres was calculated, which is equivalent to three 
methylene spacer between the nitrogens, is the ideal spacing to interacting with the DNA.130 This 
spacing was found only in 12-7N-12 and 12-7NH-12 with 5.1Å between the two quaternary 
ammoniums, calculated from molecular modelling studies. The 12-7NH-12 showed superior 
transfection to that of 12-7N-12, which was rationalized based upon the pH dependent nature of 
the secondary amine group in the 12-7NH-12 surfactant. This surfactant, upon protonation of the 
secondary amine group (forming a 3rd quaternary ammonium in the head group) undergoes a 
vesicle to micelle transition, resulting in either fusion or a destabilization of the endosomal 
membrane leading to its rupture and the release of the complex from the endosome. 
     In another study, a homologous series of hexyl pyridinium gemini surfactants with pyridinium 
rings replacing the quaternary ammonium groups and with different spacer lengths (s = 4, 8, and 
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12) connecting the pyridinium head groups were synthesized (see Figure 1.7). These were 
employed as a non-viral gene delivery of plasmid vector in human rhabdomyosarcoma cell lines 
(RD-4) with or without DOPE as the helper lipid. Only bispyridinium with hexadecyl tails (P16) 
was chosen for gene transfection studies with three different lengths of the methylene spacer. All 
the three surfactants were able to compact the plasmid DNA, however, 1.1`-dihexadecyl-2,2`-
tetramethylene bispyridinium dichloride (P16-4) were able to transfect DNA with P16-4 having 
the highest efficiency. This was attributed to a stacking behavior of the surfactant. Its ability to 
function like molecular tongs that are able to grip aromatic bases of the DNA and the phosphate 
groups. The phosphate groups can substitute the counter-ions between the aromatic rings, 
reducing the electrostatic repulsion existing between the head groups. Then, the hydrophobic 
interactions between the chains are capable of fully compacting the DNA and assembling into 
nanoparticles. When the length of the spacer increases, this arrangement becomes more difficult 
because the pyridinium rings are interacting with DNA sites that are far from each other. This 
resulted in little to no transfection being observed with 1,1`-dihexadecy-2,2`-octamethylene 
bispyridinium dichloride (P16-8), and 1,1`-dihexadecyl-dodecamethylene bispyridinium 
dichloride (P16-12), respectively. From molecular modelling, the latter may adopt an extended 
confirmation in solution due to the association of the long spacer into the hydrophobic core, 
resulting in the interaction of the head groups with the DNA sites that are far apart, which hinders 
the penetration through the cellular membrane. This reduces the intensity of the compaction and 
the ability of the nanoparticle to interact cellular membranes. However, in this study, the 
presence or absence of DOPE did not have any impact on the transfection efficiency.131  
35 
 
N
+
C16H33
N
+
C16H33
{   }
s-2
Cl
-
Cl
-
s =   4 - P16 - 4
s =   8 - P16 - 8
s = 12 - P16 - 12
 
Figure 1.7 Structure of the bispyridinium gemini surfactants with different polymethylene 
spacer lengths 
 
 
Cationic gemini surfactants with cholesterol moieties as their alkyl tails and two different spacer 
groups, hydroxyl ethyl (CH2CH2OH), and oligooxyethylene (CH2CH2O)n , as well as alkyl 
(−CH3) and/or hydroxyethyl (−CH2CH2OH) moieties attached at the quaternary ammonium 
groups were synthesized and evaluated for their transfection ability by Misra et al..132  These 
molecules  (shown in Figures 1.8A and 1.8B) are  made  of    cholesterol  skeletons  attached  via  
a  linker  to  the  cationic  head groups, both the linker and  the nature of the cationic head groups 
are of great importance to determine the efficiency of the transfection and the level of 
cytotoxicity. Formulations of DOPE/Cholesterol GS at a molar ratio of 1:1 enhanced the same 
level of transfection activity in the presence of serum in HeLa cells. As the spacer length of the 
oligooxyethylene was increased from1 EO unit to 4, the transfection efficiency decreased. The 
introduction of a hydroxyethyl moiety in the spacer led to a further decrease in the transfection 
activity. Enhanced transfection efficiency was observed for the oligo-oxyethylene with n = 1. 
(CholHG-1ox) exhibiting∼65%GFP expression in the absence of serum, and increasing to 
approximately 90% GFP expressing cells in the presence of serum. The gemini  with a 
hydroxyethyl spacer showed  approximately 75% GFP expression in the presence of serum and 
the same level of transfection was observed for other oligo-oxyethylene substituted ompounds, 
with n = 2, 3 and 4  in the presence of serum. The zeta potential of the lipoplex containing 
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CholHG-1ox was ∼18 mV at an N+/P- charge ratio of 0.5 compared to that of CholHG-3ox (∼12 
mV at an N+/P- charge ratio of 0.5) in the presence of serum. A DNA release study using 
ethidium bromide re-intercalation assay with the same serum condition for the lipoplexes 
revealed that CholHG-1ox managed to release approximately 50% DNA, whereas the other 
gemini surfactants released only 30%. Dynamic light scattering data showed aggregates of an 
average size of approximately 137nm for CholHG-1ox, whereas CholHG-3ox displayed larger 
aggregates of approximately 220 nm. While the reason(s) for the enhanced transfection activity 
of the CholHG-1ox gemini surfactant is not clear, it was hypothesized that a shorter 
oxymethylene spacer group in addition to the presence of the cholesterol moiety in the tail group 
may play a crucial role in the DNA compaction in these lipoplexes. Cholesterol is known to form 
domains in the presence of serum proteins that can interact with cellular membranes through a  
lipid raft/membrane mechanism.133 This can enhance the transfection efficiency. The presence 
of the hydroxyl groups in the spacer of the CholHG-1ox interacted with serum proteins found in 
the fetal bovine serum (FBS), and enhanced lipoplex association in the presence of serum. A 
DNase stability assay revealed that CholHG-1ox based lipoplexes displayed higher stability 
against DNase I in comparison to CholHG-3ox in presence of serum, which also may have 
accounted for some of the observed increases in transfection efficiency.  
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Figure 1.8 A Molecular structure of cholesterol-based gemini surfactants with hydroxyl spacer 
 
 
Figure 1.8.B Molecular structures of cholesterol-based cationic gemini surfactants with oligo-
oxyethylene spacer132 
 
The literature review indicates that gemini surfactants with shorter spacer lengths (s ≤ 4) or 
longer spacer lengths (s > 10) exhibited better transfection efficiency than those with the 
intermediate spacer length (s = 5, 6 methylene units). This can be attributed to the fact that these 
surfactant may be able to induce favorable morphologies with preferred packing parameters for 
the complexes; either gemini-DNA or gemini-DNA-helper lipids. An example of these 
morphologies include lamellar, inverted hexagonal or cubic. Another important aspect is the 
introduction of specific functional groups within the spacer and/or head group region may add 
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advantage to the complexes, such as; the presence of acid-labile functional groups. Also, the 
presence of cholesterol, spermine, pH-sensitive amide group (NH), guanidiniums, cardiolipin 
analogues, nucleolipids, and pyridinium, could impact compaction and condensation with 
negatively charged DNA molecules. 
1.3.2 Transfection efficiency in vitro and in vivo 
 
A promising tool to treat broad spectrum diseases, such as Alzheimer, and cancer , is gene 
therapy as in theory, it provide a specific cell with the necessary missing DNA or RNA to 
produce a therapeutic proteins and either correct or add an old malfunction gene/ or a new gene. 
Due to major obstacles facing gene delivery, many vectors have been exploited and gemini 
surfactants are one of these vectors.134 A review of literature revealed that so many  gemini 
surfactants have been synthesized and characterized in recent years, with a number of these 
compounds have been examined for applications of gene therapy.34 This section will review 
some of the recent examples; however, readers are referred to recent reviews for a more 
comprehensive reviews of gemini surfactants that have been applied to gene delivery.135,136 
McCregor et al. synthesized biocompatible peptide-based gemini surfactants (PGSs).137 These 
surfactants were generated by varying the composition of the head groups, which contained the 
peptides, and the length of the tail (saturated, or unsaturated, but not branched), with two cysteine 
residues joined in the spacer by a thioether linkage (Figure 1.9) to increase the stability of the 
compounds, which could not be conferred when a thiol linkage was used. The capability of these 
PGSs to mediate transfection of a Chinese hamster ovary (CHO-DG44) cells, either alone or in 
the presence of DOPE in the formulation as a helper lipid was compared to a positive non-viral 
transfecting control.  Gene transfection in these PGSs was dependent on the hydrophobic tails as 
well as the nature of the amide linkage between the three lysines in the head group area. Gene 
expression of PGS1 was superior to the rest and this possibly was because of the presence of 
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three lysines linked through their ε-amino group and the nature of the alkyl tails, which was 
unsaturated oleyl tail.137 
 
 
Figure 1.9 Peptide-based gemini surfactants with thioether linkage (PSG) with AA: lys-α-lys-
α-lys-, lys-α-lys-ε-lys-, or (lys)2lys-, and R= C16, C18 and C12137 
 
Alqawlaq et al. developed and characterized non-viral gene delivery nanoparticles, composed of 
12-7NH-12 gemini surfactant as the cationic moiety with pH- sensitive functional –NH- group 
within the spacer linker, pCMV-tdtomato as the plasmid, and two helper lipid systems; DOPE, 
and DOPE:DPPC at different N+-P- ratio (5:1, 7.5:1, 10:1, 12.5:1, 15:1) were added to the 
nanoparticles.138 The ability of these systems to treat glaucoma was tested in vitro and in vivo. 
PGLDOPE nanoparticles showed the highest transfection efficiency in a model retinal cell line 
(RGC-5). This system also showed ability for binding and permeation across the corneal 
epithelium at a 10:1 charge ratio. After intravitreal administration of the gemini-DOPE-DNA, 
nanoparticles were localized in the nerve fiber layer of the retina. When the topical 
administration was tested, it was less effective with the nanoparticles being localized within the 
limbus, iris and conjunctiva. The presence of the helper lipids was reported to produce coexisting 
lamellar and inverted hexagonal phases at lower pH (endosome or lysosome), and this may have 
induced better transfection efficiencies in the formulations that contained DOPE. These features 
are important for better gene transfection and release of DNA into the cytosol.138 
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Many of the gemini surfactants currently employed in gene therapy applications are symmetrical 
ones with either quaternary ammonium, carbohydrates, aminoacids, or pyridinium head groups 
and hydrocarbons alkyl tails with various length. More interest is growing in using gemini 
surfactants with different structures and dissymmetrical ones; Oda et al. synthesized these 
surfactants with dimethylene spacers139, and Wang et al. synthesized asymmetrical gemini 
surfactants with six methylene units in the spacer, and two different hydrocarbon groups as the 
alkyl tails, with a total of m+n=24.140 Dissymmetric gemini surfactants have been synthesized 
and their physiochemical properties have been characterized, but only few of these surfactants 
have been actually employed as non-viral gene delivery vectors. One of these few studies is the 
utilization of phytanyl gemini surfactants with DNA- helper lipid in gene delivery in OVCAR-3 
cell-lines, which showed improved transfection when phytanyl-3-16  was used instead of 16-3-
16, which has higher transfection efficiency than other surfactants that have been employed for 
such purposes.141 
1.3.3 Gemini surfactants-DNA lipoplex and the interaction with cell membranes 
 
Transfection efficiency of gemini surfactants-DNA has been investigated numerous times by 
many research scholars, and several of those have noticed partial, or transient, or complete 
improvement in transfection efficiency when helper lipids, whether its DOPE or a mixture of 
DOPE and other helper lipids, are added to the mixture forming a lipid-based vector.135 Javid 
Akbar et al. showed that a non-ideal mixing behaviour is exhibited when DOPE is added to the 
gemini surfactants,112 however, the interaction mechanisms between the helper lipid with the 
Gemini-DNA complex has not been yet identified. Various approaches and techniques have been 
utilized to study the modes of interaction(s) between these components of a non-viral vector and 
between these components and the lipid membranes; whether it is the cellular membrane or the 
endosomal membrane. Some of the techniques that have been utilized to examine these 
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interactions are:  particle size and zeta potential, isothermal titration calorimetry,112 atomic force 
microscopy, 142 small X-ray scattering (SAXS) ,105 and recently Langmuir Blodgett monolayer 
studies.143 These studies aim to shed light on the interactions of the cationic surfactants with the 
DNA and the effect of their condensation and compaction of DNA on the ability of the 
nanoparticles to interact with lipid membranes. The Langmuir Blodgett technique is an approach 
used to increase the understanding of the interactions between the DNA/gemini surfactant 
complexes as part of the bulk water (sub-phase) in the presence of an amphiphile (gemini 
surfactants) with its ability to adsorb at the interphase due to its dual nature; and its possible 
interaction with the insoluble monolayer, which is deposited at the air/water interface, with its 
hydrophilic part facing the water sub-phase and its hydrophobic moiety toward the air. In this 
thesis, this approach was applied in order to mimic cellular membranes, to understand how the 
GS-DNA vector interacts with the membrane, how it may be endocytosed, and more importantly 
how the components of the delivery vector (i.e. gemini surfactants and helper lipids) disrupts or 
become incorporated into cellular membranes. It is anticipated that such studies can improve our 
understanding of some of the mechanisms involved in the transfection process when a non-viral 
vector is being used. 
 
1.4 Langmuir-Blodgett (LB) monolayer studies and Brewster Angle Microscopy technique 
(BAM) 
 
Investigation of the interactions of DNA with cationic moieties in the presence of model 
membranes resembling biological membranes is of great importance. This kind of study can 
clarify the role of these interactions and the effect of them on the delivery of a desired segment 
of the DNA into the cells by means of a non-viral vectors.144 The LB method is a technique that 
allows the preparation of model membranes in a two dimensional system by spreading 
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phospholipids at the air-water interface145 and it also offers a unique opportunity to investigate 
the nature and possible interactions between these monolayers and different molecules.146 A 
molecular-level understanding of these interactions is necessary because depending on the lipid 
composition of cell membranes and tissues, biophysical interactions are altered, and this can be 
beneficial in developing target-specific drugs and drug delivery systems. So far, single or double 
component model membranes have been employed in such studies, and while these differ from 
the multicomponent biological systems, they offer a unique method to understand the mechanism 
by which exogenous molecules interact with lipid membranes.147 The Langmuir trough, used to 
prepare Langmuir monolayer is often coupled to Brewster Angle Microscope (BAM), which 
allows direct visualization and determination of domains in the monolayer and the phases at 
which these domains exist at the air/water interface, thus allowing real-time observation and 
recording of film structure.  
     The Brewster Angle method is based on the fact that if a p-polarized light beam hits a surface, 
a reflection of that light occurs. However, if the surface is hit at the Brewster angle at 53°or near 
it, no reflection occurs. When the monolayer is spread at the air/water interface, the refractive 
index of the surface changes accordingly and some reflection occurs, allowing for images (based 
upon the differences in the refractive index) to be taken using a CCD camera.148  In order to 
determine the surface pressure and the molecular areas associated with the components of the 
monolayer, a monolayer is spread on the water surface and the barriers found at each end of the 
trough are compressed at a constant speed. This process provides an isotherm of the surface 
pressure as a function of mean molecular area (Π-A) for the monolayer. The surface pressure of 
a monolayer can be calculated from the difference of the surface pressure of pure water at 
20C°(72mN/m) and the new recorded surface pressure of the monolayer.148 In an ideal isotherm 
generated from a Langmuir monolayer, four principal phases can be observed; a gaseous phase 
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(G), liquid expanded phase (Le or L1), liquid condensed phase (Lc or L2), and solid or solid-like 
phase (S). These phases and the transitions are illustrated in Figure 1.10. 
 
Figure 1.10 π-A isotherm obtained by compressing an insoluble lipid monolayer formed at an 
air-water interface. Adapted from reference149,148 
 
In the gaseous phase, surfactant molecules remain far apart and disoriented as can be seen in 
Figure 1.10. As the surface pressure increases (brought about by bringing the barriers on the 
Langmuir trough closer together), the surface area available to the molecules of the monolayer 
decreases, resulting in the formation of the liquid expanded, then liquid condensed, and finally 
the so-called solid phase.  Additionally, there is the possibility of co-existence regions, where 
more than one phase exists (i.e. a liquid expanded – liquid condensed phase; LE – LC). Further 
compression of the monolayer results in the collapse of the monolayer; the monolayer may be 
squeezed into either the water or air phase, possibly into bi- or multilayer phases. Certain 
parameters of importance can be obtained from the Langmuir monolayer; as an example, the 
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minimum sectional area (A°) can be obtained from by extrapolating the isotherm at the steepest 
slope prior to collapse back to zero surface pressure.143  
For a Langmuir monolayer, surface tension changes as the compressibility of the monolayer 
increases, and this change is denoted as interfacial elasticity150. This compressibility is defined 
as  
                                                      C =−1/A(dA/dπ)T                                            (1.2) 
Where A is the molecular area, and π is the surface pressure. The reciprocal of compressibility 
is denoted as compressibility modulus (Cs-1). Cs-1 provides information on the phase transition(s) 
of a Langmuir monolayer, for instance, the more sharp the phase transition, the higher is the 
differential dπ/dA and stiffer the monolayer 150b 
                                               Cs
-1 =1/C =−A(dP/dA)T                                    (1.3) 
1.4.1 Lipid membrane composition 
 
Lipids within the body have three different functions.151 First, lipids are used for energy storage, 
mainly as triacylglycerol and steryl esters, in lipid droplets. These reserves serve as caches of 
fatty acid and sterol components that are needed for membrane biogenesis. Second, cellular 
membranes are composed of polar lipids, which consist of a hydrophobic and a hydrophilic 
portion. The hydrophobic moieties have the propensity to self-associate and assemble into 
different morphologies (driven by the surrounding water). This fundamental principle of 
amphipathic lipids is a chemical property that enabled the first cells to segregate their internal 
constituents from the external environment.152 And this same principle assisted in the formation 
of discrete organelles within the cells. This function of lipids enables segregation of specific 
chemical reactions for the purposes of increased biochemical efficiency and restricted 
dissemination of reaction products. In addition to the barrier function, lipids provide membranes 
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with the potential for budding, characteristics that are essential for cell division, biological 
reproduction and intracellular membrane trafficking.151 The function of interest to our current 
study is the assembly of polar lipids into cell membranes and how in particular, molecules of 
foreign origins to the body can interact with the components of these membrane and be able to 
fuse or disrupt the homogeneity of these membranes. Lipids in cellular membranes are mainly 
glycerophospholipids (9600 species), sphingolipids (more than 100,000 species), and mono-, di-
, or triglycerides variants.153 Fatty-acid and sterol-based structures are also highly abundant. 
Cellular membrane lipids are divided into three distinct groups: phospholipids (glycerol-based 
lipids, 40-60 mol % of the total lipid fraction, ceramide-based sphingolipids, and sterols. 
Phospholipids are further subdivided into several groups according to their hydrophilic head 
groups; phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine, 
phosphatidylinositol, and cardiolipin. The first three mentioned lipids are the principle lipids in 
cellular membranes. Sphingolipids possess sphingoid base as a backbone; and are responsible 
for the hydrophobicity of the core of the cellular membrane bilayer. cholesterol (30-50 mol % of 
the total lipid fraction) is responsible for the fluidity and packing of the lipid membrane.143 Figure 
1.11 illustrates how glycerophospholipids can be very diverse based on the linkages, degree of 
saturation, the length of the fatty acids, and the moiety of the head group area  
 
Figure 1.11 Glycerophospholipid structure and their diversity, depicted from Reference153 
46 
 
 
                            
1.4.2 Model membranes 
 
Mammalian cell membranes consist of a lipid bilayer, which is composed mainly of 
phospholipids and cholesterol. Proteins of important cellular functions, such as, receptors, 
enzymes, and transporters are embedded in the lipid bilayer.154 Depending on the function of the 
cell, the cellular membranes lipid composition may vary and different ratios of phospholipids, 
cholesterol, and sphingolipids become more or less abundant accordingly. Cellular membranes 
act as a barrier to many compounds and molecules and these membranes allow selective 
permeability through the interactions of certain compounds with these membranes or by the 
interactions of the compounds with certain receptors or transporters in order to grant them 
passage through cellular membranes and access to the cellular matrix. A method that can be 
employed to better understand the interactions between a drug and the cellular membranes, and 
to elucidate a mechanism of action through which a drug, or a compound can access the selective 
permeable membranes is the use of model membranes. Model cell membranes are systems in 
which their lipid organization mimics the arrangement of lipids in natural cell membranes.145  A 
mixture of different lipids like cholesterol, dipalmitoyl phosphatidylcholine (DPPC), dioleoyl 
phosphatidylcholine (DOPC) and 1-palmitoyl-2-oleoylphosphatidylcholine (POPC) are used to 
make up model membranes that will be studied in this work. Depending on the cell type, the 
composition and the ratio of these lipids will vary.155 Beside the cellular membrane and its 
importance in understanding the mechanism of how non-viral gene delivery vehicle can gain 
access to the cell, the endosomal membrane is of great importance as well.  As mentioned earlier, 
lipid composition in the cellular membranes vary from one organelles or tissue to the other, and 
also it varies from the cellular membrane to the endoplasmic membrane. Mammalian cells 
maintain large differences in the sterol: phospholipid ratio in different organelles.156 The main 
constituents of these membranes in general are the phospholipids (phoshpatidylcholines), both 
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saturated and unsaturated.157 Some of these membranes are composed of 30% cholesterol, 
however; the levels of cholesterol vary greatly among different cellular organelles. As reported 
in the literature, cholesterol comprises 30% of the lipid molecules in the plasma membrane (PM) 
.158 This level varies in the endoplasmic reticulum (ER), which is the site of cholesterol synthesis, 
only 1–10% of the lipid molecules are cholesterol.159,160 In the endocytic recycling compartment 
(ERC), the major intracellular sterol pool is found and cholesterol comprises up to 35% of the 
lipid composition within the ERC.161 In mammalian liver, the plasma membrane, lysosomal 
membranes and nuclear membrane contains cholesterol at around 19.5%, 14% and 10% of total 
lipids, respectively.162  
Van Meer et al. have suggested that the early and late endosomes may have a cholesterol content 
of lower than 30 % or ~25-30%.163 In some of the recent Langmuir studies, a 30% composition 
of cholesterol was used and the rest of the lipid composition was usually 70%.164 In this current 
study, in both of the normal model membrane and the malignant model membrane, a composition 
of 25% cholesterol and 75% DPPC (normal) or POPC (malignant) is used in order to mimic the 
endosomal membrane. 
 
1.4.2.1 Types of model membranes 
 
As previously mentioned, to gain insight into the mechanisms of physiological activities of 
biomolecules and their interactions with other molecules at the cellular membrane level, 
researchers can study either the natural membranes themselves, whether isolated or not, or a 
simplistic model membranes.150b Many model membranes have emerged. Some examples of 
these methods are; Langmuir monolayers, liposomes and vesicles, and supported lipid 
membranes.  
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1.4.2.1.1 Langmuir monolayers 
 
A Langmuir monolayer is formed by spreading amphiphilic molecules on a sub-phase of water 
or different buffer systems using a Langmuir trough. In this technique, temperature, surface 
pressure and sub-phase composition is controlled to mimic a biological membrane.165 Surface 
pressure of biological cell membrane has been reported in the literature to range from 30-35 
mN/m.166 This range of surface pressure is readily accessible using the Langmuir method. The 
advantage of this technique arises from its simplicity in the preparation.167 The preparation of 
Langmuir monolayers will be discussed in detail in section 4.2. 
1.4.2.1.2  Liposomes / Lipid vesicles 
 
Lipids usually form lamellar bilayer structures over the majority of their phase diagram.168 In 
dilute solutions they form vesicles (liposomes). Liposomal model membrane systems have been 
extensively used as model membranes and these liposomes come in three types, uni-lammelar 
system such as; small unilammelar vesicle (SUV, 20-50 nm), large unilammelar vesicle (LUV, 
50-100 nm), or giant unilammelar vesicle (GUV,10-100 μm) .145 
 
1.4.2.1.3 Supported lipid membranes 
 
Due to the difficulty of working with lipid bilayers and membrane proteins, supported lipid 
bilayers are created by the self -assembly of lipids into bilayers on solid supports; usually mica, 
silicon, or glass.169 These systems allow for an easier way to investigate biological  processes  at 
the cellular level, and provide insight and information about; ligand–receptor interactions, drugs 
and gene delivery via the interactions with lipid bilayer membranes,170 viral attack,171 and 
cellular signaling events.172  A key finding is that the lipid molecules in supported membranes 
retain the  lateral  fluidity  associated  with  lipid  membranes  in vesicles  and  in  living  cells.173  
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Furthermore, living cells recognize components displayed on the surface of supported 
membranes; thus, if the appropriate components are present,   the   supported   membrane   can 
mimic cellular membranes.  These lipid bilayer assemble on the supported surface by orienting 
the polar head groups toward the surface and the hydrophobic tails toward the other lipid. These 
supported cell membranes have been characterized by NMR, neutron and X-ray scattering 
techniques, as well as AFM. 174  
Castano et al. synthesized a cholesterol derivative with guanidinium head groups 
(bis(guanidinium)-tris(2aminoethyl)amine-cholesterol, BGTC). Guanidinium head groups are 
inherently positive in charge due to the presence of arginine residues, which stay positively 
charged over a wide range of pH due to the high pKa value175. This cationic lipid`s monolayer 
was examined with DNA in the aqueous sub-phase, and with mixture of BGTC/DOPE 
monolayer with DNA in the water sub-phase to investigate the interactions between these 
component to understand the efficient gene transfection results obtained with this cationic lipid`s 
liposomes , both in vitro and in vivo. At a surface pressure of 20mN/m, and beyond the collapse 
surface pressure of >46mN/m, and at a charge ratio of BGTC:DNA of 1:5, with DNA excess, 
and at BGTC:DOPE molar ratio of 3:2, DNA was shown to interact with the BGTC:DOPE mixed 
monolayer, with BGTC interacting with DNA in the sub-phase through its polar head groups 
(facing the aqueous phase), and in contrast to that behaviour, DOPE acts with its polar head 
groups facing the air and the alkyl tail resides toward the aqueous sub-phase. When the pressure 
goes beyond the collapse pressure, DOPE forms a top layer, and DNA adsorbs under the BGTC 
monolayer, and manages to stabilize the BGTC molecules within the monolayer, which prevents 
it from flip-flopping like DOPE does. This behaviour is illustrated in Figures 1.12A, and 1.12B. 
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Figure 1.12 Scheme representing the interactions of DNA with BGTC and DOPE at two surface 
pressures. Scheme representing the interactions of DNA (~200bp) with BGTC and DOPE at two 
surface pressures. A) At 20mN/m, formation of an incomplete DNA monolayer at (+/-) charge 
ratio of low DNA with a layer thickness of 7Å below the BGTC/DOPE monolayer (thickness of 
~19Å). B) Beyond the collapse pressure, DOPE forms a flip-flop layer on top of the BGTC with 
its head groups toward the air and its alkyl tail toward the BGTC layer with a thickness of 50Å, 
and the BGTC interacting with adsorbed organized layer of DNA with a thickness of 27Å.[ 
Adapted from reference 175, 143]. 
 
In another study by Matti et al., cationic gemini surfactants, 2, 3-dimethoxy-1,4- bis(N-
hexadecyl-N,N-dimethyl-ammonium)-butane dibromide (SS-1) was synthesized and a 
monolayer of SS-1 together with 1-palmitoyl-2-oleoyl-sn-glycero—3-phosphate (POPC) were 
studied by Langmuir balance. A Langmuir monolayer study of the mixed system was conducted 
and surface pressure-area isotherms were measured at different Xss-1concentration and the 
compressibility moduli (CS
-1) were calculated. The mixed monolayers showed the same smooth 
isotherm of POPC alone, reflecting a liquid expanded phase, with no phase transition observed. 
However, a condensation effect was observed even at low surfactants concentration, i.e. Xss-1< 
0.05 with a reduction in the mean molecular area from 92Å2_78Å2. In the presence of the DNA 
in the sub-phase, the SS-1-POPC monolayer was oriented differently; with the phosphate –
ammonium (P+/N-) charge ratio and the lipid stoichiometry being the leading factors contributing 
to the changes happening in the monolayer and consequently the isotherm. As the DNA 
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concentration (in base-pair) increases, the monolayer was condensed from 92Å2_80 Å2. This 
condensation effect remains up to XSS-1<0.5, which corresponds to DNA/SS-1 charge ratio of 
1.25. Expansion occurs after that due to the increased available molecules of DNA. However, as 
the DNA concentration exceeds that of SS-1, the condensation effect of the monolayer remain 
intact, irrelevant of the SS-1concentration.176 These changes in the isotherm can be observed in 
Figure 1.13. 
 
 
Figure 1.13 Surface pressure of POPC with SS-1 and DNA. A) Surface pressure isotherm of 
POPC (a), SS-1(b), and their mixed monolayers on a sub-phase of 5mM HEPES, 0.1mM EDTA, 
and pH=7.4., Xss-1=0.05 (c), and Xss-1=0.13(d). B) Surface pressure-area isotherms of 
POPC/Xss-1 at Xss-1=0.05 (with straight line) and around surface pressure 27mN/m, 
discontinuity was observed, and DNA/Xss-1isotherm at a charge ratio of 1.25 is shown in the 
discontinuous line176.  
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This literature review extensively described the synthesis of numerous novel gemini surfactants, 
their behavior alone and with other components of transfection, and the interaction with DNA in 
lipoplexes (liposomes) or polyplexes, with and without helper lipids (DOPE). This chapter also 
identified the different morphologies adopted by the gemini surfactants in solution and how 
different micelle structures can factor into the complexation, condensation of DNA, and 
transfection.  Understanding the nature of the barriers that stand against the success of the non-
viral gene delivery in transfection into an actual cell, and how to scale up from a cell into an 
organ or into an animal requires the employment of several techniques that can provide insight 
into how these lipoplexes components interact with each other. Moreover, understanding the 
condensation and the de-condensation of the DNA and its subsequent release from the delivery 
vehicle can bring into light the various factors that contribute essentially in the fundamental 
processes that govern transfection, and can minimize the concentration of other components, or 
even avoid the addition of other components that can reduce the possibility of aggregation.  
This chapter also focused on understanding membrane fusion/disruption events, and how the 
interaction(s) between the transfection complex and the cell membrane is a critical step into 
gaining access to the inside of the cell. Next generation gene transfection vectors can include 
gemini surfactant coupled with surface modification of the liposome for targeting, additional 
environmentally responsive stimulus, or the formation of other “smart” vectors to deliver the 
DNA cargo to the nucleus. These modifications can reduce the toxicity caused by the vector or 
cause selective toxicity, which is favored in case of cancer cells. 
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Chapter 2: Hypothesis and objectives 
 
2.1 Rational design of gemini surfactants and the focus of this research 
 
Gemini surfactants are unique compounds that can be functionalized with different functional 
groups to yield diverse libraries of compounds that can be utilized for a variety of purposes. The 
focus of this work is to synthesize novel gemini surfactants that can serve for non-viral gene 
delivery systems and can improve transfection efficiency in in vitro studies and at the same time 
exert minimal or no toxicity on the biological hosts. For that new surfactants with specific 
functionality is required. The rational design of these surfactants can be done based on the 
observation of what has been reported in the literature. First, the presence of unsaturation can 
transform the micelles from simple structure; such as; worm-like micelles and cylindrical 
micelles177 to more highly ordered structures; such as; inverted hexagonal structure, bilayers, 
and cubic micelles.100 These latter morphologies have been reported to improve the transfection 
efficiency and many hypotheses on their mode of actions have been postulated, but little is 
known.     
      Second, the presence of bulky hydrocarbon chains also resulted in structural flexibility and 
the ability to induce phase transition and form more diverse structures when complexed with 
DNA. This has been observed in small-angle scattering technique (SAXS) in phytanyl-DNA 
complexes. Inverted hexagonal and cubic structures were related to the superior transfection 
efficiency observed in phy-3-16.178 A bulky pyrenyl moiety was introduced as a hydrocarbon 
tail in the synthesis of asymmetrical gemini surfactants. Two of these surfactants were 
synthesized; pyr-3-12 and pyr-6-12, with both demonstrating peculiar thermodynamic behavior 
when they were complexed with the DNA. Instead of showing the complex behavior observed 
with symmetric gemini surfactants (12-s-12) through the demonstration of three different phases 
in their enthalpograms as the concentration of the DNA increases, these unique surfactants 
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showed only one large peak109. The presence of a pyrenyl group in the structure of the gemini 
surfactant resulted in substantial changes in the binding interactions with DNA, disrupting and/or 
eliminating the flocculation observed with the 12-s-12 surfactants. This is possibly caused by  
strong intercalation of the pyreneyl group between DNA base pairs, that possibly forces the 
surfactant to adopt an orientation with the dodecyl tails oriented away from the complex, leading 
to a steric stabilization against flocculation.179 
Lipids form the majority of membranes in living organisms and depending on the lipids 
composition, the functions of the cellular membranes are altered. Also, certain lipids are 
abundant in different conditions; such as; unsaturated lipids in tumor tissues180 and lipid raft 
domains in endocytosis.181 Lipid rafts (sizes ~10-200 nm) are composed of cholesterol, long-
chain saturated sphingolipids and phosphatidylcholine (PC) and specific proteins. These 
microdomains are associated with the cell signaling, membrane trafficking, drug targetting and 
endocytosis.182 They also server as organizing centers for the assembly of signaling molecules It 
has been reported that sphingolipid/sterol assembly in lipid rafts can be modulated by 
glycosylphosphatidylinositol (GPI)-anchored proteins, certain transmembrane proteins, acylated 
cytosolic effectors, and cortical actin.183 Lipid based formulations (lipoplexes) might influence 
the lipid rafts of cellular membranes, which in turn results in better endocytosis and endosomal 
escape of the lipoplex, which is why we are interested in model membrane to better understand 
the interactions of the lipoplex or the nanoparticle with these membranes. 
However, the lack of understanding of how the DNA influences the arrangement of the vector 
components in a non-viral gene delivery vector once it is complexed; as well as how the vector 
components interact with biological membranes. 
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2.2 Hypothesis 
 
It is hypothesized that the introduction of dissymmetry (either in the form of two alkyl tails 
of unequal length, or one alkyl tail and one bulky pyrene substituted tail) in the structure 
of gemini surfactants will improve their ability to function as transfection vectors by 
increasing membrane disruption. 
2.3 Objectives 
 
Short-term objectives: 
1. Synthesize and characterize the dissymmetric pyrene-based, and 12-3-n gemini 
surfactants, and 
2. Determine their micellization properties. 
Long-term objectives: 
1) Characterize the complexes of the synthesized gemini surfactants with DNA by 
measuring their particle size and zeta potential. 
2) Characterization the interaction(s) of gemini surfactant based complexes on model 
biological membranes: 
a) DPPC-Cholesterol, and POPC-Cholesterol model membranes. 
b) DPPC-Cholesterol, and POPC-Cholesterol model membranes with gemini 
surfactants. 
c) DPPC-Cholesterol, and POPC-Cholesterol model membranes with Gemini 
surfactants, and DNA. 
3) Determine In vitro transfection efficiencies for the pyrenyl and 12-3-n gemini surfactants 
in two cell lines; HEK-293, and MG-63. 
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The results and discussion regarding the short-term goal will be detailed in Chapter 3. Chapter 4 
outlines the results and discussion about the long-term goals. 
 
Table 2.1 Gemini surfactants synthesized and used in this study 
 
 
 
 
 
 
 
 
 
 
 
Code name Chemical structure
n = 14, 16, and 18
Pyrenyl-3-m
m = 8, 12, 14, 16, and 18
12-3-n
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Chapter 3: Synthesis and characterization of dissymmetric Gemini 
surfactants 
3.1 Introduction 
 
The focus of this study is to rationally design and synthesize a novel dissymmetrical gemini 
surfactants and characterize them for future applications as non-viral gene delivery vehicle.  The 
spacer linker has been shown to impact the critical micelle concentration (CMC), affect micelle 
structures in solution; as well as assist in the stabilization of nanoparticles or liposomes when 
the gemini surfactant is complexed with polyelectrolytes such as DNA.184  Moreover, the spacer 
facilitates binding of the positively charged ammonium groups of gemini surfactants with the 
negatively charged phosphate backbone to help folding and compacting the DNA, to avoid its 
degradation by various nucleases; either in the endosome or the cytoplasm. Its effect has been 
studied and explored extensively and it has been shown to influence the gene transfection 
efficiencies.110  However, little work has been published that focus on the effect of the nature 
and the length of the alkyl tails. The length and volume of the alkyl tails impact the packing 
parameter which is directly linked to the morphologies displayed by the gemini surfactants in 
solution. These morphologies, especially inverted hexagonal/ cubic phases are linked to efficient 
transfection vectors71. For that, eight different dissymmetric gemini sufactants were synthesized 
and characterized, each of which can be categorized into two groups as indicated below: 
Surfactant categories Members 
m-s-n (m-3-n) Pyrene-3-8, pyrene-3-12, pyrene-3-14,  
pyrene-3-16 & pyrene-3-18 
12-3-14, 12-3-16 , 12-3-18 
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Pyrene has been widely used as a labelling molecule because of its nature as a chromophore. 
Pyrene absorbs and emits strongly due to its high molar absorbance coefficient in the near UV 
region.185 The pyrene monomer fluorescence is characterized by several sharp peaks at 
wavelengths between 370 and 420 nm. The presence of sharp peaks in the fluorescence emission 
spectrum indicates the presence of discreet vibration levels in the pyrene monomer ground-state. 
In addition to the fluorescence of the pyrene monomer in the blue wavelength region, an excited 
pyrene has the ability to complex with a ground-state pyrene to form an excimer. The excimer 
fluoresces in the blue to green wavelength region with a broad structure less emission spectra 
centered at 460 to 480nm.186 A relative indicator of the degree of association of the pyrene labels 
of macromolecules can be obtained by measuring the ratio of the fluorescence intensities of the 
excimer IE, integrated from 500 to 530 nm, to the monomer IM, integrated from 372 to 378 nm.
187 
Due to these characteristic peaks, pyrene has been widely used to characterize micelles in 
solutions and a means to determine the CMC through the relative intensities in its fluorescence 
spectrum. Also, it is used to determine the polarity of microenvironments, such as; micelles188. 
Due  to  the  low  solubility  of  pyrene in pure water, the efficiency of excimer formation is low  
at  surfactant  concentrations  below  the  CMC.  However, with concentrations higher than the 
CMC, pyrene molecules will be crowded into the micelles, which will give higher excimer peak 
formation.189 In this current study, pyrenyl derivative (hexyl pyrene) is in the structure of the 
asymmetrical gemini surfactants. Its hydrophobicity and its ability to intercalate between the 
DNA strands will be integrated into a gemini surfactants micellization system in order to focus 
on the unique properties of these surfactants and the effect of the pyrene on these properties. 
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3.2 Methods and Materials 
 
The synthesis of the gemini surfactants that were utilized in this project took place in our 
laboratory following the method of Wang et al. .190 
3.2.1.1 Synthesis of 5-bromohexane-1-pyrenyl ketone 
 
5-Bromohexyl-1-pyrenyl ketone was the first intermediate in the functionalization step of pyrene 
to synthesize 6-(1-pyrenebromohexane), which represents the first tail. The synthesis pathway is 
in scheme 3.1. The first step was to dissolve pyrene (Aldrich, 10.0 g, 49.4mmol) and AlCl3 
(Aldrich, 8g, 60mmol) in 80 mLof CH2Cl2 that had been cooled to -78ºC. Then, another 80 mLof 
CH2Cl2 that contained 6-bromohexanoyl chloride (Aldrich, 97%, 3.7mL, 24.7mmol) was added 
dropwise to the mixture, allowing the reaction to continue for 3h at -78Cᵒ. The reaction was 
quenched with 1M HCl, and then neutralized using a saturated aqueous NaCl solution, to 
separate the organic layer and let it dry with Na2SO4, overnight. Excess solvent was removed via 
rotary evaporation to yield a yellow paste that was further purified by soxhlet extraction (pentane 
100%) to produce a yield of  11g with purity of  86-90%. 1H NMR data is given in Appendix A. 
 
Scheme 3. 1 Synthesis of 5-bromohexane-1-pyrene ketone .i: AlCl3, CH2Cl2, 6-bromohexanoyl 
chloride, the reaction was run at -78ºC for 3h. 
 
 3.2.1.2 Synthesis of 6-(1-pyrenylbromohexane)191 
 
Trifluroacetic acid (15ml) and 2.3g of 5-bromohexyl-1-pyrenyl ketone (6mmol) were dissolved 
in 65 mL of CH2Cl2 and cooled to 0ᵒC. 2.7 mL of triethylsilane (Aldrich, 99%) was added, 
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dropwise to the mixture and stirred for three days under an argon (Ar) atmosphere at room 
temperature. Then, the reaction was neutralized with saturated aqueous NaHCO3 (Sigma), and 
the oil layer was separated and dried over Na2SO4 overnight (Scheme3.2.). The crude oil was 
further purified using soxhlet extraction with pentane to give yield of 92-100%. 1H NMR data is 
given in Appendix A. 
 
Scheme 3.2. Synthesis of 6-(1-pyrenebromohexane) ii. TFA, triethylsilane, with CH2Cl2  under 
Argon for 3days at room temperature 
3.2.1.3 Synthesis of pyr-3(N-(3-dimethylaminopropyl)-N, N-dimethyl-6-(pyren-6-yl)-hexan-1-
ammonium bromide) 
 
6-(1-Pyrenyl)bromohexane (1.58 g, 4.33 mmol) and N,N,N`,N`-tetramethylpropane 
diamine(Aldrich, 99%, 0.92 mL, 5.5 mmol) were added to 40 mL of anhydrous acetonitrile. The 
mixture was stirred at 45ºC for three days (Scheme 3.3). The solvent was reduced to ~10 mL 
using a rotary evaporation, leaving a light yellowish precipitate. This crude product was further 
recrystallized from hot acetonitrile and diethyl ether to yield an off-white solid with a yield of 
100%. 1H NMR data is given in Appendix 3.1A. 
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Scheme 3.3 Synthesis of pyr-3. iii. N,N,N`,N`- tetramethylpropanediamine with CH3CN reflux 
for 3 days at 45ºC in CH3CN 
 
3.2.1.4 Synthesis of pyr-3-m (m = 8, 12, 14, 16 & 18) 
 
Pyr-3(2.0 g, 4 mmol) and 1-bromododecane (2.7 mL, 9.0 mmol) or 1-bromotetradecane (3.32 
mL, 4 mmol), or 1-bromohexadecane (1.22 mL, 4 mmol), or 1-bromooctane (0.69 mL, 4 mmol) 
were added to 40 mL of anhydrous acetonitrile (Scheme 3.4). The mixture was stirred at 45ºC 
for two days. The solvent was removed using rotary evaporation. The product was recrystallized 
from a mixture of acetone and ethyl acetate and dried overnight with a yield of 46-60%.  1H 
NMR data is given in Appendix A. 
                                                                                                        
Scheme 3.4 Synthesis of pyr-3-n. iv. 1-bromooctane, 1-bromododecane, 1-bromotetradecane, 1-
bromohexadecane, and 1-bromooctadecane with CH3CN reflux for 2 days at 45ºC 
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3.1.2 Synthesis of m-3-n surfactants 
 
Synthesis of the dissymmetric gemini surfactants with the general formula of m-s-n, where m≠n, 
m =12 and n =14,16, and 18 followed the general scheme described by Menger and Littau.192 
All of the gemini surfactants were synthesized by reflux of 1-bromododecane(Sigma Aldrich, 
Canada) with one molar equivalent of N,N,N`,N`-tetramethylpropane diamine (Aldrich, Canada) 
in HPLC grade of acetonitrile for 24 h. The reaction was then stopped, cooled down in ice bath 
before applying filtration. Recrystallization in hot acetonitrile was applied. The purity of the 
intermediate is then tested by 1H NMR before the reaction was allowed to continue by refluxing 
it with either 1-bromotetradecane, 1-bromohexadecane, or 1-bromooctadecane (Sigma Aldrich, 
Canada) in acetonitrile for another 24 h. Then, filtration of the cooled product was done for the 
final product, which was further dried in the vacuum oven before it was recrystallized from a 
mixture of acetonitrile and ethyl acetate. The purity of the final gemini surfactants was confirmed 
with 1H NMR. A representative scheme of the synthesis is given below (Scheme 3.5) and 1H 
NMR data can be found in Appendix A. 
 
Scheme 3.5 General scheme for the synthesis of 12-3-n, where n =1-bromotetradecane, 1-
bromohexadecane, and 1-bromooctadecane 
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3.1.3 Determination of the Krafft temperatures 
 
Cationic gemini surfactants` solubility increases when subjecting the solutions to increasing 
temperature. At a certain temperature value for each specific surfactant, there is a characteristic 
sharp increase in the solubility and this is referred to as the Krafft temperature (TK). We can 
determine this temperature by means of specific conductivity as reported in the literature.193 
To measure the Krafft temperature, a clear-saturated aqueous solution of the surfactants should 
be prepared (the concentrations of the solutions are 5 times more than the known or speculated 
critical micelle concentration (CMC). Then, the solutions are refrigerated overnight until 
precipitation is observed. The solution is then placed in a temperature-controlled vessel that is 
connected to a circulating water bath Model RE304 (Lauda, Germany). The initial temperature 
was set at 10.00°C ± 0.01 and it was incrementally increased. The conductivity solution was 
measured as a function of temperature using a SevenEasyTMS30 conductivity meter (Mettler 
Toledo, Switzerland) and double-walled glass titration cell (Fisher Scientific, USA), with a cell 
constant of 0.475 cm-1. Two break points are observed in the temperature-conductivity plot; one 
representing the Krafft temperature (TK) and the other break point representing what might be a 
transition point. 
3.1.4 Surface tension measurement 
 
Surface tension was measured using a TE3 automated tensiometer (Lauda, Germany), applying 
the Du Nuoy ring method and all of the surfactants surface tension values were corrected using 
the method of Harkins and Jordan.194 The surface tension was measured after each titration of a 
surfactant solution in Milli-Q water to a 40 mL of Milli-Q water at 25°C. Triplicate readings 
were taken automatically in each experiment and each experiment is run twice. The critical 
micelle concentration is determined from the plot of the surface tension and the logarithm 
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concentration of the surfactants194. Surface tensions were measured until the variability between 
measurements was less than 0.1mN/m.   
3.1.5 Specific conductivity 
 
The specific conductivities were measured using a SevenEasyTMS30 conductivity meter 
(Mettler Toledo, Switzerland) and double-walled glass titration cell (Fisher Scientific, USA), 
with a cell constant of 0.475cm-1 at 25C°. Temperatures were controlled using RE304 circulating 
water bath purchased from Lauda (Germany). Specific conductivities were measured after each 
addition of a concentrated solution of the gemini surfactant to a 30 mL of pure water after 
calibrating the meter using KCl solution (at1413µS.cm-1).195 The CMC is determined at three 
different temperatures (25ºC, 30ºC, and 35ºC). The CMC values can be determined from the 
abscissa of the inter-section of the trend lines connecting the experimental points before and after 
the CMC (hypothesized) in a surface tension vs. log concentration plot 10 or fit from the 
conductivity points according to Carpena et using this equation (1)196: 
Κ= κᵒ +A1c+d(A2-A1)ln (1+e(c-cmc)/d) 
                                    (1-e(-cmc/d) 
The degree of micelle ionization (α) is calculated by the ration of the slopes of the two areas in 
the graph. 
3.1.6 Fluorescence studies 
 
Fluorescence emission spectra of pyrenyl gemini surfactants in aqueous solutions and pyrene in 
methanol have been recorded using Spectra max M5 microplate reader (molecular devices, USA) 
at excitation wavelength 363nm after scanning the excitation spectrum of pyrene in methanol. 
These samples were measured in transparent disposable cuvettes (ZEN0118) (Malvern 
instruments, UK). The excitation and emission slit-widths were set at 1 nm. An average of 40–
50 scans was recorded. 
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3.1.7 Docking studies 
Molecular docking studies for pyrene based surfactants were performed to give additional 
information on how pyrenyl surfactants interact with each other (either via self and/or 
intermolecular aggregation) when present in the aqueous phase. This study was conducted 
through a collaboration study with Dr. Praveen Nekkar Rao`s lab.  Discovery studio (DS) 
Structure-based-design software (version 4.5, BIOVIA/Accelrys, San Diego, USA) was used for 
the docking studies. Briefly, 3D models of the pyrene based surfactants surrounded with water 
molecules were designed using the Build fragment tool. Energy minimization was performed 
using the steepest descent and conjugate gradient minimizations for 1000 interactions. The 
distance dependent dielectric model was used as the implicit solvent model for the energy 
minimization step. The CDOCKER algorithm was used to dock a surfactant monomer with 
another monomer after defining a 25Å sphere radius around the surfactant molecule. The 
CHARMm force field was used for the docking studies using 25 top hits and random 
conformations and full potential as true value. The most stable interaction conformation between 
the pyrene based surfactants was evaluated based on CDOCKER energy and CDOCKER 
interaction energy in Kcal/mol. The type of interaction occurring between the self- aggregating 
pyrene surfactants (i.e. self or intermolecular) were also visualized using the docked molecules. 
3.2 Results and Discussion  
 
3.2.1 Krafft temperature 
 
Below the Krafft temperature (TK), the solution was not homogenous. Once the Krafft 
temperature is hit, micelle formation begins and the solubility is increased. This sharp increase 
in solubility represents the Krafft temperature, which is the temperature when the CMC is 
reached and aggregates formation becomes spontaneous. This sharp increase in temperature is 
signaled also by rapid increase in conductivity.  Several factors affect the Krafft temperature`s 
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increase in surfactants; such as,  in the presence of unsaturation, branching and substitution of 
either the alkyl tails, or the counter ions, or the head groups.197 All of the pyrenyl gemini 
surfactants showed precipitation after 24-48h of refrigeration and after that, the solutions were 
left at room temperature to thaw in order to run the experiments. Pyr-3-8 TK was <20ºC and as 
the alkyl tail of the pyr-GSs increases from octyl to octadecyl the Krafft temperature increase, 
and this shows a linear correlation. The 12-3-n gemini surfactants behaved in the same manner 
of the pyrenyl surfactants, but with a less significant increase between 12-3-14 and 12-3-16 and 
significant increase for 12-3-18. TK of 12-3-14= 33ºC, 12-3-16 = 35ºC, and TK of 12-3-18 = 
60ºC. However, at higher temperatures there was a second break point and we believe it indicates 
a phase transition and the beginning of the formation of higher and more complicated 
morphologies. This break point was witnessed in both of the pyrene-3-m surfactants and the 12-
3-n surfactants. The values of Krafft temperatures and the transition temperatures of the eight 
surfactants were obtained from the plots of the temperature-specific conductance and are 
presented in Figure 3. 1 and Figure 3.2. 
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Figure 3.1 Krafft temperatures and transition temperatures inflicts of pyrenyl gemini surfactants 
of pyr-3-8 (□), pyr-3-12 (○), pyr-3-14 (x), pyr-3-16(+), pyr-3-18 (▲), The arrows indicate both 
TK and TT, respectively. 
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Figure 3.2 Krafft temperatures and Krafft temperatures of 12-3-14 (Δ), 12-3-16 (▼), 12-3-18 
(●) 
 
The results of the Krafft temperatures in both of the groups followed the trend that was observed 
for symmetrical gemini surfactants of m-3-m category, where m=12, 16, and 18. The longer the 
alkyl tail, the higher the hydrophobicity and the higher the Krafft temperature.100 The same 
observation was noticed in a previous study on phytanyl dissymmetric gemini surfactans 
conducted by Wang and Wettig in 2011.105 Below the TK, the increase in both the temperature 
and the conductivity was slow for all the dissymmetric surfactants, however, once the TK is 
reached and its onset represents the beginning of micellization, a rapid incline in both of the 
temperatures and the conductivity can be noticed. The Krafft temperatures of all of the 
synthesized surfactants are summarized in Table 3.1. 
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Table3.1. Krafft temperatures (TK) and the transition temperatures (TT) of the dissymmetric 
gemmini surfactants 
Gemini surfactant TK TT 
Pyr-3-8 <20 72 
Pyr-3-12 42 75 
Pyr-3-14 45 90 
Pyr-3-16 60 95 
Pyr-3-18 <60 <95 
12-3-14 33 85 
12-3-16 35 85 
12-3-18 60 90 
12-3-12 - 12.7 
14-3-14 - RT 
 
3.2.2 Surface tension analysis and favored interactions 
 
Plots of surface tension as a function of the logarithm concentration of the pyrenyl gemini 
surfactants in aqueous solutions are shown in Figure. 3.3 and Table 3.2 with the CMC gradually 
decreasing with the increase in the alkyl tail length from octyl to octadecyl. In a plot of surface 
tension as a function of the logarithm of surfactant concentration, the CMC can be determined 
from the intersection of two lines, which represents the area below and above the CMC.  The 
first line shows a linear decline, and the other one represents the plateau area (minimal surface 
tension). In a logarithmic plot of the CMC as a function of the hydrocarbon tail, shown in Fig.3.4 
the symmetrical m-3-m gemini surfactants show a linear pattern with the exception of (18-3-18) 
.105, 198 When the CMCs of the pyrenyl surfactants are plotted in this manner, they show a slight 
decrease from pyr-3-12 (0.21mM) to pyr-3-14 (0.15mM) then pyr-3-16 (0.113m M), followed 
by a greater decrease between pyr-3-16 and pyr-3-18 (0.024mM). Most of the pyrenyl gemini 
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surfactants show a clear break point at the CMC. However, that of  pyr-3-18 was poorly defined, 
suggesting the presence of  premicellar aggregation and this kind of behavior was reported before 
in gemini surfactants with longer alkyl tails, m<18, in 12-s-12; where s=12,14, and 16.98 The 
same behavior was reported in dissymmetric gemini surfactants with bulky unsaturated tails, 
such as, phytanyl-3-16.105 As seen in Fig. 3.4, the CMC of 12-3-14 was dramatically smaller 
than that of 12-3-12 (0.32mM versus 0.98mM, respectively).96 The CMC values decreases 
gradually for both of 12-3-16 (0.22mM), and 12-3-18 (0.17mM). Although the CMC of these 
gemini surfactants are dramatically lower than their symmetrical counterparts, the onset of 
micellization required higher concentrations for it to occur, especially for 12-3-14 and this can 
be noticed in the surface tension results (γcmc for 12-3-14 = 26.22mN/m, 12-3-16 = 32.21mN/m, 
and 12-3-18 = 40.24mN/m). The longer the tail, the higher the hydrophobicity and the easier for 
surfactant monomers to aggregate. For the pyrene-based surfactants, the onset of micellization 
occurred earlier than the corresponding m-3-m surfactants. This may be caused by the presence 
of pyrene ring within the surfactants, which adds to the hydrophobicity of the gemini surfactant 
through the pyrene stacking, leading to enhanced hydrophobic interactions. The contribution of 
additional methylene unit to the CMC value in both groups of surfactants was more like that of 
a single-tail surfactant.199 This may be attributed to the increased intermolecular hydrophobic 
interactions between tails of same length between the monomers within the micelles. Similar to 
the symmetric gemini surfactants, γcmc decreases with the increase in the gemini surfactant`s 
concentration, which indicates the formation of a monolayer at the air/water interface, thus 
reduces the surface tension of water. In pyrenyl surfactants, γcmc values are relatively higher than 
the corresponding m-3-m as well as those of m-3-n surfactants, suggesting an earlier onset of 
micellization (with the exception of pyr-3-8). Pyrene-3-8 has a short tail, rendering the surfactant 
more hydrophilic and increasing its solubility in water, favoring the bulk over the surface. The 
low value for γcmc (27.61mN/m) is consistent with this interpretation.  
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Table 3.2 Critical micelle concentration (CMC), head group area (a˳), packing parameter (P), 
and surface excess concentrations (Γi) of Pyrene-based and 12-3-n surfactants 
Surfactant CMC (mM)a γ(mN/m) Γi(mol/nm2)*10-6 
ɑ˳ 
(nm2/mol) 
P 
Pyrene-3-8 0.178 ±0.02 27.6 9.47x10-7 0.35 <1  
Pyrene-3-12 0.21±0.02 43.14 2.97 0.56 1 
Pyrene-3-14 0.15±0.03 41.2 1.47 1.13 0.46 
Pyrene-3-16 0.14±0.03 43.58 3.16 0.526 0.91 
Pyrene-3-18 0.024±0.07 40  2.38  0.7  0.65  
12-3-14 0.32±0.014 26.22 5.74 0.3 <1 
12-3-16 0.22±0.014 32.21 8.07 0.21 <1 
12-3-18 0.17±0.02 40.24 8.68 0.19 <1 
 12-3-12  0.98±0.04     1.11 0.38 
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Figure 3.3 Surface tension of pyrene-based gemini surfactants of pyr-3-8 (■), pyr-3-12(x), pyr-
3-14 (+), pyr-3-16(○), and pyr-3-18 (▲). Linear fits are indicated by lines and CMC values are 
calculated from the intersection of these two lines. Plots values are in Appendix A 
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Figure 3.4 Surface tension plots of asymmetric gemini surfactants; 12-3-14 (x), 12-3-16(+), and 
12-3-18(□). Linear fits are indicated by lines and CMC values are calculated from the 
intersections. Plots values are in Appendix A 
 
A plot of the logarithm of the CMC as a function of hydrocarbon tail length for the pyrenyl and 
the 12-3-n surfactants are plotted in Figures.3.3 and 3.4. The symmetrical gemini surfactants 
showed linear decrease with the increase in the alkyl tail length with the exception of 18-3-18, 
which skewed from the linear behavior.105 Pyrene based surfactants followed the linear trend 
with barely observed decrease from pyr-3-14 to pyr-3-16, followed by larger decrease for pyr-3-
18. However, pyr-3-12 did not follow the same decreasing trend. 12-3-n surfactants followed the 
same behavior observed in the pyrenyl surfactants. 
Pyrene has been widely used as a fluorescent probe to characterize micro-heterogeneous systems, 
such as; micelles.200 This is largely due to the significant sensitivity to the polarity of the solvent 
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being used. Based on that, pyrene shows characteristic vibronic bands around 370-420nm in its 
fluorescence spectrum. The absolute and relative intensity, width and position of this band 
depends highly on the polarity of the microenvironment.201 Due  to  the  low  solubility  of  pyrene 
in pure water, the efficiency of excimer formation is low  at  surfactant  concentrations  below  
the  CMC.  However, with concentrations higher than the CMC, pyrene molecules will be 
crowded into the micelles, which will give higher excimer peak formation.202 This is not the case 
when pyrene is existing within the structure of the surfactants. The excimer may be formed in 
all the concentrations whether below or above the CMC and this is due to the high abundance of 
pyrene molecules. However, with concentrations below the CMC, formation of pre-micellar 
aggregates may trigger the appearance of excimer signal. Pineiro et al. showed that pyrene 
molecules interact with the surfactant molecules far below the CMC, which confirms our 
results.203 The emission spectra of all of the pyrenyl surfactants in water showed more or less the 
same pattern of the pyrene spectrum in methanol with the monomer fluorescence maximum at 
390 nm and the spectra are well resolved and different from the red-shifted broad peak in the 
fluorescence band at 460 nm for pyrene and pyr-3-8 spectra which indicates the formation of the 
excimer. However, the peak shifted more toward the red for the rest of the pyrenyl surfactants. 
This small red shift is most likely the effect of increased hydrophobicity of the medium and this 
is caused by the formation of the micelles and with the increase in the alkyl tail length, the onset 
of micellization occurs earlier, which contributes to the hydrophobicity. As mentioned earlier, 
post and below the CMC concentrations of these gemini showed the presence of the excimer 
formation at around 480-490nm with weaker intensity. This reflects the abundance of the pyrene 
surfactants within the hydrophilic region before the micellization and in the hydrophobic 
micelles after the CMC. However, the presence of the dimer peak around 480 nm, indicates the 
formation of the excimer. Also, this is an evidence of the formation of premicellar aggregates 
that might be caused by the pi-pi stacking, highlighting the importance of these weak interactions 
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between surfactants in solution. However, pyrene-3-12 with concentration lower than the CMC 
showed very little evidence of dimer formation in its fluorescence spectrum. This can be 
attributed to the length of the hexyl pyrenyl tail which is equal to 11-11.5 bonds and this makes 
pyr-3-12 acts as symmetrical gemini surfactants below the CMC, thus minimize the effect of the 
intermolecular hydrophobic interactions, limiting the pi-pi stacking and enhancing the 
interactions with the dodecyl tail (Figure 3.5). Pyrene stacking in pyrene-based gemini 
surfactants can be seen in Figure 3.6. 
  
Figure 3.5 Fluorescence spectra of pyrenyl gemini surfactants: a) before the CMC, b) After the 
CMC (pyrene black, pyr-3-8 blue, pyr-3-12 grey, pyr-3-14 pink, pyr-3-16 navy, and pyr-3-18 
orange). The intensity of the excimer peak in pre-CMC solution is lower than the intensity of the 
peak after the CMC, which indicates the presence of the pyrene within the hydrophobic micelles. 
Relative intensity has been used to determine the CMC values based on the excited state and the 
ground state of the pyrene molecules. 
 
To further explore the nature of the interaction(s) between the tail groups of the py-3-n 
surfactants, docking simulations were carried out in a collaboration project with Dr. Praveen 
Nekkar Rao and his Msc. Student, Sarabjeet Singh. The docked poses obtained were ranked 
based on CDOCKER energy and CDOCKER interaction energies in Kcal mol-1and the type of 
polar and nonpolar interactions observed between adjacent surfactants were analyzed. The 
results of the studies indicate that pi-pi stacking interactions between pyrene rings on adjacent 
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py-3-8 surfactant molecules was the most favored type interaction occurring between the 
molecules (Figure 3.6A). It was also observed that pi-pi cation and pi-sigma stacking interactions 
occurred (Figure 3.6B) and these interactions gave the most stable biomolecular complex. 
Similar results were obtained for each of the py-3-n surfactants, although the tendency for self-
aggregation within a single surfactant molecule increases as the alkyl chain length increases as 
can be seen in the case of Py-3-18, where cation-pi and pi-sigma interactions were observed in 
Figure 3.7.  
 
                                          
Figure 3.6 Docking studies of interactions between two pyr-3-8 monomers. A) Pi-Pi interactions 
between two pyrene rings in tow monomers of pyr-3-8 surfactants. B) Pi-cation (yellow line) 
and Pi-sigma (purple) are other means of interactions 
 
Figure 3.7 Self-aggregation behavior of Pyr-3-18 in the presence of water  
 
A B 
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Figure 3.8 Variation of the logarithmic CMC as a function of alkyl tail length (determined by 
tensiometery), m3-m. (■), pyr-3-n (▲), 12-3-n (●) 
 
The minimum head group areas for the pyrenyl surfactants are also reported in Table. 3.2. The 
head group area can be calculated from the surface excess concentration according to equation 
2 below: 
a˳= (NAΓ)-1 (3.2) 
 
NA is Avogadro number 6.022 x 10
23, and Γi is the surface excess concentration calculated from 
the Gibb`s adsorption equation: 
 
Γi= (-1)/2.303nRT (dɣ/dlogC)T  (3.3) 
 In equation (3), R is the gas constant, T is the absolute temperature in Kelvin, ɣ is  the surface 
tension in mN.m-1, (dɣ/dlog C) is the slope of the linear part of the γ-logC plot and n is 3 for 
gemini surfactants, accounting for one dimeric ion and two monomeric counter ions. The head 
group areas (a˳) for the pyrenyl gemini surfactants are all smaller than that of their symmetrical 
counterparts.190 Increased asymmetry, enhances the hydrophobic intermolecular interactions, 
leading to lower CMC values and higher aggregation ability.190 Also, with longer hydrocarbon 
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tails, a˳ values decrease due to higher packing density at the air/water interface in comparison to 
their symmetrical counterparts. For pyr-3-18, although a˳ is higher than the previous surfactant 
pyr-3-16, it is still lower than that of its symmetrical counterpart 18-3-18198, similarly, the a˳ of 
pyr-3-14 is lower than that of 14-3-14.204 The non-existence of a trend to follow in the minimum 
head group area for the pyrene based surfactants with the increase in the alkyl tail stems from 
the presence of the pyrene rings in one of the alkyl tail, which hinders and limits the interaction 
with the other alkyl tail, depending on its length. These results contradict the reported data that 
indicates that a higher degree of asymmetry results in stronger interactions , leading to smaller 
head group areas, especially with small spacer as in our case; s = 3. The variations in head group 
areas of m-3-n surfactants, result from the packing of the hydrophobic tails at the air/water 
interface. The a˳ values decreased for the dissymmetric gemini surfactants in our studies, whether 
for pyr-3-n or for m-3-n surfactants compared to their symmetrical counterparts (m-3-m), which 
suggests the higher packing at the air/water interface due to greater dissymmetry of the tails. A 
trend was established for 12-3-n surfactants.  
For 12-3-14, 12-3-16, and 12-31-8, a˳ values are smaller than the a˳ values of their symmetrical 
counterpart.  As the hydrophobicity of the 12-3-n surfactants increase, the CMC values decrease, 
and the surfactants monomers favors adsorption at the air/water interface. This leads to higher 
degree of intermolecular interactions between the alkyl tails, resulting in smaller mean molecular 
area. However, the discrepancy found in the pyrenyl gemini surfactants was reported in other 
surfactants, such: phytanyl-3-m by Wang et al.105 The head group areas for both of phy-3-12, 
and phy-2-16 surfactants were smaller than those of 12-3-12, and 16-3-16 surfactants, 
respectively.105, 178 However, phy-3-18 was approximately 1.5 times that of 18-3-18 .141 The 
same trend of increasing a˳ despite the increase in the asymmetry was reported by Wang et al. 
when they tested the effect of dissymmetry of gemini surfactants in a non-aqueous solution; 
protic ionic liquid (EAN). For m-2-n surfactants, 16-2-8 minimum head group area was 67.6Å2 
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and 14-2-10 was 80.5 Å2, respectively. Both of these surfactants a˳ values are lower than their 
symmetrical counterpart 12-2-12199.  
Table 3.3 Values of symmetric and dissymmetric gemini surfactants head group areas (a˳) as 
reported in the literature 
Gemini surfactant Head group area (a˳) (nm2/mol) 
14-3-14 1.35 
18-3-18 1.28 
12-2-12 1.2 
Phy-3-12 0.78 
Phy-2-16 0.91 
Phy-3-18 1.92 
16-2-8 0.67 
14-2-10 0.81 
 
  
The shape of the micelles formed in solution plays a key role in determining the properties of 
gemini surfactants and how these GSs can be utilized in different industries. The packing 
parameter ˵P˶ of a surfactant describes the shape of the aggregates formed by a surfactant in 
aqueous solution, and can be calculated from: 
                                                                    P=v/a˳l                                                                                  (3.4) 
 
where v is the hydrophobic volume of a surfactant molecule calculated from Tanford’s equation  
and l is the length of the hydrocarbon tails (also calculated from Tanford’s equations) 205 
                                                             V=0.0274+0.0269n                                                                        (3.5) 
                                                             l=0.154+0.1265n                                                                             (3.6) 
The calculated values of the volume, length, and the packing parameter for the py-3-n are 
reported in Table 3.3 in Appendix A. The total volume of the hydrophobic tails is given by (v1 
+ v2) and the length of the hydrophobic group will be equal to the length of the longest tail. As 
seen in Table 3.3, as well as in the literature, aggregates formed by m-3-m gemini surfactants 
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tend to form cylindrical micelles with a P value of approximately 0.35 depending upon the alkyl 
tail length. The replacement of one of the tail group by a pyrenyl ring dramatically impacts the 
hydrophobic volume due to the bulkiness of the fused rings without impacting the overall length 
of the hydrophobic group except for the py-3-8 surfactant. This restricts the geometry of the 
system such that cylindrical, lamellar and inverted micelles are now the predicted favorable 
geometry. These different packing values are affected by the head group area as well. The head 
group areas of the pyrenyl surfactants showed no consistency whatsoever in the data obtained 
from the surface tension. In equations 3.5 and 3.6, n is the number of carbon atoms in the 
hydrocarbon tails of the surfactant. The packing parameter for the pyrene-3-n gemini surfactants 
is dramatically impacted by the presence of the bulky pyrenyl ring in the molecule. The 
aggregates shapes predicted by equation 3.4 are cylindrical (pyr-3-14), vesicles (pyr-3-16), 
inverted micelles (pyr-3-8), or lamellar (pyr-3-12 and pyr-3-18). This may be due to the presence 
of the bulky pyrene ring which adds to the hydrophobic volume, but not to the length of the 
tail.105 For 12-3-n surfactants, inverted micelles were formed. This is largely due to the small 
head group areas that were caused by tight packing at the air/water interface due to increased 
intermolecular hydrophobic interactions.  
3.2.3 Conductivity measurements 
 
The graphs of specific conductivity versus concentration of the pyrene-based gemini surfactants 
are plotted in Figures.3.9 (a, b, and c) and those of 12-3-n in Figures 3.10(a, b, and c). The CMCs 
for pyr-3-8 pyr-3-12, pyr-3-14, and pyr-3-16 obtained from the conductivity studies are in 
agreement with those obtained from tensiometry, and from the literature for pyr-3-12 at 25°C.109 
However, less agreement between those methods was obtained for pyr-3-18 with 
CMC=0.024mM in surface tension and 0.06mM in conductivity studies, which is common when 
comparing the results using different techniques to measure different properties in self-assembly 
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.105 CMCs for 12-3-14, 12-3-16, and 12-3-18 are in good agreement with those obtained from 
the surface tension measurements. Also, conductivity measurements of all of the surfactants were 
investigated at two different temperatures (303.15-308.15K). In conductivity studies, ҡ increases 
as C increases; however, the rate of increase in ҡ, relative to C, is different below and above the 
CMC. At low concentrations, surfactant molecules are completely ionized and above the CMC, 
only some of the counterions are bound to micelles, which causes a reduction in the effective 
charge of the micelle.140 Thus, the slope of ҡ vs C above the CMC is smaller than that below the 
CMC.  This came in agreement for all of the dissymmetric surfactants in the current study. The 
degree of micelle ionization parameter is defined as a fraction of an ionic surfactant’s counter 
ions that are dissociated from micelles, leaving the micelles charged.206 This parameter can be 
obtained from the ratio of A2/A1. Counterion binding increases with increasing alkyl tail length 
for an ionic surfactant,207 which means α decreases with the increased tail length for ionic 
surfactants. The trend has been attributed to the increased in micelle surface charge density on 
increasing tail length.  However, the degrees of micelle ionization are higher for pyrenyl 
surfactants compared to m-3-m surfactants, despite having low CMC values. Higher α values 
correspond to greater degree of dissociation of the counter ions from the surface of the micelles. 
Why these dissymmetric gemini surfactants behave differently from what is generally reported 
in the literature is still unknown. With higher α, the repulsive forces between the partially charged 
micelles will play greater role in the aggregate structures within the micelles. The pyrenyl 
surfactants also exhibit a strong upward curvature in the plot of қ vs. C in the region of the CMC, 
which is an indication of the presence of premicellar aggregates formation108. Similar behavior 
was observed for 12-3-n surfactants. The same behavior was reported in phytanyl-3-n gemini 
surfactants. Phy-3-16 α value was 0.67 and phy-3-12 was 0.46105.  
Wang et al. synthesized a series of dissymmetric gemini surfactants, designated as CmC6Cn 
(m+n=24). They found that CMC decreases with the increase in the asymmetry and α values 
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decrease as a result of higher packing of the head groups and the higher charge density at the 
micelle/solution interface.140 In a series of 12-s-12 with s = 2, 3, and 4, Menger et al. concluded 
that α values increase with the increase in the spacer length and this is probably due to increase 
in the space between the head groups, which leads to an increase in the degree of micelle 
ionization and the binding of Br- to the micelle in solution.208  The CMC values decreased with 
the increase of the alkyl tail length, and the increase in the temperature as can be seen in Figures 
3.9 and Figure 3.10. The decrease in the CMC with the increase in the temperature is a 
consequence of the decreased hydrophilicity of the surfactants molecules and reduction of 
hydration, which favors micellization. Also, the increase in temperature breaks down the 
structured water surrounding the hydrophobic groups,209 which means that the process of 
removing an alkyl tail from the water is endothermic210. With the increase in the temperature, 
the dissociation of the bound counterions increases, and α values increase. In pyrene-based 
surfactants, the highest α values were reported at 30ºC, then for some of the surfactants, the 
values either decreases or increases. This inconsistency may be attributed to the arrangement of 
the pyrene within the surfactants in the micelles. Pyrene bulky structure affect the assembly of 
the surfactant monomers into the micelle, and according to the length of the alkyl tail, the 
interaction can be either tight or loose, which can impact the structure of the micelle, and the 
binding of the counter-ions. Pyr-3-8 α values increased with the increase in the temperature 
(α25ºC= 0.42±0.01, α30ºC=0.72±0.007, and α35ºC= 0.74), but pyr-3-14 α values decreased (0.67 at 
25ºC to 0.54, and 0.56 at 30ºC, and 35ºC, respectively). The same trend was observed for 12-3-
n gemini surfactants with the highest α values at 30Cº. The increase in the temperature favors 
micellization as can be noticed from the CMC values for all of the surfactants. Data of both CMC 
and α values are reported in Table 3.4.  
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Table 3.4 Critical micelle concentration (CMC), and the degree of micelle ionization values (α) 
obtained from the conductivity measurements at three different temperatures (25°C, 30°C, and 
35°C) 
Temperature (°C) Surfactant CMC(mM) α 
25°C Pyr-3-8 0.13 ± 0.007 0. 42 ± 0.01 
Pyr-3-12 0.16 ± 0.007 0.61 ± 0.00 
Pyr-3-14 0.16 ± 0.028 0.67 ± 0.02 
Pyr-3-16 0.13 ± 0.002 0.61 ± 0.02 
Pyr-3-18 0.06 ± 0.014 0.57 ± 0.01 
12-3-14 0.34 ± 0.070 0.28 ± 0.00 
12-3-16 0.18 ± 0.020 0.39 ± 0.02 
12-3-18 0.18 ± 0.020 0.44 ± 0.02 
30°C Pyr-3-8 0.12 ± 0.002 0.072 ± 0.00 
Pyr-3-12 0.16 ± 0.007 0.78 ± 0.00 
Pyr-3-14 0.08 ± 0.007 0.54 ± 0.04 
Pyr-3-16 0.12 ± 0.001 0.79 ± 0.01 
Pyr-3-18 0.04 ± 0.007 0.53 ± 0.04 
12-3-14 0.25 ± 0.141 0.38 ± 0.00 
12-3-16 0.18 ± 0.007 0.49 ± 0.141 
12-3-18 0.18 ± 0.002 0.49 ± 0.00 
35°C Pyr-3-8 0.10± 0.000 0.74 ± 0.00 
Pyr-3-12 0.12 ± 0.000 0.73 ± 0.00 
Pyr-3-14 0.05 ± 0.000 0.56 ± 0.00 
Pyr-3-16 0.09 ± 0.000 0.6 ± 0.00 
Pyr-3-18 0.04 ± 0.000 0.66 ± 0.00 
12-3-14 0.23 ± 0.000 0.23 ± 0.03 
12-3-16 0.17 ± 0.000 0.44 ± 0.00 
12-3-18 0.16 ± 0.000 0.46 ± 0.00 
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Figure 3.9.A Specific conductivity (ҡ) –concentration (C) studies for pyrene-based gemini 
surfactants at 25°C. The    CMC is represented by the intersection of two lines below and above 
the CMC. The experimental data is listed in Appendix B 
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Figure 3.9B Specific conductivity (ҡ) –concentration (C) studies of pyrene-based gemini 
surfactants at 30°C.The CMC is represented by the intersection of two lines below and above the 
CMC 
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Figure 3.9C Specific conductivity (ҡ) –concentration (C) studies for pyrene-based gemini 
surfactants at 35°C. The CMC is represented by the intersection of two lines below and above 
the CMC 
 
 
 
Figure 3.10A Specific conductivity (ҡ) -concentration (C) studies of 12-3-n gemini surfactants 
at 25°C. The CMC is represented by the intersection of two lines below and above the CMC 
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Figure 3.10B Specific conductivity (ҡ) –concentration (C) studies of 12-3-n gemini surfactants 
at 30°C.The CMC is represented by the intersection of two lines below and above the CMC 
 
 
Figure 3.10C Specific conductivity (ҡ) -concentration (C) studies of 12-3-n gemini surfactants 
at 35°C. The CMC is represented by the intersection of two lines below and above the CMC 
The thermodynamic parameters of the micellization process of the pyrene-based surfactants and 
the 12-3-n gemini surfactants were calculated by applying the pseudo-phase separation model 
for ionic surfactants according to: 
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ΔGm°=2(1-α)RTlnXcmc   211                                                                                                                       (3.7)         
where α is the degree of micelle ionization, which was obtained from the ratio of the two slopes 
of the two regions in the conductivity-concentration plot ,and Xcmc is the molar fraction at the 
CMC, Xcmc= CMC/55.4, 55.4M+ CMC moles of water/L at 25ºC. Table 3.4 presents all the 
thermodynamic parameters of micellization of the dissymmetric gemini surfactants at different 
temperatures. For the pyrenyl surfactants, the results show that at a certain temperature, as the 
m/n ratio increases, ∆Gmº values become more negative and this implies the spontaneity of the 
aggregation process, also ∆Gmº increases for the same surfactant at different temperatures, which 
lead to lower CMC. The higher the temperature, the lower the CMC with the increased 
hydrophobicity as a result of increased alkyl tail length. However, the process of micellization 
is entropy driven as ∆Hmº is positive throughout the pyrenyl and the asymmetrical surfactants as 
well and this means that the removal of a surfactant tail from the water into the core is 
endothermic.   
In the asymmetric gemini surfactants, ∆Gm° values were decreasing from 12-3-14 to 12-3-18 at 
a specific temperature, which suggests that the addition of one methylene unit to one tail requires 
energy. This might be attributed to the increase in the disorder of the solution, leading to a 
decrease in ∆Gm°. This was confirmed by the plot of the variation of (∆Gm° (CH2)) with the 
degree of dissymmetry m/n, which shows the relationship between the Gibbs free energy per 
mole of CH2 (∆Gm° (CH2)) with the degree of the dissymmetry (see Figure 3.11) In the pyrenyl 
surfactants, as the m/n increases, the ∆Gm° becomes more negative, which favors the aggregation 
led by the hydrophobic interactions. Values of |T∆Sºm| for all of the asymmetric gemini 
surfactants in this study were higher than those of |∆Hºm|, which again suggests that the 
aggregation process of these surfactants is entropy-driven.140 However, when comparing the 
dissymmetric gemini surfactants to the pyrenyl surfactants, we notice that ∆Gºm of 12-3-14 > 
pyr-3-14, 12-3-16 > pyr-3-16, and 12-3-18>pyr-3-18 at the same temperature, although the 
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latter`s difference is not that significant as those of 12-3-14 and 12-3-16. This suggests that 
substituting an alkyl tail with hexyl pyrene requires more energy due to the geometric restraints 
created by the aromatic pyrene.  The values of the thermodynamic parameters at different 
temperatures is enlisted in Table 3.5. 
Table 3.5 Gibbs free energy of micellization (∆Gm°), enthalpy of micellization (ΔHm°), and the 
entropy of micellization (ΔSm°) of pyrene-based gemini surfactants and 12-3-n surfactants at 
different temperatures 
Temperature Surfactant ∆Gºm (KJ.mol-1) ΔHm°(KJ.mol-1) ΔSm°(KJ.K-1.mol-1) TΔS 
298.15K 
Pyr-3-8 -49.24 34.72 0.28 83.96 
Pyr-3-12 -56.27 17.00 0.25 73.27 
Pyr-3-14 -52.64 81.26 0.45 133.90 
Pyr-3-16 -57.11 27.50 0.28 84.61 
Pyr-3-18 -64.00 31.80 0.32 95.80 
12-3-14 -72.55 28.81 0.34 101.36 
12-3-16 -69.57 3.47 0.24 73.04 
12-3-18 -66.39 8.35 0.25 74.74 
12-3-12 -70.00 
 14-3-14 -78.32 
    303.15k 
Pyr-3-8 -51.10 35.89 0.29 86.99 
Pyr-3-12 -46.36 17.56 0.21 64.00 
Pyr-3-14 -65.25 84.00 0.49 149.26 
Pyr-3-16 -46.86 28.41 0.25 75.27 
Pyr-3-18 -68.91 32.91 0.33 101.82 
12-3-14 -69.50 29.78 0.32 99.28 
12-3-16 -64.88 3.74 0.23 68.62 
12-3-18 -64.31 8.63 0.24 72.94 
 
Pyr-3-8 -51.50 37.10 0.29 88.59 
Pyr-3-12 -51.23 18.15 0.23 69.40 
Pyr-3-14 -67.013 86.80 0.5 153.80 
Pyr-3-16 -61.00 29.35 0.29 90.35 
Pyr-3-18 -61.10 34.00 0.31 95.10 
12-3-14 -66.63 30.77 0.31 97.40 
12-3-16 -68.85 3.70 0.24 72.56 
12-3-18 -67.91 8.92 0.25 76.83 
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Figure 3.11 The variation of the free of micellization (∆Gºm(CH2)) with the degree of 
dissymmetry m/n from the conductivity studies of Pyr-3-n (▲), and 12-3-n (●) 
 
3.3 Conclusion 
The pyrene-based gemini surfactants, pyr-3-n, (n=8, 12, 14, 16, and 18), and the dissymmetric 
gemini surfactants, 12-3-n, n= (14, 16, 18) were synthesized, The aggregation properties of these 
surfactants were characterized. The Krafft temperatures of pyrene-3-n and 12-3-n increased with 
the increase in the alkyl tail length. This finding follows the general observations with all other 
gemini surfactants.212 Pyr-3-n and 12-3-n showed much lower CMC values than those of their 
symmetrical counterparts. This is due to increased hydrophobicity of the pyrene-3-n surfactants, 
and due to the dissymmetry of the 12-3-n surfactants, which imparts unique properties on the 
gemini surfactants. The docking studies showed that the first interaction happening in the pyr-3-
n surfactants is the pyrene-pyrene interactions, and this may cause the initiation of the micelle 
formation start at a very high surface pressure. The pyrene is included as a guest molecule into 
the micelle.  The higher degrees of micellization were also observed in both of the groups, the 
pyrenyl surfactants and the dissymmetric ones. The higher the α, the easier the binding of the 
DNA as it replaces the counter ions to reduce the repulsive attraction forces between the two 
head groups.  Head group areas are smaller in pyrene-based surfactants than those of the 
symmetrical counterparts, indicating enhanced intermolecular hydrophobic interaction, which 
results in smaller a˳. However, pyrene-3-14 has a relatively larger head group area. This may be 
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caused by the asymmetry effect appearing at this surfactant, because before that pyr-3-12 is close 
to symmetry and pyr-3-8 has very low surface tension due to their high solubility in aqueous 
phase. The packing parameter is calculated for the pyr-3-n and 12-3-n compounds are indicative 
of the formation of various morphologies, especially in the pyr-3-n surfactants. Pyr-3-8 form 
inverted micelles, whereas pyr-3-14 forms cylindrical micelles, pyr-3-16 forms vesicles and pyr-
3-12 and pyr-3-18 form lamellar. Both vesicles and inverted micelles have been linked to better 
transfection results in the literature.  
These key parameters such as low CMC values, small head group area (a˳), and high α values 
indicate that these surfactants, at lower concentrations, they can form micelles of various 
morphologies in solutions and they are capable of easily binding and electrostatically interacting 
with DNA in order to decrease the repulsive interactions between the head group area. These 
properties favors the complexation and formation of nanoparticles of relatively small size with 
DNA, which means a possibility for a better transfection vector and possibly yielding a better 
transfection efficiency. 
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Chapter 4 Characterization of the Gemini Surfactant-DNA complexes  
Langmuir-Blodgett (LB) and Brewster`s Angle Microscopy (BAM) 
 
4.1 Introduction 
 
As previously mentioned in Chapter I, one of the most interesting applications of gemini 
surfactants is as non-viral gene delivery vectors.135,34 Transfection using a non-viral vector is not 
as efficient as the viral vectors, which also highly dependent on the type of cell line being 
transfected (for in vitro studies), the structure of the compounds used in the formulation of the 
vectors (more specifically the type(s) of modifications implemented in the structure of the vector 
component), the types of helper lipids used, the morphologies the resulting complexes adopt in 
solution, and the duration of post-transfection (time for transgene expression), which depends 
on the surfactant`s structure as well as the cell-line used in the experiment. Moreover, 
transfection complex surface charge and size can play essential roles, it has been extensively 
discussed in the literature,213,214 although a specific correlation to surfactant structure has 
remained quite elusive.  
     In our study of gemini surfactant based non-viral transfection vectors, the impact of gemini 
surfactants, and the complete gemini surfactant transfection complex on model membranes of 
both healthy and cancerous cells are being investigated, prior to attempting in vitro transfection 
studies. The aim of this investigation is to better understand the mode of interaction between the 
molecules of the monolayer, usually zwetterionic lipids, and the gemini surfactants and the 
resulting transfection complexes, In addition, this study can give us insight into how the gemini 
surfactant-DNA complexes can escape the endosomal membrane. The Langmuir-Blodgett (LB) 
monolayer method is a technique that allows the preparation of monolayers (as model 
membranes) in a two dimensional system by spreading phospholipids ( in our case either 
DPPC/Cholesterol or POPC/Cholesterol at a ratio of 75%_25% at the air-water interface).145  
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Surface pressure – molecular area isotherms can be collected, and analyzed to determine the 
phase behaviour of the lipids within the monolayer as a function of surface pressure. This method 
also offers a unique opportunity to investigate the nature and possible interactions between these 
monolayers and different molecules146 by combining the Langmuir trough with the Brewster 
Angle Microscope. The BAM instrumentation allows high resolution and real-time imaging of 
monolayers, and this allows a molecular-level understanding of the interactions between the 
components of the monolayer together with the components of the sub-phase.  This is necessary 
because the lipid compositions of cell membranes and tissues vary based on the organ or the 
tissues of origin. The lipid compositions alter the biophysical interactions, this knowledge led to 
the development of target-specific drugs and drug delivery systems.145  
In the current study, the eight synthesized gemini surfactants` monolayers alone, with two 
different lipid systems; DPPC/Cholesterol, and POPC/Cholesterol at 75%_25% ratio, and with 
the DNA in the sub-phase was investigated and images of the topography formed at different 
surface pressure were taken by BAM with a CCD camera embedded in the system.  Several 
projects within our lab are investigating the interactions between different cationic moieties with 
DNA  employing Langmuir monolayer with the BAM technique as non-viral gene delivery 
vehicle to assess the interactions, and whether or not certain components can enhance 
transfection or not143. Although transfection with gemini surfactants alone or with helper lipids 
have been investigated in numerous cell lines, model membranes have not been implemented to 
access the mode of interactions at the cell membrane level. However, drug targeting model 
membranes have been characterized using Langmuir monolayer in several studies. Wnetrzak et 
al. investigated the interaction of alkylphosphocholines (APCs), which are antineoplasmic 
selective moiety, with three individual model membranes; cholesterol, DPPC, and POPC.150b 
DPPC and POPC are the most abundant phospholipids, both in healthy and cancerous tissues 
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(Leukaemia), and cholesterol was chosen because of its crucial role in regulating membrane 
physicochemical properties in eukaryotic cells.215   
4.2 Materials and Methods 
 
4.2.1 Materials 
 
Gemini surfactants pyr-3-8, pyr-3-12, pyr-3-14, pyr-3-16, pyr-3-18, 12-3-14, 12-3-16, and 12-3-
18 were synthesized and characterized as described in chapter 3 according to procedures 
previously reported in the literature. 109,192 The degree of purity was determined by using 1H 
NMR and surface tension measurements. 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (POPC), and cholesterol was purchased 
from Avanti Polar Lipids (Alabaster, USA). Double-stranded salmon sperm DNA (Sigma-
Aldrich, Oakville, Canada) was used without further purification. Chloroform was obtained from 
Sigma-Aldrich (Oakville, Canada). 
4.2.2 Preparation of Langmuir monolayer 
 
Surfactants, lipids, and mixtures were dissolved in chloroform at a concentration of 2.5 mmol/L. 
A salmon sperm DNA stock solution was prepared by dissolving DNA in Millipore-Q a 
concentration of 100 mg/L. The final concentration of DNA in all the monolayer experiments 
was 0.2 mg/mL. Monolayers were prepared on a large (14.5 cm by 53 cm) Langmuir trough 
(KSV Instruments, Helsinki, Finland), with surface pressure monitored using the Wilhelmy plate 
method. A volume of 20 μL of surfactant and/or lipid solution was carefully deposited onto the 
surface of the sub-phase using a micro-syringe (GASTIGHT®, Hamilton-Bonaduz, Schweiz, 
Switzerland) and the chloroform. For experiments that involved only water as the sub-phase, the 
monolayer was allowed to equilibrate for 10 minutes. For experiments involving aqueous DNA 
(0.2mg/mL) as a sub-phase, the sub-phase was given 30 minutes to equilibrate with DNA prior 
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to the addition of the surfactant or lipids, and an additional 30 minute equilibration time was 
allowed for the monolayer after deposition of the surfactant and/or lipids. After equilibration, 
compressions of the monolayers on the trough were carried out at a rate of 15 mm/min. and the 
surface pressure – mean molecular area isotherms were collected.143  When DNA and the gemini 
surfactants (2.5 mM) were dissolved in the sub-phase, the DNA was added first with 30 minutes 
equilibration, followed by the addition of gemini surfactant and additional 10 minute 
equilibration to allow interactions between the DNA and the GS to occur. Isotherms and BAM 
images of monolayers prepared from the gemini surfactants (in the absence or presence of DNA), 
as well as for monolayers of DPPC/Chol or POPC/Chol (as model membranes) in the absence 
or presence of the gemini surfactants or the gemini surfactant/DNA complexes. 
4.2.3 Brewster`s Angle Microscopy (BAM) 
 
The Langmuir trough is equipped with a Brewster angle microscope (BAM) (KSV Instruments, 
Helsinki, Finland). The BAM consists of a standard He-Ne laser used as a light source with a 
power of 50 mW, wave length of 658 nm and a spatial resolution of the device was 2 μm. Briefly 
the p-polarized light is reflected at the air/water interface, and monitored at the Brewster angle 
(~53.1o) using a CCD camera that can capture either images or real-time video of the monolayer. 
4.3 Analysis of Surface pressure-Area isotherms (π-A)  
 
The surface pressure-area isotherms obtained for the Langmuir monolayers were used, along 
with the compressibility modulus (CS
-1), to determine the phase behavior of the monolayer. The 
compressibility modulus is calculated from the following equation: 
                                                      CS
-1= -A(δπ/δA)T                                                                4.1 
where A is the molecular area at a certain surface pressure π. Several parameters can be derived 
from the π-A isotherm, such as; the molecular area at collapse (AC), the collapse pressure (πc), 
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the lift-off area (AL), and the limiting area or the minimum cross-sectional area (A∞). The lift-
off area (AL) is the molecular area at which the isotherm starts rising above the baseline, and 
provides insight into the molecular orientation at the gas-liquid phase region.216 The limiting area 
or the minimum cross-sectional area (A∞) is the area occupied by the molecules within the 
monolayer, prior to collapse, can be calculated by extrapolation of the isotherm at the steepest 
slope prior to the collapse back to the zero surface pressure.148  
     As mentioned earlier, the compressibility modulus provides information regarding the phase 
behavior of the monolayer. For values of CS
-1<12.50mN/m, the monolayer is in the gaseous 
phase, at a CS
-1 =12.5-50mN/m, the monolayer is in the gas-liquid phase, and for CS
-1 =50-
100mN/m, the monolayer is in a liquid expanded phase, for values of 100-150mN/m, the 
monolayer is in the liquid expanded-liquid condensed coexistence, for values of > 150-
250mN/m, the monolayer is in the liquid condensed phase, and for values of CS
-1 above 
250mNn/m, the monolayer is in the solid phase. As CS
-1 value becomes higher, this is an 
indication of the stability of the monolayer, corresponding to a less elastic membrane 
4.4 Results and discussion  
 
While the model membranes in this work are comprised of 75% DPPC or POPC and 25% 
cholesterol, in order to understand the isotherms of the mixed lipid monolayer, an examination 
of the isotherms of each component is of a great importance. Our group has previously 
characterized the behavior of monolayers prepared from pure cholesterol, DPPC, or POPC.143 
Pure cholesterol forms a typical condensed monolayer with liftoff areas of ~43.2Å2 with a 
collapse pressure of the monolayer of ~45 mN/m, and the minimum cross sectional area for 
cholesterol in the monolayer is 34.4 Å2 /molecule. 143 All of the parameters determined in our 
lab for the cholesterol monolayers are consistent with the results described in the literature217,218 
(See Appendix B). Cholesterol forms a condensed monolayer in which molecules arrange 
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themselves in a vertical position or slightly tilted towards the surface. DPPC exhibits a 
characteristic transition region (at π= 5 mN/m), corresponding to orientation changes of 
molecules upon compression, with a minimum cross-sectional area of 60.2Å2 and collapses at a 
surface pressure of 53.3 mN/m (see Appendix B). POPC forms a liquid-expanded monolayer 
without any visible transition throughout the isotherm (see Appendix B), with a minimum cross-
sectional area of 75Å2, with a lower collapse pressure (~40 mN/m) compared to the saturated 
phospholipid (DPPC) .150b  When a small fraction of cholesterol is added to the DPPC or POPC 
monolayers, it profoundly alters the morphology of phospholipid monolayers. Cholesterol forms 
distinctive domains and lowers surface viscosity by orders of magnitude. Introducing cholesterol 
to DPPC monolayer can alter the rheology and isotherm, suggesting fundamentally different 
molecular organization.219 Cholesterol increased the rigidity of the system once it was added to 
it and reduce permeability, however, in the DPPC/Cholesterol, at biological surface pressure (30-
35mN/m), at pH = 7, the monolayer is found in the solid phase (S).143 
4.4.1 Langmuir isotherms of pyrene-based Gemini surfactants 
 
The Langmuir monolayer studies of the pyrenyl and the 12-3-n gemini surfactants were carried 
out at room temperature in Millipore milli Q water. These isotherms are illustrated in Figures 
4.1 to 4.8 and the parameters derived from the surface pressure-area isotherms are listed in Tables 
4.1 and 4.2 for both types of model monolayers; DPPC-Cholesterol, and POPC-Cholesterol. To 
gain a better insight into the interactions, we have injected the surfactant systems into the sub-
phase (with or without DNA), mixed them and subsequently spread the DPPC-Cholesterol, or 
POPC-Cholesterol model membrane monolayers on top of the sub-phase that now contains the 
complete gene delivery system. Many researchers have used the DPPC-cholesterol based system 
to evaluate drug-membrane interactions,220 and phospholipid-model membrane interactions.150b 
Since the surface pressure of the actual cell membrane ranges from 30-35 mN/m,218 we will be 
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focusing on this surface pressure range along with the detailed analyses of the isotherms 
presented below. 
 For pyrenyl gemini surfactants, the monolayers of these surfactants alone at the air/water 
interface, whether for pyrene-3-8 with the shortest tail, or for pyrene-3-18 with the longest tail, 
are enlisted in Table 4.1. All the pyrenyl gemini surfactants when spread as monolayers were 
soluble and they submerged in the sub-phase. None of these surfactants formed a monolayer that 
could be characterized by an isotherm (the πC of pyr-3-8 was 0.25mN/m and the highest was that 
of pyr-3-18 with a collapse pressure of 1.7mN/m). This can be attributed to the very low CMC 
values of these surfactants, favoring micelle formation, and thus disillusion of these surfactants 
occurred in the bulk aqueous phase as micelles, rather than adsorbing to the interface. Similar 
results were reported for the 12-6-12 gemini surfactants, which showed no surface pressure 
change at the air/water interface despite the compression of a monolayer.221   
The π-A isotherms for the model membrane monolayers show that the addition of the 
pyrenyl gemini surfactants (either with or without DNA) has a dramatic effect on the monolayer 
properties. DPPC-Cholesterol monolayer`s lift-off area is 56.48Å2 (see Figure 4.1 and Table 
4.1). After the addition of pyrene-3-8, the lift-off area increased up to 98 Å2. This is indicative 
of high abundance of gemini surfactant molecules at the interface and strong attraction between 
the GS and the monolayer (hydrophobic interactions between the octyl tail and the DPPC alkyl 
tails, the hexyl tail of the hexyl pyrene with the DPPC, and may be electrostatic interactions 
between the positive charge of the ammonium head groups and the negative charge of the 
phosphate group). These molecules assemble in the spaces between the monolayers particles at 
a low surface pressure. This effect can also be observed in the compressibility modulus below 
surface pressure of 20mN/m (Figure 4.1B). As the compression increases, gemini surfactant 
molecules are squeezed out of the monolayer and back into the bulk, restoring the compressibility 
modulus to values comparable to those for DPPC-Chol monolayer alone (Figure 4.1B). Based 
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upon both the apparent slope/shape of the π-A isotherm (Figure 4.1A), the values obtained for 
the compressibility modulus (Figure 4.1B), the DPPC-Chol monolayer exhibited an LE phase, 
as opposed to the solid phase formed by DPPC-Chol alone in the presence of pyr-3-8 at a surface 
pressure ranging from approximately 20mN/m-40mN/m. At 40mN/m, the monolayer exhibits a 
phase transition from LE-LC phase with a compressibility modulus rising up to 150mN/m. The 
monolayer stayed in the LC phase until the collapse at a surface pressure (πc) of 53.021 mN/m 
and with a collapse area (Ac) of 46.71Å
2 (see Table 4.1). 
 
 
Figure 4.1: Compression isotherms (π-A) for A) DPPC/Cholesterol (75%/25%, black line) and 
C) POPC/Cholesterol (75%/25%, black line) monolayers treated with: pyrene-3-8 (grey), py-3-
8:DNA at a 10:1charge ratio (green), py3-8:DNA at a 5:1 charge ratio (Purple).   Compressibility 
modulus (CS
-1) as a function of surface pressure (π)  for B) DPPC/Cholesterol and D) 
POPC/Cholesterol (75%/25%, black line) were calculated according to Equation 4.1; the line 
colors correspond to the same treatments described for A) and C). 
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Table 4.1 Monolayer properties for the DPPC/Chol (75/25) and POPC/Chol (75/25) monolayers 
at 20°C treated with py-3-m or py-3-m/DNA complexes 
System 
AL 
(Å2) 
A∞ 
(Å2) 
AC 
(Å2) 
πC 
(Å2) 
CS-130 
(mN/m) 
CS-135 
(mN/m) 
DPPC (75%)/Chol (25%) 61 44.0 36.7 50.7 255 275 
POPC (75%)/Chol (25%) 121 70.0 47.2 40.6 58 ± 3 56 ± 3 
Pyrene-3-8 
Py-3-8 - DPPC/Chol 98 75.0 46.7 53.0 146 192 
10:1 Py-3-8:DNA - DPPC/Chol 100 74.0 45.3 43.2 63 ± 7 92 
5:1 Py-3-8:DNA - DPPC/Chol 109 50.8 32.1 50.2 58 75 
Py-3-8 - POPC/Chol 255 158 95.8 47.2 81 ± 5 89 ± 8 
10:1 Py-3-8:DNA - POPC/Chol 167 115 68.2 43.9 76 86 
5:1 Py-3-8:DNA - POPC/Chol 160 99.8 58.0 42.3 62 74 
Pyrene-3-12 
Py-3-12 - DPPC/Chol 150 130 101 49.5 332 243 
10:1 Py-3-12:DNA - DPPC/Chol 225 175 119 50.9 118 142 
5:1 Py-3-12:DNA - DPPC/Chol 245 175 117 50.8 109 128 
Py-3-12 - POPC/Chol 145 100 52.6 40.5 69 75 
10:1 Py-3-12:DNA - POPC/Chol 200 110 55.1 39.6 52 41 
5:1 Py-3-12:DNA - POPC/Chol 200 110 56.5 39.8 42 48 
Pyrene-3-14 
Py-3-14 - DPPC/Chol 103 76.0 45.8 52.5 143 175 
10:1 Py-3-14:DNA - DPPC/Chol 153 80.0 39.0 50.3 69 63 
5:1 Py-3-14:DNA - DPPC/Chol 120 53.1 24.7 49.4 58 62 
Py-3-14 - POPC/Chol >255 180 119 47.1 90 108 
10:1 Py-3-14:DNA - POPC/Chol 225 127 66.2 39.6 53 47 
5:1 Py-3-14:DNA - POPC/Chol 250 135 68.4 39.4 49 50 
Pyrene-3-16 
Py-3-16 - DPPC/Chol 69.1 57.0 32.1 45.6 78 128 
10:1 Py-3-16:DNA - DPPC/Chol 124 66.0 34.6 51.1 89  90 ± 3 
5:1 Py-3-16:DNA - DPPC/Chol 93.4 61.4 34.0 44.3 73 ± 2 77 ± 8 
Py-3-16 - POPC/Chol 150 85.2 54.0 45.2 67 80 
10:1 Py-3-16:DNA - POPC/Chol 162 119 58.1 44.2 46 54 
5:1 Py-3-16:DNA - POPC/Chol 183 107 62.8 40.3 40 48 
Pyrene-3-18 
Py-3-18 - DPPC/Chol 65.4 53.1 33.4 44.3 104 142 
10:1 Py-3-18:DNA - DPPC/Chol 68.3 60.1 32.4 41.4 65 ± 3 83 ± 5 
5:1 Py-3-18:DNA - DPPC/Chol 78.6 58.3 33.2 45.1 52 ± 5 69 
Py-3-18 - POPC/Chol 176 132 63.6 48.6 74 95 ± 4 
10:1 Py-3-18:DNA - POPC/Chol 177 127 47.5 43.6 60 64 
5:1 Py-3-18:DNA - POPC/Chol 179 126 48.5 43.6 60 34 
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When DNA is added to the DPPC-Cholesterol and py-3-8 system, at a 5:1 surfactant: DNA 
charge ratio, distinct differences in the monolayer behaviour are observed. A new phase 
transition can be seen in both π-A isotherm and the compressibility modulus, which can be 
attributed to result from electrostatic interactions between the DNA phosphate groups and the 
GS`s ammonium group. This transition is consistent with a G to LE transition, based upon the 
values observed for the compressibility modulus. As surface pressure continues to increase, a 
small plateau (or shoulder) is observed over a range of surface pressures from approximately 15 
– 20 mN/m, corresponding to a decrease in the compressibility modulus, which corresponds to 
an LE – LC co-existence region. As surface pressure continues to increase, the LC phase is 
observed, over a broad range of surface pressures of from 30-45mN/m.  
For the system containing DNA at a 10:1 gemini surfactant/DNA charge ratio, the sharp 
discontinuity observed in the π-A isotherm, corresponding to the onset of the LE – LC 
coexistence region, disappears; however, the compressibility modulus clearly shows similar 
phase behaviour. Different parameters, such as, AL, A∞ and AC also help characterize the 
monolayer. The AL values for DPPC/Chol monolayer in the presence of both py-3-8 and DNA 
at a charge ratio of 10:1 and 5:1 are 100Å2 and 109Å2, respectively (Table 4.1), and do not appear 
to differ from that observed for the DPPC-Chol monolayer treated with py-3-8 alone (98.1 Å2). 
The cross-sectional area (A∞) for the DPPC-Cholesterol monolayer is 61.1Å
2 in the absence of 
gemini surfactants or DNA, which increases to 75Å2 upon the addition of pyr-3-8. A slight 
decrease is observed for the addition of DNA at a 73.9 Å2 at a charge ratio of 10:1. A much 
greater decrease in A∞ value is seen with a further increase in the concentration of DNA at a 
charge ratio of 5:1 (50.8Å2). At this point, the limiting area is approximately equal to that for the 
monolayer in the absence of any added DNA and suggests the complete extraction of gemini 
surfactant from the monolayer, into DNA bound complexes.   
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However, if we compare the compressibility modulus for the monolayers treated with the 
GS:DNA at 10:1 and 5:1 ratios, the values of CS
-1 in the range of surface pressures from 30 – 40 
mN/m are more or less the same, and for both ratios at 30 mN/m, and 35 mN/m, there is a 
substantial reduction in the compressibility modulus, to approximately 75 – 95 mN/m (Table 
4.1), corresponding to an LE phase. This is indicative of very strong interactions and significant 
incorporation of either the GS alone or the GS-DNA complexes at higher surface pressures. The 
overall effect of pyrene-3-8 alone or with DNA is in fluidizing the monolayer, thus allowing 
molecules either to interact with the monolayer through hydrophobic interactions at the surface, 
or by incorporating the GS molecules within the monolayer. Several drugs have similarly been 
observed to have a fluidizing effect in the literature. Examples include paclitaxel,222 and 
prazosin223 with DPPC-Cholesterol membranes, hexadecylphosphocholine and 
erucylphosphocholine with POPC-cholesterol membranes,150b and toremifene with dipalmitoyl-
phosphatidyl-glycerol (DPPG) membranes.224 In all cases, the presence of the drug molecule 
substantially reduced the compressibility modulus of the pure model membrane, which was 
considered to be a result of the fluidizing effect of drug to the model membrane. 
In contrast to the very solid-like DPPC-Chol monolayer, the POPC-Cholesterol system 
is much more fluid with two distinctive phase transitions observed (Figure 4.1C); one at surface 
pressure of 0.8-25mN/m and the other at surface pressures ranging from 20-40mN/m. The first 
is a transition from a gaseous phase to a LE phase (with a compressibility modulus of 43 mN/m 
– 50 mN/m, see Figure 4.1D), the second phase transition is what appears to be from an LE to 
LE-LC coexistence phase (CS
-1 = 98 mN/m).  Just prior to collapse, it appears that there is a shift 
back into an LE phase, followed by collapse; however it is more likely that the onset of this “LE” 
phase is actually the point of monolayer collapse. The compressibility modulus plots (Figure 
4.1D) for the POPC-Chol system are much more informative for the identification of the phase 
behaviour of this monolayer, given the almost featureless shape of the π-A isotherm. When the 
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GS was added to the monolayer, the collapse surface pressure increased from 40mN/m to 47 
mN/m, which is an indication of increased stability of the monolayer. When the GS was added 
to the monolayer, which is an indication of increased stability of the monolayer.   When py-3-8 
or the py-3-8:DNA complexes were added to the POPC/Chol monolayer, the isotherms were 
shifted to higher molecular area, but retained essentially the same shape, further confirmed by 
the similarity of the compressibility modulus curves.  This indicates that while the addition of 
the surfactant or surfactant:DNA complexes did disrupt the monolayer, most likely due to some 
incorporation of these components into the monolayer (giving rise to the increase in molecular 
area), they did not have the same extent of disruptive impact as for the DPPC/Chol monolayers.  
Given the fact that the POPC/Chol monolayer is meant to be a model for a “diseased” cellular 
membrane, this has concerning implications for the effectiveness of these systems as delivery 
vectors. 
BAM images of the mixed DPPC-Cholesterol system, at low surface pressure (~0.27 to 
1.22 mN/m) where the monolayer is in the G-LE phase transition, show circular or ovoid 
domains.143 Upon compressing the monolayer, the LE phase transitions into the LC phase 
transition where blurred images are observed (Figure 4.1E). As the monolayer is further 
compressed and transitions into an S phase, the domains merge together and form a solid film 
(shown by the uniform grey background, with bright dots that likely correspond to domains rich 
in cholesterol). The same types of domains are observed for the DPPC/Cholesterol monolayer 
treated with py-3-8 (Figure 4.2). At low surface pressures of 0.2-1.6 mN/m, when the monolayer 
is in the G phase, the ovoid domains of the DPPC-Chol monolayer are again observed. Upon 
compression, during the G-LE phase transition, a grey background containing small bright 
domains are observed.  The bright domains likely correspond to areas that into which the gemini 
surfactant has been incorporated, possibly containing cholesterol, allowing a more homogenous 
monolayer to form overall, although given the compressibility modulus described above, one 
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that is more fluid in nature. The domains remained essentially unchanged, visually, during the 
remainder of the compression. 
 As the DNA is added (regardless of charge ratio) at low surface pressures ~0.1-0.2 
mN/m, distinct differences in the BAM images are observed (Figures 4.2). The different domains 
that corresponded to either DPPC or cholesterol rich domains can no longer be observed, and a 
more heterogeneous, less differentiated grey background is observed.   As the surface pressure 
is increased, and consistent with the isotherm data (above), the images become consistent with 
the LE-LC domain characterized by a uniform grey background with small bright domains 
distributed throughout.  Interestingly, there is a clear linear pattern to the bright domains 
observed for the image of the DPPC-Chol monolayer treated with py-3-8 at a surface pressure 
of 20 mN/m (Figure 4.2).  This could be a direct visualization of the DNA adsorbed at the 
interface; however it should be noted that this was not generally observed for all of our systems. 
For the POPC-Cholesterol system treated with py-3-8, due to the pre-existing fluidity of 
the POPC-Cholesterol system, no clear distinctive domains are observed, although a somewhat 
uniform distribution of small bright domains is already evident even at low surface pressures 
(Figure 4.2C).  As the compression increases, these small bright domains remain, and there are 
no further indications in the BAM images of any other phase transitions.  The BAM images for 
the POPC-Cholesterol monolayer treated with py-3-8/DNA (Figure 4.2D) shows comparable 
behaviour to that for the POPC-Cholesterol monolayer treated with the same system; however 
the bright domains appear even smaller, and more uniformly distributed, which may indicate that 
the py-3-8 surfactant is able to bridge between the POPC and cholesterol molecules as compared 
to the DPPC and Cholesterol molecules, giving rise to a more uniform, and more fluid 
monolayer, also consistent with the isotherm data, above. 
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Figure 4.2 BAM images for DPPC/Cholesterol and POPC/Cholesterol monolayers treated with 
py-3-8 gemini surfactant or py-3-8/DNA complexes. A) DPPC/Cholesterol treated with py-3-8, 
B) DPPC/Cholesterol treated with py-3-8/DNA (5:1 charge ratio), C) POPC/Cholesterol treated 
with py-3-8, D) POPC/Cholesterol treated with py-3-8/DNA (5:1 charge ratio) 
 
Pyrene-3-12 acts in the same way as pyrene-3-8 when it is spread on the surface of the 
trough, it cannot be compressed to form a monolayer (due to its solubility) and does not give an 
isotherm. When pyrene-3-12 was added to the sub-phase in the presence of DPPC-Cholesterol, 
the isotherm and compressibility modulus plots are very similar to that for the pure DPPC-Chol 
monolayer, although for the isotherm, it again has been shifted to much higher molecular areas 
(Figures 4.3A and B). The DPPC-Chol monolayer is predominantly found in the LC phase over 
most surface pressures, ranging from ~ 10 – 40 mN/m, as observed from the compressibility 
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modulus (Figure 4.3B).  Interestingly, as noted above, when treated with py-3-12, the π – A 
isotherm for the monolayer shifts to higher molecular areas, which suggests an expansion of the 
monolayer; however, the compressibility modulus over the same surface pressure range (~10 – 
30 mN/m) clearly indicates that the monolayer enters a solid phase in the presence of the py-3-
12.  The surfactant is clearly becoming incorporated into the DPPC/Cholesterol monolayer, and 
appears to enhance the rigidity of the monolayer, possibly by occupying gaps between DPPC 
and cholesterol.  The CS
-1 value at 30 mN/m showed increase in the compressibility modulus 
from 255mN/m for DPPC-Cholesterol alone to 332 mN/m when treated with pyr-3-12, and a 
slight decrease at 35mN/m from 274.6 mN/m 243.35 mN/m for pyrene-3-12/DPPC-Cholesterol 
system. This suggests that the system is becoming more rigid upon the addition of pyr-3-12 
despite the increase in the lift-off area from 61.6Å2 to 150Å2, which is higher than all of the 
DPPC-Cholesterol monolayers with pyrene-3-8 and DNA. The A∞ value for this system is 
130Å2 (compared to 75 Å2 for the untreated DPPC/Chol monolayer), indicative of the monolayer 
becoming more elastic due to incorporation of the py-3-12 molecules into the monolayer. Despite 
the incorporation of the pyrene-3-12 molecules in the monolayer, due to the unique structure of 
this surfactant in particular, whether for its bulkiness (the presence of pyrene and the presence 
of the dodecyl tail), or for symmetrical behavior (as described previously in chapter III), it 
appears to fit much better into the DPPC-Chol monolayer as compared to pyr-3-8. Because of 
the larger area occupied by the py-3-12 at the interface (as compared to either DPPC or 
cholesterol, this would lead to the observed increase in the lift-off area and the limiting area, 
giving rise to a false indication of fluidity of the monolayer.  It is much more likely that the 
increased rigidity indicated by the compressibility modulus more accurately reflects the structure 
of the DPPC-Chol monolayer upon treatment by py-3-12.   
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Figure 4.3 Compression isotherms (π-A) for A) DPPC/Cholesterol (75%/25%, black line) and 
C) POPC/Cholesterol (75%/25%, black line) monolayers treated with: pyrene-3-12 (grey), py-
3-12:DNA at a 10:1charge ratio (green), py3-12:DNA at a 5:1 charge ratio (Purple).   
Compressibility modulus (CS
-1) as a function of surface pressure (π)  for B) DPPC/Cholesterol 
and D) POPC/Cholesterol (75%/25%, black line) were calculated according to Equation 4.1; the 
line colors correspond to the same treatments described for A) and C). 
 
Upon the addition of DNA to the sub-phase containing pyr-3-12, as observed for the py-
3-8 systems, the presence of several new phases can be observed in the monolayer both in the π 
– A isotherms (Figure 4.4) and the compressibility modulus (Figure 4.2B). A key difference 
between the py-3-8 and py-3-12 systems is that for the py-3-8 systems, the addition of DNA had 
little effect on the observed lift off areas (98Å2 vs. 100Å2 or 108Å2).  For the py-3-12 systems, 
the addition of DNA results in a much more dramatic shift of the isotherms, giving rise to 
correspondingly larger lift off areas, i.e. 225Å2, and 245Å2 in the presence of DNA at 10:1 and 
5:1 charge ratios, respectively, vs. 150Å2 in the absence of DNA. The phases formed for the py-
3-12/DNA treated DPPC-Chol monolayers are similar to those for the py-3-8/DNA treated 
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monolayers; however, the transitions are much sharper, and much clearer evidence of the LE, 
LE-LC coexistence, and LC phase can be observed.  Again, the impact of added DNA is much 
stronger for the 5:1 charge ratio, as compared to the 10:1 charge ratio, due to the increased 
concentration of DNA. 
     While the addition of py-3-12 had a much greater impact on the DPPC-Chol monolayer as 
compared to the POPC monolayer (Figure 4.3A vs 4.1A), the reverse is true for the POPC-Chol 
monolayers, where py-3-12 appears to have less of an effect on these membranes (Figure 4.3C 
vs 4.1C).  The isotherm for the pyrene-3-12 treated POPC-Cholesterol monolayer is essentially 
the same shape as that for POPC-Cholesterol alone; with the exception of a small shift to higher 
molecular area, giving rise to a slightly larger lift off area (145Å2 vs 121Å2, Table 4.1) (see 
Figures 4.3C and 4.3D). The similarity of the compressibility modulus plot confirms this 
observation (Figure 4.3D). As for the DPPC-Chol monolayer, the addition of DNA to py-3-12 
again resulted in substantially more disruption to the POPC-Chol monolayer, as compared to the 
addition of py-3-12 alone. The same LE and LE-LC coexistence phases are observed; however, 
the compressibility modulus clearly indicates that the POPC-Chol monolayer (Figure 4.3D and 
Table 4.1) never enters a true LC phase.  These results suggest the py-3-12 is more disruptive to 
the disease model (POPC-Chol) membranes and a much greater potential for the py-3-12 
surfactant as a transfection vector. 
From the BAM images (see Figure 4.4)  for the DPPC/Chol monolayer in the presence 
of py-3-12, very different domains are observed compared to that seen for the py-3-8 surfactant, 
which likely arises from the decreased solubility of the py-3-12 surfactant in the bulk and an 
increased affinity for the interface. Circular and irregular bright domains are observed consistent 
with the transition from G to LE phase. As the surface pressure increases, the monolayer 
transitions from LE to the LE-LC and eventually the LC phase the monolayer becomes more 
compact as the domains become densely packed, and small bright domains are again observed. 
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As the monolayer finally transitions into the S phase no distinctive domains can be seen, which 
is suggestive of the homogeneity of the monolayer, and thus the increase of the rigidity of the 
system.  
As the DNA is added to the sub-phase of the pyrene-3-12 full system, irregular bright 
domains are observed, and as the surface pressure increases, the net-work like domains of DPPC-
Cholesterol are seen with bright circular (dots) domains found on top of these networks (within). 
The underlying structure of these domains could again be attributed to the adsorption of DNA at 
the interface, interacting with py-3-12 within the monolayer, although in this case, the linear 
structure seen for py-3-8/DNA and DPPC/Chol (Figure 4.2B at 20 mN/m) is not observed.  As 
surface pressure continues to increase, these irregular structure persist, and suggest a much 
stronger interaction with DNA at the interface; however the nature of this interaction is still 
somewhat unclear. For the POPC/Cholesterol monolayers in the presence of py-3-12 or py-3-
12/DNA, the BAM images were quite similar to those observed for POPC/Chol with py-3-8 or 
py-3-8/DNA (Figure 4.4C).  A grey homogeneous background is generally observed, again with 
small bright domains distributed uniformly throughout.  The irregular structure seen in the 
presence of py-3-12:DNA for the DPPC/Chol system is NOT observed with POPC/Chol, 
suggesting that the composition of the monolayer itself (namely DPPC) is important in defining 
the interaction(s) that occur at the interface, and that POPC, possibly due to its non-symmetric 
tails, is better able to accommodate the disruptive effect that the large DNA molecules have on 
the monolayer structure. 
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Figure 4.4 BAM images for DPPC/Cholesterol and POPC/Cholesterol monolayers treated with 
py-3-12 gemini surfactant or py-3-12/DNA complexes. A) DPPC/Cholesterol treated with py-3-
12, B) DPPC/Cholesterol treated with py-3-12/DNA (5:1 charge ratio), C) POPC/Cholesterol 
treated with py-3-12, D) POPC/Cholesterol treated with py-3-12/DNA (5:1 charge ratio) 
 
The π-A isotherm for the DPPC/Cholesterol monolayer in the presence of py-3-14 is 
shown in Figure 4.5A. As seen for the py-3-12 surfactant, the addition of py-3-14 shifts the 
isotherm to higher molecular areas, although not as high as for py-3-12, in fact the isotherms are 
more similar to those seen in the presence of py-3-8.  The lift off area in the presence of py-3-14 
is 103 Å2 compared to 150 Å2 observed in the presence of py-3-12 and the 98 Å2 seen in the 
presence of py-3-8, again suggesting that the effect of py3-14 is similar to that for py-3-8.  The 
cross-sectional areas also show the same trend (Table 4.1). Three phases can be observed in the 
compressibility modulus plot; the LE phase seen at very low surface pressures (0 to 2 mN/m), a 
very long LE-LC phase at surface pressures up ~ 15 – 20 mN/m and finally an LC phase that 
extends up to the point of collapse at surface pressures above 20 mN/m. The compressibility 
modulus decreases from 255.2mN/m for DPPC-Cholesterol monolayer alone  
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Figure 4.5 Compression isotherms (π-A) for A) DPPC/Cholesterol (75%/25%, black line) and 
C) POPC/Cholesterol (75%/25%, black line) monolayers treated with: pyrene-3-14 (grey), py-
3-14:DNA at a 10:1charge ratio (green), py3-14:DNA at a 5:1 charge ratio (Purple).   
Compressibility modulus (CS
-1) as a function of surface pressure (π)  for B) DPPC/Cholesterol 
and D) POPC/Cholesterol (75%/25%, black line) were calculated according to Equation 4.1; the 
line colors correspond to the same treatments described for A) and C). 
 
to 143mN/m for pyrene-3-14/DPPC-Cholesterol monolayer around surface pressure of 30mN/m, 
and another decrease around surface pressure of 35mN/m (from 274.6mN/m to 174.96mN/m), 
again comparable to the effect of py-3-8. As for py-3-8, it would seem, based upon the isotherms 
alone, that py-3-14 also does not appear to strongly interact with the DPPC/Chol monolayer, and 
despite the apparent increase in hydrophobicity, py-3-14 prefers to form micelles rather than 
incorporate into the monolayer as py-3-12 does.  The BAM images obtained for the DPPC/Chol 
monolayer treated with py-3-14 are consistent with this interpretation, although the size of the 
bright domains observed at a surface pressure of ~35 mN/m (Figure 4.6A) is increased relative 
to lower surface pressures, indicating some incorporation of py-3-14 into the monolayer. 
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Figure 4.6 BAM images for DPPC/Cholesterol and POPC/Cholesterol monolayers treated with 
py-3-14 gemini surfactant or py-3-14/DNA complexes. A) DPPC/Cholesterol treated with py-3-
14, B) DPPC/Cholesterol treated with py-3-14/DNA (5:1 charge ratio), C) POPC/Cholesterol 
treated with py-3-14, D) POPC/Cholesterol treated with py-3-14/DNA (5:1 charge ratio) 
 
When DNA is with py-3-14 in the sub-phase, the LE, LE-LC coexistence and LC phase 
are again clearly observed in the DPPC/Chol monolayer (Figure 4.5A).  The behaviour again 
appears to mirror that for the py-3-8, with small differences in the magnitudes of the molecular 
areas.  The py-3-14/DNA has a substantial disruptive effect on the structure of the monolayer, 
confirmed by the low compressibility modulus values seen in Figure 4.5B and Table 4.1.  This 
large disruptive effect is additionally confirmed from the BAM images for the monolayer treated 
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with py3-14:DNA.  As shown in Figure 4.6B, regardless of surface pressure, large networks of 
aggregates are observed, the assembly of which is most likely due to the interaction of the py-3-
14:DNA complexes at the interface.  The monolayer appears to be somewhat more uniform at a 
surface pressure of ~31 mN/m; however networked aggregates are still observed (lower right 
corner of the image at 31 mN/m in Figure 4.6B) as are dark, pinhole defects that correspond to 
holes in the monolayer.  
The presence of pyr-3-14 in the sub-phase of POPC/Cholesterol monolayer shifts the π – 
A isotherm to higher molecular areas (Figure 4.5C), also shown by the increase in the various 
area properties derived from the isotherm (see Table 4.1), although the monolayer remains 
essentially featureless. The compressibility modulus shows that the monolayer remains in an LE 
phase over a wide range of surface pressures (~ 2 – 20 mN/m); however it eventually enters and 
LC phase, with the py-3-14 increasing the compressibility modulus of the system, both at 
30mN/m, and 35mN/m (CS
-1
30 = 90 mN/m, and CS
-1
35 = 108 mN/m), increasing the rigidity of 
the POPC/Chol monolayer, likely due to integration of py-3-14 into the monolayer as a result of 
the hydrophobicity of the surfactant.  The BAM images (Figure 4.6 C) clearly show a change in 
the nature of the small bright domains with the monolayer becoming densely packed with a high 
abundance of the bright circular domains that seem to be growing in shape; this is consistent 
with incorporation of py-3-14 into the monolayer and the transition of the monolayer into the LC 
phase (Figure 4.6C, image at π ~ 18 mN/m). As the surface pressure continues to increase the 
small bright domains appear to be clustered on larger, grey circular domains that grow in size 
with further increases in π.  This highly ordered monolayer is consistent with the above 
discussion where the py-3-14 appears to increase the rigidity of the POPC/Chol monolayer.    
Upon addition of DNA (regardless of charge ratio), a significant disruption of the monolayer is 
again observed, greater than that observed with the DPPC/Chol monolayer, described above (see 
Figure 4.5C and D, as well as Table 4.1).  Multiple phases are observed in both the isotherm 
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(Figure 4.5C) and the compressibility modulus (Figure 4.5D); however all these were appearing 
in the LE or LE-LC coexistence region, again indicative of extensive disruption upon treatment 
with the py-3-14/DNA complexes.  This can also be observed from the BAM images (Figure 
4.6D), which still show small bright domains; however these are very randomly dispersed 
throughout the monolayer at low (0.24 mN/m) and intermediate (22 mN/m) surface pressures. 
The addition of py-3-16 or py-3-18 to the DPPC/Chol monolayer has very similar effects.  
Small increases in AL, A∞, and Ac are observed, with the increase being larger for py-3-16, 
compared to py-3-18 (Table 4.1).  The shapes of the π – A isotherms are also quite similar, with 
both suggesting a decrease in the order of the monolayer (Figures 4.7A and 4.8A) that the 
compressibility modulus indicates is an LE-LC transition phase (Figures 4.7B and 4.8B).  Again, 
as observed for py-3-8, the isotherms do not suggest a strong interaction on their own; however 
the impact is much more evident by looking at the magnitude of the reduction in CS
-1
30 (or CS
-
1
35) from 250 mN/m for the DPPC/Chol monolayer to 78 mN/m for py-3-16 and 104 mN/m for 
py-3-18 (Table 4.1). BAM images of the DPPC/Chol monolayer treated with py-3-16 (Figure 
4.9A) or py-3-18 (Figure 4.10A)  are again consistent with this interpretation, with the same 
types of domains being observed (at surface pressures associated with a given phase) as 
previously described for py-3-14.  
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Figure 4.7 Compression isotherms (π-A) for A) DPPC/Cholesterol (75%/25%, black line) and 
C) POPC/Cholesterol (75%/25%, black line) monolayers treated with: pyrene-3-16 (grey), py-
3-16:DNA at a 10:1charge ratio (green), py3-16:DNA at a 5:1 charge ratio (Purple).   
Compressibility modulus (CS
-1) as a function of surface pressure (π)  for B) DPPC/Cholesterol 
and D) POPC/Cholesterol (75%/25%, black line) were calculated according to Equation 4.1; the 
line colors correspond to the same treatments described for A) and C). 
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Figure 4.8 Compression isotherms (π-A) for A) DPPC/Cholesterol (75%/25%, black line) and 
C) POPC/Cholesterol (75%/25%, black line) monolayers treated with: pyrene-3-18 (grey), py-
3-18:DNA at a 10:1charge ratio (green), py3-18:DNA at a 5:1 charge ratio (Purple).   
Compressibility modulus (CS
-1) as a function of surface pressure (π)  for B) DPPC/Cholesterol 
and D) POPC/Cholesterol (75%/25%, black line) were calculated according to Equation 4.1; the 
line colors correspond to the same treatments described for A) and C) 
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Figure 4.9 BAM images for DPPC/Cholesterol and POPC/Cholesterol monolayers treated with 
py-3-16 gemini surfactant or py-3-16/DNA complexes. A) DPPC/Cholesterol treated with py-3-
16, B) DPPC/Cholesterol treated with py-3-16/DNA (5:1 charge ratio), C) POPC/Cholesterol 
treated with py-3-16, D) POPC/Cholesterol treated with py-3-16/DNA (5:1 charge ratio) 
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Figure 4.10 BAM images for DPPC/Cholesterol and POPC/Cholesterol monolayers treated with 
py-3-18 gemini surfactant or py-3-18/DNA complexes. A) DPPC/Cholesterol treated with py-3-
18, B) DPPC/Cholesterol treated with py-3-18/DNA (5:1 charge ratio), C) POPC/Cholesterol 
treated with py-3-18, D) POPC/Cholesterol treated with py-3-18/DNA (5:1 charge ratio) 
 
Upon the addition of DNA (regardless of charge ratio) to either pyr-3-16 or py-3-18, the 
effects on the DPPC/Chol monolayer are again very similar for the two surfactants.   For both 
surfactant:DNA systems, the monolayer is predominantly in the LE phase, although the slight 
inflection observed in the π – A isotherm (Figure 4.7A or 4.8A) and the valley observed in the 
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compressibility modulus (Figure 4.7B or 4.8B), clearly indicate a coexistence LE-LC phase at 
higher surface pressures (above 15 to 20 mN/m).    In our studies, the surfactants having the 
highest transfection efficiency in OVCAR-3 cells were 16-3-16, which was previously shown 
by the group to be efficient not only in in vitro transfection, but also as an in vivo topical 
transfection vector in a mouse study;225 and phytanyl-3-16, which gave even greater transfection 
efficiency (in vitro) than 16-3-16.105 This efficacy may have resulted from the ability of both 16-
3-16 and phy-3-16 to form vesicle like micelles in the absence of DNA, and may trigger the 
formation of high order structures once the DNA is added to it, including inverted micelles, and 
cubic structures, which have been linked to improved transfection efficiency.71 When 16-3-16 
was added to a DPPC/Cholesterol monolayer, it was not as efficient in reducing the 
compressibility modulus as pyr-3-16 was (CS
-1
30 = 131 mN/m and CS
-1
35 = 105 mN/m for the 16-
3-16 surfactant; unpublished data). Based upon this observation, our monolayer study suggests 
that the presence of the bulky pyrenyl moiety impacts the structure of the monolayers, and 
possibly corresponding cellular membranes, to a greater extent than a second hexadecyl tail 
would; however, this will be examined with transfection studies for the py-3-m surfactants, in 
Chapter V of this thesis. The BAM images are again consistent with the above interpretation of 
the isotherms and compressibility modulus plots; interestingly at low surface pressures, the BAM 
images for py-3-18 show an extensive network of bright, almost linear domains, even in the 
absence of DNA (Figure 4.10A and 4.10B).  Given the overall length of the alkyl hydrophobic 
tail for this surfactant in particular, it may be the case that it prefers to form threadlike aggregates, 
consistent with the threadlike micelles observed for long-chain symmetric gemini surfactants 
such as the 18-3-18 surfactant.101 
For the POPC/Cholesterol monolayers, the addition of either py-3-16 OR py-3-18 to the 
sub-phase again (as seen for py-3-14) creates a more rigid monolayer, as evidenced by the 
increases seen in the compressibility modulus values (Table 4.1).  Again consistent with the 
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previous discussion for py-3-14, this is in contrast to the increases in lift-off and cross-sectional 
areas, which both are observed to increase for the monolayer in the presence of either py-3-16 
or py-3-18. The BAM images for the POPC/Chol monolayers treated by either py-3-16 (Figure 
4.9C) or py-3-18 (Figure 4.10C) again show evidence of the incorporation of the surfactant into 
the monolayer structure (particularly in Figure 4.9C), consistent with the increase in rigidity.  
Based upon the results obtained for ALL of the py-3-m surfactants, the increases in the various 
area values (Table 4.1) for the POPC/Chol monolayers, are attributed to the greater area occupied 
by the py-3-m head groups at the air/water interface.  As these area values represent an average 
value for monolayers comprised of more than one type of molecule, and given that the variations 
in the area values are only modest in going from py-3-14 to py-3-16 to py-3-18, this interpretation 
is quite consistent with our results.  The differences seen for py-3-8 and py-3-12 again relate to 
their molecular structure; with a lower hydrophobicity, py-3-8 is less likely to prefer the bulk 
monolayer as opposed to the interface, resulting in these molecules occupying a greater area at 
the interface.  Py-3-12, being almost symmetrical with respect to the length of the alky tails, also 
occupies a large area at the interface.  As the hydrophobicity of the surfactant continues to 
increase, the tails become increasingly compatible with the POPC or cholesterol tails, effectively 
decreasing the area occupied by the surfactant at the interface.  
As for py-3-14, the addition of py3-16:DNA or py-3-18:DNA (at either 5:1 or 10:1) 
charge ratio causes fluidization of the POPC/Chol monolayer, as shown by the inflections in the 
π-A isotherms (Figures 4.7C or 4.8C) and the low values for the compressibility modulus 
(Figures 4.7D or 4.8D and Table 4.1).  These monolayers are again mostly found in an LE phase, 
with evidence of an LE-LC coexistence phase at higher surface pressures.  The BAM images for 
these systems (Figure 4.9D or 4.10D) are again consistent with this observation. 
To summarize the effect of the pyrenyl gemini surfactants on the two model membranes; 
these surfactants, on their own (i.e. in the absence of added DNA) generally fluidize the DPPC-
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Chol monolayers (representative of the “normal” cell membrane) and increase the rigidity of the 
POPC-Chol monolayers (representative of a “diseased” membrane. For the DPPC-Chol 
monolayers, the longer the alkyl tail (m) in the py-3-m surfactant, the greater the apparent 
fluidization; with the exception of py-3-12 which acted in an opposite fashion compared to the 
other surfactants for both the DPPC/Chol and the POPC/Chol monolayers. This is attributed to 
peculiar structural properties of the surfactant, which makes it closely resemble the symmetrical 
surfactants more than the dissymmetrical ones (the pyrene moiety adds to the volume of the 
surfactants, but not to the length). DNA increased the fluidization effect of py-3-m surfactants 
on the DPPC-Cholesterol monolayer. Pyrenyl gemini surfactants increased the compressibility 
moduli of the POPC-Cholesterol monolayer, when added to the sub-phase. All of the pyrene-
based surfactants integrated into the POPC-Cholesterol monolayer, irrelevant of the alkyl tail 
length. Addition of DNA to the py-3-m surfactants induces a fluidization of the POPC/chol 
monolayer, although possibly not to the same extent as seen for the DPPC/Chol monolayers 
where the addition of DNA resulted in extensive reorganization of the monolayer, as observed 
from the BAM images. Given that escape from endosomes is one of the critical stages of DNA 
transfection, the ability of the surfactant to incorporate into and/or fluidize these membranes is 
essential.  Based upon our results, the py-3-m surfactants are clearly capable of doing so and 
hold excellent promise as DNA transfection vectors.  
 
4.4.2 Langmuir monolayer studies of dissymmetric gemini surfactants (12-3-n) 
 
When 12-3-14 gemini surfactant is spread on the sub-phase as a monolayer, it dissolves into the 
sub-phase with the surface pressure remaining constant, and an isotherm is never formed, as 
observed for the py-3-m surfactants.  The 12-3-n surfactants are more soluble than the py-3-m 
surfactants and so compression again forces the molecules from the interface into micelles within 
the bulk aqueous phase. The situation again changes as the 12-3-14 is added to the sub-phase 
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with DPPC-Cholesterol as the monolayer. The isotherm rises with a lift-off area of 50 Å2, and a 
cross sectional (A∞) area similar to that of DPPC-Cholesterol system alone (44 Å
2 vs 45 Å2 in 
the presence of 12-3-14; see Table 4.2 and Figure 4.11A). As the surface pressure increases, the 
compressibility modulus decreases from 250mN/m to 127mN/m at 30mN/m, and from 
274mN/m to 121mN/m at 35mN/m, which is suggestive of strong interaction(s) between the 12-
3-14 molecules and the monolayer, resulting in increasing fluidity of the monolayer. From the 
BAM images (Figure 4.12A) the addition of 12-3-14 results in a network of narrow, bright 
domains; however, these domains look different from those found in the DPPC-Cholesterol 
system alone, and suggest that some of the surfactant may be locating at domain boundaries. As 
the surface pressure is increased, the bright circular domains, and at higher pressures clusters of 
these domains, are observed, consistent with previous observations for the py-3-m surfactants 
described above. At 14mN/m, all these distinct domains disappear and only a homogenous 
monolayer can be observed. This is an indication of higher compression and the transition from 
LE to LE-LC phase.   
Once the DNA is added to 12-3-14, substantial disruption to the monolayer is evident 
from the  - A isotherms, which show a clear LE phase between surface pressures of 0 to ~17 
mN/m, an LE-LC coexistence phase, and no evidence of the formation of either an LC or S 
phase.  The strong interactions between the GS and the DNA resulted in a large increase in the 
lift-off area (139Å2, and 146Å2 at a charge ratio of 10:1, and 5:1, respectively), suggesting 
extensive reorganization of the monolayer at the surface.  The A∞ for both charge ratios is 125Å
2, 
which indicates that the monolayer is more fluid than that of DPPC-Cholesterol alone. In the 
compressibility modulus plot (Figure 4.11B), there is a shift from LE to LE-LC phase around 
10mN/m and it persists till the collapse. The compressibility modulus values at  = 30 mN/m 
dropped from 255 mN/m to ~36 mN for both charge ratios, with a similar drop for CS
-1
35 (see 
Table 4.2). This dramatic drop in the compressibility modulus values is indicative of the 
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Table 4.2 Monolayer properties for the DPPC/Chol (75/25) and POPC/Chol (75/25) monolayers 
at 20°C treated with 12-3-s or 12-3-s/DNA complexes. 
System 
AL 
(Å2) 
A∞ 
(Å2) 
AC 
(Å2) 
πC 
(Å2) 
CS-130 
(mN/m) 
CS-135 
(mN/m) 
DPPC (75%)-Cholesterol (25%) 61.1 44 36.7 50.7 255 275 
POPC (75%)-Cholesterol (25%) 121 70.0 47 40.6 58±3 56±3 
12-3-14 
12-3-14/DPPC-Chol 50.0 45.0 28.5 37.9 127  121 
10:1 12-3-14-DNA/DPPC-Chol 139 125 29.8 49.5 36 78 
5:1 12-3-14-DNA/DPPC-Chol 146 125 30 49 37 61 
12-3-14/POPC-Chol 89.7 69 40.5 42.9 80 98 
10:1 12-3-14-DNA/POPC-Chol 176 152 44.8 42.6 46 65 
      5:1  12-3-14-DNA/POPC-Chol 225 197 35.8 48 49 61 
12-3-16 
12-3-16/DPPC-Chol 70.5 49.8 31 42.8 90 91 
10:1 12-3-16-DNA /DPPC-Chol 165 157 38 45.0 11 28 
5:1 12-3-16-DNA/DPPC-Chol 171 166 39.5 44 2 27 
12-3-16/POPC-Chol 120 85 49.9 40.6 64 58 
10:1 12-3-16-DNA/POPC-Chol >225 125 35.8 48 2 42 
5:1 12-3-16-DNA/POPC-Chol >225 207.8 38 53 4 39 
12-3-18 
12-3-18 93 93.6 52 25.0   
12-3-18/DPPC/Chol 62.9 58.3 31.7 44 59 55 
10:1 12-3-18-DNA /DPPC-Chol 151 156 36.7 51 26 55 
5:1 12-3-18-DNA/DPPC-Chol 151 136 46.8 45.6 35 79 
12-3-18/POPC/Chol 255 250 49.9 56 63 71 
10:1 12-3-18-DNA /POPC-Chol >180 160 46.0 39 8 30 
5:1 12-3-18-DNA /POPC-Chol >180 134 47.7 39.9 19 42 
 
fluidizing impact of the GS- DNA complex on the DPPC-Cholesterol monolayer.   The BAM 
images (Figure 4.12B) confirm the extensive reorganization, with very disorganized domains 
being observed at all surface pressures. A previous study of 2,3-dimethoxy-1,4-bis(N-hexadecyl-
N-N-dimethyl-ammonium)butane dibromide (SS-1; a symmetric methoxy-substituted analogue 
of the 16-4-16 surfactant, which we have not studied), demonstrated that the addition of DNA 
and SS1 condensed a pure POPC monolayer, irrelevant of the DNA/GS charge ratio.176 It was 
noted that the impact on the monolayer structure was highly on the structure of the DNA (whether 
it is ss-DNA or ds-DNA), on the structure of the GS, and also on the composition of the 
monolayer. 176, 226 
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Figure 4.11 Compression isotherms (π-A) for A) DPPC/Cholesterol (75%/25%, black line) and 
C) POPC/Cholesterol (75%/25%, black line) monolayers treated with: 12-3-14 (grey), 12-3-
14:DNA at a 10:1charge ratio (green), 12-3-14:DNA at a 5:1 charge ratio (Purple).   
Compressibility modulus (CS
-1) as a function of surface pressure (π)  for B) DPPC/Cholesterol 
and D) POPC/Cholesterol (75%/25%, black line) were calculated according to Equation 4.1; the 
line colors correspond to the same treatments described for A) and C). 
 
The 12-3-14 surfactant, when added to the POPC/Chol monolayer, behaves in the same 
way as seen for the addition of the pyrenyl surfactants to POPC/Chol monolayer, with a decrease 
in the lift-off area (89Å2), and the cross-sectional area remained more or less unchanged (69Å2), 
indicating that the GS is making the monolayer less fluid, also suggested by the shift in the 
isotherm to lower molecular areas (Figure 4.11C). This can also be observed from the rise in the 
compressibility modulus (Figure 4.11D), which at  = 30mN/m increases from 58mN/m to 
80mN/m, and at  = 35mN/m from 55mN/m to 98mN/m. The BAM images are again consistent 
with this interpretation, with an increased ordering of the small bright domains seen formed 
within the monolayer as surface pressure is increased (Figure 4.12C). As soon as the DNA is 
added, the monolayer behaves quite differently, with higher lift-off areas 
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Figure 4.12 BAM images for DPPC/Cholesterol and POPC/Cholesterol monolayers treated with 
12-3-14 gemini surfactant or 12-3-14/DNA complexes. A) DPPC/Cholesterol treated with 12-3-
14, B) DPPC/Cholesterol treated with 12-3-14/DNA (5:1 charge ratio), C) POPC/Cholesterol 
treated with 12-3-14, D) POPC/Cholesterol treated with 12-3-14/DNA (5:1 charge ratio) 
 
(from 121Å2 to 176Å2 and 255Å2 at 10:1 and 5:1 charge ratio, respectively), and higher cross 
sectional area (from 70.0 Å2 to 152Å2 and 179Å2 at 10:1 and 5:1 charge ratio, respectively), 
which suggests increased fluidity of the monolayer. This fluidity confirms by the low 
compressibility modulus values (Figure 4.11D); CS
-1
30 drops from 58 mN/m to 46 mN/m and for 
the 10:1, and 5:1 charge ratios, respectively, indicating that the monolayer is in an LE phase at 
most surface pressures. No domains were observed at low surface pressure in the BAM images 
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(Figure 4.12D) and a mixture of network like domains and bright circular domains as well as the 
compression increases, similar to previous observations for the py-3-14 to py-3-18 surfactants. 
  The presence of 12-3-16 to the sub-phase for the DPPC/Chol monolayer shifts a part of 
the π-A isotherm to higher molecular area and part to lower molecular areas, such that it crosses 
over the isotherm for the pure monolayer (Figure 4.13).  Effectively this means that the slope of 
the isotherm in the presence of 12-3-16 is less than for the absence of 12-3-16, which itself is 
evidence for fluidization of the monolayer by the surfactant.  As the surface pressure increases, 
the large effect of the 12-3-16 surfactant can be observed, with a strong decrease in 
compressibility modulus (Figure 4.13B and Table 4.2), The compressibility modulus decreases 
from 255mN/m to 90mN/m at 30mN/m, and from 274mN/m to 91mN/m at 35mN/m, 
respectively, indicating the strong interactions between the monolayer and the GS molecules.   At 
low surface pressure, BAM images (Figure 4.14A) show bright circular domains similar those 
described above, although not the network of narrow domains seen with the py-3-14 surfactant 
(Figure 4.12A).  As the monolayer transitions into the LE phase, the BAM images show a mix 
of bright and dim circular domains, consistent with increased incorporation of the surfactant into 
the monolayer. As the surface increases further, a mixture of network like domains and circular 
domains are observed until a heterogeneous mix of different sized domains is observed, again 
consistent with increased fluidity. 
 As DNA is added to the DPPC-Chol monolayer in the presence of 12-3-16 in the sub-
phase, extensive disruption of the monolayer occurs, clearly evident in both the isotherms (Figure 
4.13A), which again show the characteristic shape indicating LE, LE-LC coexistence and LC 
phases, and the compressibility modulus (Figure 4.13B), which shows that instead of an LC 
phase, the phases seen more likely correspond to LEA, LEA - LEB coexistence, and LEB phases, 
based on the very low compressibility modulus values observed.  The interaction(s) between the 
DPPC/Chol monolayer and the 12-3-16:DNA complexes lead to a very large  
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Figure 4.13 Compression isotherms (π-A) for A) DPPC/Cholesterol (75%/25%, black line) and 
C) POPC/Cholesterol (75%/25%, black line) monolayers treated with: 12-3-16 (grey), 12-3-
16:DNA at a 10:1charge ratio (green), 12-3-16:DNA at a 5:1 charge ratio (Purple).   
Compressibility modulus (CS
-1) as a function of surface pressure (π)  for B) DPPC/Cholesterol 
and D) POPC/Cholesterol (75%/25%, black line) were calculated according to Equation 4.1; the 
line colors correspond to the same treatments described for A) and C). 
 
reduction in the CS
-1
30 values from 255mN/m to 11 mN/m and 2 mN/m for charge ratios of 10:1, 
and 5:1, respectively, and in the CS
-1
35 values from 275 mN/m to 28 mN/m and 27 mN/m (Table 
4.2). The deep minima observed in the compressibility modulus plots (Figure 4.13B) when the 
surfactant:DNA complexes are added to the system are somewhat misleading in that they result 
from the fact that the compressibility modulus is based upon the derivative of surface pressure 
as a function of molecular area (recall equation 4.1).  As such, if the rate of change in the surface 
pressure as a function of a change in molecular are is zero, i.e. the surface pressure shows a 
plateau in the  - A isotherm (as we see in Figure 4.13A) then the compressibility modulus drops 
to zero as well.  Two valleys are seen for the 12-3-16 systems  
       
128 
 
 
Figure 4.14 BAM images for DPPC/Cholesterol and POPC/Cholesterol monolayers treated with 
12-3-16 gemini surfactant or 12-3-16/DNA complexes. A) DPPC/Cholesterol treated with 12-3-
16, B) DPPC/Cholesterol treated with 12-3-16/DNA (5:1 charge ratio), C) POPC/Cholesterol 
treated with 12-3-16, D) POPC/Cholesterol treated with 12-3-16/DNA (5:1 charge ratio). 
 
as a result of the large plateau at a surface pressure of ~30 mN/m and the small shoulder seen at 
~ 45 mN/m in the isotherms for the 12-3-16:DNA systems.   The BAM images of the monolayer 
in the presence of both 12-3-16 and DNA (Figure 4.14B) extensive disruption of the monolayer 
and clear evidence of multiple different phases.  At a surface pressure of 30 mN/m, a mixture of 
both small circular, and larger “snowflake” domains can be seen, consistent with the coexistence 
of 2 different LE phases. 
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Both the  - A isotherm (Figure 4.13A) and compressibility modulus (Figure 4.14D) 
show that the POPC/chol monolayer appears to be unchanged by the addition of 12-3-16 to the 
system.  A slight decrease in the lift-off area from 121Å2 to 120Å2 is seen (Table 4.2), while a 
slight increase in cross-sectional area from 70Å2 to 85Å2 is observed.  This could suggest some 
minimal insertion of the 12-3-16 surfactant into the monolayer, but may also simply be within 
the experimental error of the system. The BAM images (Figure 4.14C) for POPC/Chol treated 
with 12-3-16 also show no evidence of reorganization within the monolayer, again suggesting 
little to no interaction. 
     POPC/Cholesterol monolayers treated with the 12-3-16:DNA complexes, at either 10:1 or 5:1 
charge ratios, again resulted in extensive fluidization of the monolayer, as seen from both the 
isotherms (Figure 4.13C) and compressibility modulus (Figure 4.13C).  As for the 12-3-14:DNA 
systems, multiple phases are observed for the 12-3-16:DNA complexes, that appear to be 
different LE phases based upon the low values seen for the compressibility modulus (Table 4.2).  
The BAM images obtained for these systems again show a relatively featureless monolayer at 
low surface pressures, and the same pattern of small bright domains at high surface pressures, 
again consistent with the phases inferred from the isotherms and compressibility modulus as 
described above.  
In contrast to all of the surfactants previously discussed (i.e., 5 py-3-m surfactants plus 
12-3-14 and 12-3-16) the 12-3-18 gemini surfactant is the only surfactant investigated that is 
able to form a monolayer at the air-water interface.  When spread as a monolayer, it forms a 
monolayer that collapses at a relatively low surface pressure of ~25 mN/m, although it may be 
the case that this “collapse” actually represents a coexistence phase and that the true collapse 
occurs at a molecular area of 0, which is a clear indication that molecules are being forced from 
the monolayer into the bulk aqueous phase to form micelles (Figure 4.15A).  Because of this, the 
molecular areas (Table 4.2) determined from the isotherm are somewhat artificial; however,  
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Figure 4.15 Compression isotherms (π-A) for A) DPPC/Cholesterol (75%/25%, black line) and 
C) POPC/Cholesterol (75%/25%, black line) monolayers treated with: 12-3-18 (grey), 12-3-
18:DNA at a 10:1charge ratio (green), 12-3-18:DNA at a 5:1 charge ratio (Purple).   
Compressibility modulus (CS
-1) as a function of surface pressure (π)  for B) DPPC/Cholesterol 
and D) POPC/Cholesterol (75%/25%, black line) were calculated according to Equation 4.1; the 
line colors correspond to the same treatments described for A) and C). 
 
the cross-sectional area (A∞) value of 93Å
2 is quite consistent with head group areas reported in 
the literature for various m-3-m type gemini surfactants, although much larger than the head 
group area determined from our own surface tension measurements, described in Chapter III).  
The small lift-off area ~93Å2 in comparison to the lift-off area value for 16-7-16 (111.6Å)2. 143 
The compressibility modulus (Figure 4.15B) indicates that the monolayer formed is consistent 
with an LE phase, and exhibits circular domains in the BAM images. 
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Figure 4.16 BAM images for DPPC-Cholesterol and POPC/Cholesterol monolayers treated with 
12-3-18 gemini surfactant or 12-3-18/DNA complexes. A) 12-3-18 monolayer, B) DPPC-
Cholesterol treated with 12-3-18, C) DPPC/Cholesterol treated with 12-3-18/DNA (5:1 charge 
ratio), D)POPC-Cholesterol treated with 12-3-18/DNA (5:1 charge ratio). POPC-Chol with 12-
3-18:DNA showed no domains. 
 
The addition of 12-3-18 to DPPC-Cholesterol monolayer resulted in an isotherm again 
similar to that for 12-3-16 (Figure 4.13A vs 4.15A) with similar increases in AL and A∞ (Table 
4.1) as was also observed for 12-3-16. This, combined with the similarly low compressibility 
modulus values (Figure 4.15B), with CS
-1
30 decreasing from 255 mN/m to 59 mN/m and CS
-1
35 
decreasing from 274mN/m to 55mN/m, is again consistent with a strong interaction of the 
surfactant with the monolayer, and the fluidization into an LE or LE-LC coexistence phase. BAM 
images of DPPC/Chol monolayer in the presence of 12-3-18 (Figure 4.16A) showed circular 
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domains of varying size randomly scattered over the image, consistent with a disordered LE-LC 
phase. 
  For DPPC/Chol monolayers treated with 12-3-18:DNA complexes (at either 5:1 or 10:1 
charge ratios) again show clear indications of fluidization of the monolayer into multiple 
expanded phases (see Figure 4.15). The π-A isotherms shift to higher molecular areas as the 
monolayer becomes more fluid, with higher lift-off areas (151Å2 for both charge ratios) and 
higher minimum cross sectional areas of 156Å2 at 10:1 charge ratio, and 136Å2 at 5:1charge 
ratio. The same LEA, LEA - LEB coexistence, and LEB phases seen for the 12-3-16 surfactant, 
can again be seen here, although the compressibility modulus values (Figure 4.15B) suggest that 
the LE-LC and LC phases could also be a possibility. BAM images of this monolayer (Figure 
4.16B) are featureless at low surface pressure, but at intermediate surface pressures, the multiple 
LE phases are clearly seen.  At high surface pressure, the domains are more ordered, consistent 
with the possibility of an LC phase.  
  The addition of 12-3-18 to the sub-phase of POPC-Cholesterol monolayer has dramatic 
impact on the monolayer. Strong interactions cause high initial surface pressure values 
(~5mN/m) in the absence of any compression (Figure 4.15C), and dramatically increase the lift-
off area and the cross-sectional area to AL=255 Å
2 and A∞ < 250Å
2.  Overall the shape of the 
isotherm contains a number of small features at higher surface pressure, that suggest an 
extraordinarily complex mixture of phases, that based upon the compressibility modulus (Figure 
4.15D, and Table 4.1) are again consistent with LE phases. Interestingly, the BAM images are 
remarkably boring given the extensive disruption indicated by the isotherm and compressibility 
modulus, and it is strongly recommended that these be repeated in future work. 
The addition of DNA to12-3-18 has the same type of effect on the POPC/cholesterol 
monolayer as the other 12-3-n surfactants, shifting the π-A isotherm to higher molecular areas; 
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although again a non-zero surface pressure is observed in the absence of compression due to 
apparently strong interactions. Lift-off and cross sectional areas are again dramatically increased 
(Table 4.1) and the low compressibility modulus values (Figure 4.15D and Table 4.2), indicates 
the fluidizing effect the 12-3-18-DNA complexes have on the POPC-Chol monolayer. BAM 
images of this system only displayed round domains throughout the entire compression, which 
is the characteristic of the POPC-Chol (showing no distinct domains). 
In summary, the addition of the dissymmetric 12-3-n gemini surfactants generally 
fluidizes the DPPC/Chol and increases the rigidity of the POPC/Chol monolayer. For the most 
part, all three surfactants behaved similarly; although 12-3-16 acted differently when added to 
POPC-Chol as it did not increase the rigidity of the monolayer. In general, the disruptions 
resulted in the formation of LE, LE-LC coexistence, or LC phases; however as the tail length 
increased, the possibility of multiple LE phases in coexistence was also hypothesized.  Addition 
of the DNA, regardless of the monolayer composition, and regardless of the alkyl tail length of 
the surfactant, resulted in the fluidization of the both types of monolayer again demonstrating 
the potential for transfection complexes comprised of these surfactants to be able to successfully 
disrupt endosomal membranes allowing for endosomal escape. 
Overall, through our characterizations the DPPC/Chol and POPC/Chol monolayers using 
Langmuir monolayer studies combined with BAM, we have successfully characterized models 
of the endosomal membranes of normal cells (DPPC-cholesterol = 75:25 %), and of cancer cells 
(POPC-Cholesterol= 75%:25%). The mixed monolayer of DPPC-Cholesterol showed solid 
phase at a surface pressure from 30 to 35 mN/m, indicating the rigidity of the membrane. 
POPC/Cholesterol system found to be much more fluid at the same surface pressures, in the LE 
phase. Once the gemini surfactants were added to the DPPC-Cholesterol; whether those of 
pyrene-based surfactants, or the 12-3-n surfactants; with or without the DNA, the rigidity of the 
membrane was reduced substantially and fluidity was induced. In the absence of DNA this 
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appeared to be due to insertion of the surfactant molecules themselves into the monolayer 
structure, while in the presence of DNA appeared to result from interactions between the 
complexes and the monolayer at the air-water interface. The effect of the surfactants on the 
POPC/Chol system, whether the pyrenyl or the dissymmetric surfactants was to increase the 
rigidity of the monolayer in general, again due to insertion of the surfactant into the monolayer, 
however in this case, this may hinder the motion of the oleyl chain in the POPC molecules in the 
monolayer, giving rise to an increase in rigidity. The addition of DNA again resulted in increased 
fluidity of the monolayer, further suggesting that in the presence of DNA, the interactions are 
between the monolayer and the surfactant:DNA complexes at the air/water interface.  It appears 
that the expected strong electrostatic interaction that occurs between the cationic head groups of 
the surfactant molecules and the phosphate ions in the DNA backbone is stronger than any 
driving force that would allow for incorporation of the surfactant into the monolayer.  This may 
have implications for DNA transfection, which not only requires successful endosomal escape, 
which our results clearly indicate is a reasonable expectation for these systems, but also the 
release of the DNA from the transfection complex.  If the interaction of the surfactants with DNA 
is strong enough to prevent incorporation of surfactant molecules into the monolayer, it is 
possible that DNA release could be impeded within the cells.  The transfection activity of these 
surfactants will be studied in Chapter 4. 
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Chapter 5: Transfection and structural properties of dissymmetrical gemini surfactant 
based transfection complexes 
 
5.1 Introduction 
 
The lack of safe and efficient gene-delivery methods is a limiting obstacle to human gene 
therapy. Although synthetic gene-delivery vectors are safer than recombinant viruses, they 
generally possess low efficacy rates. In recent years, a variety of effective cationic compounds 
have been designed specifically for gene delivery (polymers, lipids and gemini surfactants).214 
A growing understanding of gemini surfactant`s gene-delivery mechanisms and the ability to 
manipulate the basic chemical structure of these unique molecules to cater to the growing need 
of a better transfection agent, it is possible that the gemini surfactants will be an important tool 
in gene therapy applications.56 The gemini surfactants encountered in gene delivery are generally 
symmetric, with their head groups usually made of quaternary ammonium, or primary, secondary 
or tertiary amine groups.34  
The cationic groups are necessary for the neutralization and compaction of DNA. gemini lipids 
are interesting compounds and this is largely due to their biocompatibility and longer half-life in 
the body. Also, carbohydrates and peptides have been recently used as head groups or alkyl 
tails.34 These have showed superior biocompatibility and in some cases gave better transfection 
results, depending on the cell line. Dissymmetric gemini surfactants have also been used in 
transfection. Phytanyl surfactants synthesized by Haitang Wang in Dr. Wettig`s lab, and the phy-
3-n surfactants showed better transfection results in OVCAR-3- cell lines than 16-3-16 and 12-
3-12 gemini surfactants.178 To improve the transfection results many parameters have to be 
considered. Average particle size of the nanoparticle (lipoplex, or polyplex) is of great 
importance to assist in endocytosis. Also the flexibility of the nanoparticle to release the DNA 
is another important step. As mentioned earlier, the size of the nuclear pores in the nuclear 
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membrane is <50 nm, and the release of the DNA from the cationic portion of the complex is the 
only way to gain access to the nucleus. Another important parameter in gene delivery is the zeta 
potential of the complex. An overall positive charge is necessary to interact with negatively 
charged cell membranes and before that to complex and compact DNA. In this current project, 
physical characterization of the GS-DNA complex at different charge ratio is measured by means 
of particle size and zeta potential. Based on these results, charge ratios will be picked to test 
transfection in two cell lines,  Human embryonic kindey cell line (HEK-293), and osteosarcoma 
cell line (MG-63). The first is an example of a healthy cell line and the second is an example of 
a diseased (cancer) cell line. Transfection efficiency and cell viability of the eight gemini 
surfactants was determined by flow cytometry technique. Also, Pyrene-based gemini surfactants 
was mixed with DNA (at charge ratios of (5:1, and 10:1), and DOPE lipid (3:2). These ratios 
were only determined after a process of testing and optimization. Protein expression was 
determined by means of ELIZA in African green monkey fibroblasts cell line (COS-7) cell line 
(this experiment is done in collaboration with Dr. Ildeko Badea). One-way ANOVA statistical 
analysis was conducted to determine the significance of the results. 
 
5.2 Materials and Methods 
 
DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), and sodium bicarbonate were 
purchased from Sigma-Aldrich (Oakville, Ontario). The plasmid used in our transfection studies 
was pGTINF coding enhanced green fluorescence protein (EGFP) gene. A gift from Dr. Ildiko 
Badea (College of Pharmacy and Nutrition, Saskatchewan). The amplification of the plasmid 
took place in our laboratory. DOPE was prepared at 1 mM in PBS (pH9) and the preparation will 
be discussed in Chapter 4 section 4. LipofectamineTM 2000 was purchased from Invitrogen and 
used according to the manufacturer’s protocol (Fisher scientific, Ottawa, Canada), HPLC grade 
ethanol (Sigma-Aldrich, Oakville, Canada), Dulbecco phosphate buffer saline (DPBS) (Fisher 
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scientific, Ottawa, Canada), NaOH (Sigma-Aldrich, Oakville, Canada), 0.25% 1X 
Trypsin(Fisher Scientific, Ottawa, Canada), TryplETM Xpress (Fisher Scientific,Ottawa, 
Canada), Penicillin/Streptomycin antibiotics (Hyclone, Fisher Scientific, Ottawa, Canada), Fetal 
bovine serum (FBS) (GIBCO, Fisher Scientific, Ottawa, Canada), α-tocoferol (Sigma-Aldrich, 
Oakville, Canada), DMEM (ATCC, Cedarlane labs, Burlington, Canada), human osteosarcoma 
(MG-63) and human embryonic kidney cells (HEK-293)  (Cedarlane labs, Burlington, Canada), 
EMEMTM (high glutamine)(Fisher scientific, Ottawa, Canada), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, Oakville, Canada). Milli-Q water was 
used in the preparation of all solutions. 
5.2.1 Particle size and Zeta potential 
 
Particle size of eight gemini surfactants alone and with DNA at different charge ratios (+/-) was 
measured by dynamic light scattering at 25 °C using a Malvern Zetasizer Nano ZS instrument 
(Malvern instruments, UK). ZEN0118 (light scattering) and DS1070 (zeta potential) cuvettes 
were purchased from Malvern instruments (UK).  The particle size distribution in water was 
obtained from the light scattered by particles illuminated with a laser beam (633 nm) at a 
scattering angle of θ = 173°. The particle size measurements are reported using a % volume 
distribution, and are repeated three times automatically in transparent disposable cuvettes 
(ZEN0118) (Malvern instruments, UK), with the average particle size being reported ± standard 
deviation. The measurement of zeta potential of the complexes was performed by using 
electrophoretic light scattering with the same instrument. Zeta potentials were measured three 
times per sample and are expressed as the mean± standard deviation.  
5.2.2 Plasmid DNA (pTGINF-GFP) 
 
The recombinant plasmid DNA was amplified in K-12 strains of Escherichia coli (a Gram 
negative, anaerobic, rod-shaped bacterium) (provided from Dr. Roderick Slavcev`s lab at the 
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School of Pharmacy, University of Waterloo) in the generation of the recombinant cell 
constructs, extracted using centrifugation protocol of the E.Z.N.A.® Endo-Free Plasmid DNA 
Maxi Kit (OMEGA bio-tek, Georgia, USA), and treated with restriction enzymes followed by 
gel electrophoresis for sequence confirmation. Two restriction enzymes, xba-1 (Cat #R3104T, 
New England Biolabs, Whitby, Canada), and HINDIII-HF (Cat#R0145C, Biolabs, Canada) were 
used (in cut smartTM buffer, Cat #B72045, Biolabs, Canada) to cut the DNA into specific 
fragments for identification in using gel electrophoresis (Agarose gel, Cat#BP1356, Fisher 
scientific, Canada, with ethidium iodide (B392-5). 0.5g of agarose was dissolved in 500mL of 
6X TE buffer, which was heated in the microwave for 1min-1.5min with. This 1-1.5min heating 
was done in intervals of 30seconds to avoid bubbling and over flowing of the buffer (provided 
from Dr. Roderick Slavcev`s lab at the School of Pharmacy, University of Waterloo).  
The protocol followed for agarose gel electrophoresis was as described by Lee et al.227 with 
minor modification. Prior to the sample preparation, the agarose gel is cast on the tray and left 
to dry for approximately an hour. The required volume (for ≥ 500 ng of plasmid) of the extracted 
plasmid sample, 1 µL of the DNA-ladder standard (as control, 500 µg /µL, 1 kb size), and 6X 
Sample Loading Buffer/Dye solution (in glycerol) at a ratio of (Loading Buffer : Plasmid =) 1 : 
5 was carefully pipetted, and separately mixed in appropriate combination (either Ladder + Dye 
or Samples + Dye). After adjusting the final volume of the individual mixture(s) by adding Milli 
Q water, 10 µL of each mixture was separately pipetted into the designated wells before running 
the power. The electrophoresis power (potential difference of 100 volts, and 3 amperes of 
current) was allowed to run until the blue dye approaches the end of the gel (generally for >1.5 
hr). As DNA diffuses within the gel over time, it becomes difficult to see the DNA bands, thus, 
UV imaging (provided in Figure 5.1) was done, shortly after the electrophoresis stopped, through 
an UV transilluminator at 302 nm. 
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Figure 5.1 Gel electrophoresis of pGTINF-GFP plasmid extracted after the treatment with 
restriction enzymes (xba-1 and HINDIII-HF). Three bands (751kb, 1095kb, and 3742kb) can be 
seen in the image 
 
5.2.3 In vitro transfection 
 
Transfection complexes were composed of the plasmid, gemini surfactants, and DOPE, or as a 
control of ONLY the plasmid with the gemini surfactants (no DOPE added). The media used 
was dependent upon the identity of the cell line used, DMEM, high glucose (GIBCO®, Fisher 
scientific, Ottawa, Canada) was used for the HEK-293 cell line, and high glutamine EMEM 
(ATCC, Cedarlane, Canada) was used for the MG-63 cell-line. The plasmid pGTINF-GFP 
coding enhanced green fluorescence protein (EGFP) gene, obtained as a gift from Dr. Ildiko 
Badea (College of Pharmacy and Nutrition, University of Saskatchewan), was used at an amount 
of 0.2µg/well for the transfection. All the dissymmetric gemini surfactants and the symmetric 
16-3-16 gemini surfactant (as a control) were prepared at concentration of 1.5mM, filtered 
through a 0.2µm syringe filter (Cat #09719A, Fischer scientific, Canada), and was used at a 
volume of 1.01µL/well to obtain a surfactant to plasmid charge ratio of 5:1. DOPE vesicles were 
prepared according to Wettig et al.126 at concentration of 1mM in PBS (pH=9), filtered using a 
0.45 µm syringe filter (Fisher scientific, Ottawa, Canada), and used at a volume of 3.7 µL/well. 
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The transfection complexes were prepared as follows: 0.2µg of the plasmid was mixed with 1.01 
µL of the gemini surfactant solution and incubated at room temperature for 15 minutes. After 
that, 3.7µL of the DOPE vesicle solution was added to the mixture and incubated for 30 minutes 
at room temperature. The complexes were then used to transfect cells as described below. 
Transfection assays were carried out as reported in previous studies.228,225 One day prior to the 
transfection, HEK-293 and MG-63 cells were seeded onto a 96-well plate at a density of 2.5x104 
cells/mL and 1.5x104 cells/ mL, respectively. The cells were incubated at 37 °C in a 5% CO2 
atmosphere for approximately 24 h to reach 85% confluency in 75-cm2 tissue culture flasks in 
Dulbecco’s modified Eagle’s medium (DMEM) or (EMEM) obtained from Fisher scientific 
(Ottawa, Canada). These cells were supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) 
antibiotic antimycotic agents on the day of transfection. One hour prior to transfection, cells 
media was removed and changed to medium prepared without fetal bovine serum (FBS) and 
antibiotics. Then the transfection complexes prepared as described above and added to the cells 
dropwise. The cells were then incubated at 37 °C in a 5% CO2 atmosphere for 3h for both cell 
lines. Cells were also transfected using 16-3-16 (prepared as above for the dissymmetric gemini 
surfactants) and LipofectamineTM 2000 (Invitrogen, used according to the manufacturer’s 
protocol) as the positive control, plasmid only, and dissymmetric gemini surfactant controls. 
After 3h incubation, the supernatant media was replaced by fresh media (DMEM or EMEM, 
depending on the cell type) with 20% FBS (without antibiotics) and the cells were again 
incubated in a 37 °C with 5% CO2 atmosphere overnight to allow for EGFP expression. On the 
third day, cells were collected and resuspended in PBS mixed with propidium iodide. The 
samples were analyzed using a Guava easycyteTM 8HT benchtop flow cytometer (EMD 
Millipore, Etobicoke, Canada) which is a part of Dr. Spagnuolo’s lab in the School of Pharmacy, 
University of Waterloo. 5,000 cells were analyzed for each sample. Transfection efficiency was 
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expressed in terms of the % of cells expressing the EGFP expression. Cell viabilities were 
expressed as the % cells that were dead (as determined by PI staining). 
As there was some concern regarding possible contamination of the EGFP fluorescence by 
potential fluorescence from the pyrenyl groups in the structure of the py-3-m surfactants, 
transfection efficiencies were also obtained using an ELISA method, described below.  All 
ELISA transfection and cell culture studies were carried out by the Badea group (Dr. Ildiko 
Badea) in the College of Pharmacy and Nutrition, University of Saskatchewan.  For the ELISA 
measurements, COS-7 African green monkey kidney fibroblasts (ATCC, CRL-1651) were 
grown to 80% confluency in 75-cm2 tissue culture flasks in Dulbecco’s modified Eagle’s 
medium (DMEM) obtained from ATCC (Manassas, VA USA). These cells were supplemented 
with 10% (v/v) fetal bovine serum, 1% (v/v) antibiotic antimycotic agents and incubated at 37°C 
in a 5% CO2 atmosphere. A day prior to transfection, 96-well tissue culture plates were seeded 
at a cell density of 1 × 104 cells/well. The DMEM medium was changed one hour prior of the 
transfection with DMEM containing no FBS or antibiotics. Cells were transfected in the same 
manner described for the HEK-293 and MG-63 cells with the exception that 5 hrs incubation 
was allowed for transfection, rather than 3 hours. Lipofectamine Plus (Invitrogen Life 
Technologies) was used as a positive control according to the manufacturer’s protocol. After the 
incubation period, the transfection mixtures were replaced with fresh DMEM containing 10% 
FBS. Supernatants were collected at 48 and 72h and replaced with fresh medium. The collected 
supernatants were stored at −20°C. The results presented are the average of three plates of 
quadruplicate wells. 
5.2.4 Enzyme-Linked Immunosorbent Assay (ELISA) 
 
ELISA was carried out to measure the level of interferon gamma using flat bottom 96-well plates 
according to the BD Pharmingen protocol.229 A standard IFN-γ curve was created using 
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recombinant mouse IFN-γ standard (BD Biosciences, Mississauga, ON, Canada) to calculate the 
concentration of the IFN-γ expressed by the cells after transfection. A 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to determine the cytotoxicity of the 
pyrene-based gemini surfactants in the COS-7 cell-line, also at the University of Saskatchewan. 
For the MTT assay, three 96-well cell culture plates were seeded with cells at a density of 1 x104 
cells/well and treated with the complete complexes containing plasmid, GS, and DOPE (P/G/L) 
nanoparticles. These Plates were incubated for 5h at 37°C in a 5% CO2 atmosphere before 
replacing the old media with fresh media as described above. Cell toxicity was evaluated at 48h 
and 72 hours post-transfection. Lipofectamine was again used as a positive control. A sterile 
solution of 5 mg/mL of MTT (Invitrogen, USA) in PBS was prepared, mixed with supplemented 
media and added to the cells. Then cells were incubated for 3h. The supplemented media was 
removed and the formed, purple formazan crystal was dissolved in dimethyl sulfoxide 
(spectroscopy grade, Sigma-Aldrich, ON, Canada). The plates incubated at 37 °C for 10 minutes 
and absorbance was measured at 550 nm using a microplate reader (BioTek® Microplate 
Synergy HT, Vermont, USA). The results are the average of three plates (treated with 
individually prepared formulations of quadruplicate wells) and the cytotoxicity was expressed 
as a percentage of the non-transfected control cells± standard deviation. 
5.2.5 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
  
MTT assay was performed to examine the cytotoxicity of the pyrene-based gemini surfactants 
in the COS-7 cell-line. Three 96-well cell culture plates were seeded with cells at a density of 1 
× 104 cells/well and treated with the GDP nanoparticles. Plates were incubated for 5 h at 37°C 
with 5% CO2 before replacing the old media with fresh media as described in the transfection 
section. Cell toxicity was evaluated 48h after treatment. Lipofectamine, a commercial 
transfection agent, was used as a positive control. A sterile solution of 5 mg/mL of MTT (Fisher 
Scientific, Ottawa, Canada) in phosphate-buffered saline (PBS) was prepared, mixed with media 
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containing 10% FBS, then added to the cells and incubated for 3 h. The supplemented media was 
removed and the formed, purple formazan crystal was dissolved in dimethyl sulfoxide 
(spectroscopy grade, Sigma-Aldrich, Oakville, Canada) and the plates incubated at 37°C for 10 
m. Absorbance was measured at 550 nm using a microplate reader (BioTek® Microplate 
Synergy HT, Vermont, USA). The results are the average of three plates (treated with 
individually prepared formulations of quadruplicate wells) and the cytotoxicity is expressed as a 
percentage of the non-transfected control cells± standard deviation. 
 
5.3 Results and Discussion 
 
5.3.1 Particle size and zeta potential measurement 
 
Physical characterization of the gemini surfactant- DNA complexes was conducted by measuring 
the particle size and zeta potential with Zetasizer Nano ZS (Malvern, UK). Average particle size 
of the gene transfection vector is of great importance and has been reported numerous times. 
Lipoplexes are used to protect the DNA from endonucleases from degradation, and they possess 
different morphologies ranging from, toroidal or spherical structures to inverted hexagonal and 
cubic230. Diameters of these particles range from about 10s of nanometers to several hundred 
nanometers. There is a general agreement that lipoplex size plays a significant role in 
determining the nature of the entry pathway of the lipoplexes into the cells. On one hand, larger 
polyplexes may result in more cell membrane contact and active phagocytosis231. Although the 
main pathway of entry and access into cells happen through active endocytosis, clathrin-
mediated and caveolin-mediated endocytosis have been reported to play a role in mediating entry 
into the cell, hence, transfection.232 Qaddoumi and colleagues have shown that in primary 
cultures of rabbit conjunctival epithelial cells (RCEC), endocytosis of poly (DL-lactide-co-
glycolide) (PLGA) NPs occurs mainly via clathrin- and caveolin-1-independent pathways.233 
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These authors suggested that nanoparticle uptake occurs by adsorptive endocytosis.234 These 
different entry pathways depend highly on the size of the nanoparticles (polyplex). 500nm or 
larger particles cannot gain access to cells via the clathrin pathway. A size-dependent mechanism 
has been proposed with clathrin-mediated pathway. Rejman et al.235 tested NPs in B16F10 
(murine melanoma cell line) cells and showed a significant inhibition of internalization of 
nanoparticles with sizes between 200 and 50 nm, while the uptake of those with a size of 500 nm 
was unaltered or even slightly higher, which means large particles are internalized through a 
different pathway.  
The size and zeta potential of the lipoplexes of dissymmetric gemini surfactants, and 
DNA were measured and tabulated in Appendix C (Tables 5.1, and 5.2). As can be seen in Figure 
5.2 (py-3-m surfactants) and Figure 5.3 (12-3-n surfactants), at low charge ratios of 1:1, and 1:2 
particles size was noticeably large with an overall negative zeta potential, indicating that 
complexation happens with the DNA, but the surfactants are  unable to fully complex the DNA. 
As the charge ratio increases (5:1 and 10:1), all complexes have sizes less than 200nm with an 
overall positive net charge, except for pyrene-3-18. The reason for this remains unclear.  Larger 
nanoparticles were also formed in the presence of 12-3-18, suggesting that the longer alkyl tails 
may result in less efficient compaction of the DNA, which could help explain the unusual 
negative charge for the py-3-18 complexes.  For complexes containing pyrenyl gemini 
surfactants, the zeta potentials were above +30 mV at a charge ratio of 5:1 and greater, with the 
exception of pyr-3-8-DNA complex, indicating that the complexes are normally stable. For 
complexes containing asymmetric (12-3-n) surfactants, the zeta potential values were also above 
+30mV at higher charge ratios. In the current transfection experiments, only one charge ratio 
(5:1) was used for transfection studies, selected based upon  
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Figure 5.2 Physical characterization of nanoparticles, A) Particle size, B) Zeta potential of 
pyrene-based gemini surfactants (pyrene-3-8, pyrene-3-12, pyrene-3-14, pyrene-3-16, pyrene-3-
18), with or without DNA. 
 
the size and zeta potential results, and previous observations (for other surfactant systems) that 
the 5:1 ratio was correlated with better transfection in our lab. 178  We did not use a higher 
charge ratio due to concerns of increased toxicity associated with higher concentrations of 
quaternary ammonium surfactants. 
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Figure 5.3 Physical characterization of the nanoparticles, A) Particle size, B) zeta potential of 
dissymmetric gemini surfactants 12-3-14, 12-3-16, 12-3-18, with and without DNA. 
 
5.3.2 Evaluation of transfection efficiency in vitro  
 
The dissymmetric gemini surfactants (12-3-n) in the MG-63 cell line were internalized and the 
DNA was being released, but the transfection efficiency was very low, especially for 12-3-14 
(Figure 5.4A). This may be linked to cell viability as our cell viability results (Figure 5.4B) 
indicate these complexes are very toxic to the MG-63 cells. Cell viability after treatment with 
12-3-14GPD (12-3-14 with DOPE at a DOPE:GS molar ratio of 3:2 and a GS:DNA charge ratio 
of 5.1) complexes is 8.1 ± 0.4%, and for the 12-3-14:DNA complexes (with no added DOPE) 
the viability was even lower at 3 ± 1 % (essentially 0!) Similar behavior was observed for the 
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12-3-18 complexes, although the transfection efficiencies and cell viabilities are much greater 
than those for 12-3-14. The transfection efficiencies for the 12-3-16 complexes efficiencies were 
10.4 ± 0.8 and 11 ±3 for complexes with (GDP) and without DOPE (GP), respectively,  
 
Figure 5.4 A) Transfection efficiency of 12-3-n gemini surfactant complexes in HEK-293 cell-
line (orange), and in MG-63 cell-line (blue) and B) cell viability (violet) of dissymmetric (12-3-
n) gemini surfactants complexes in MG-63 cell line 
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which are the highest among the dissymmetric surfactants. The 12-3-16 complexes also gave 
rise to the highest cell viabilities, 74 ± 3% and 76 ± 12% for the GDP and GP complexes, 
respectively. The same behaviour was observed previously in our group with a series of phytanyl 
substituted (phy-3-n) surfactants, where the phy-3-16 surfactant gave higher transfection than 
either phy-3-12 or phy-3-18 when complexed with DNA and DOPE in an OVCAR-3 cell line.178 
Similarly, for the symmetrical m-3-m surfactants,  16-3-16 gave higher transfection compared 
to 12-3-12 or 18-3-18, again when complexed with DNA and DOPE in PAM212 cell lines.126 
Unfortunately, possibly due to the low transfection efficiencies observed, the differences in the 
transfection efficiencies for the 12-3-n surfactants are not statistically significant, indicating that 
this initial, preliminary, transfection study will need to be repeated. 
In the HEK-293 cell line, the 12-3-14 complexes again displayed low transfection GDP = 2 ± 
1% and GP=3 ± 2%; Figure 5.4), although the efficiency was higher in the HEK293 vs. the MG-
63 cells. The viability of the 12-3-14 GP complexes (12 ± 6%) is higher than for the GDP system 
(5 ± 6; again essentially 0), again consistent with the high toxicity observed in the MG-63 cells.  
The 12-3-16 complexes showed the highest level of transfection efficiency in the HEK293 cells, 
as well as the highest cell viability among the three surfactants.  For all 3 surfactants, increased 
toxicity was seen upon addition of DOPE to the complexes; an observation that has been 
previously made in our group, however, this appears to be generally inconsistent with what has 
been reported in the literature.228,236,237 The 12-3-18 complexes showed better transfection in the 
absence of DOPE (12-3-18 GDP = 6 ± 2%, GP = 14.8 ± 0.8%). The transfection results for the 
three surfactant complexes without the DOPE come in agreement with the results obtained from 
the Langmuir monolayers.213 The surfactant complexes increased the fluidity of the membranes, 
resulting in membrane fusing, and internalized. However, one of the major issues with these 
surfactants is their toxicity, which has been reported before.116 
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We attempted to examine the transfection efficiencies of the py-3-m surfactants using the 
same flow cytometry method as for the 12-3-n surfactants.  Results for the transfection 
efficiencies and the cell viabilities for both cell lines for the five pyrene-based surfactants are 
found in Figure 5.5. At first glance, the problem with this data is immediately obvious; in the 
absence of ANY added plasmid or DOPE, the py-3-m surfactants show high (for the py-3-12 
and py-3-14 surfactants very high) transfection was observed.  This was observed in multiple 
experiments, and is of course impossible from a cell biology standpoint.  Contamination was 
ruled out (by multiple experiments carried out with new samples, media, and reagents) meaning 
that an unknown cause was responsible.  As pyrene is a fluorescent molecule it could potentially 
contribute to the overall fluorescence observed by the flow cytometer; however the normal 
pyrene fluorescence emission ranges from ~370 – 450 nm, well away from the emission 
wavelength for EGFP (509nm).  What cannot be forgotten is that the pyrene moieties in our 
systems are bound to aggregating surfactants, forcing pyrene groups into close proximity with 
each other.  Pyrene is of course well known for excimer formation, which red-shifts the 
fluorescence emission to higher wavelengths (~ 475 – 530 nm).  Given this high molar ratio of 
surfactant:DNA base pairs (i.e. charge ratio), coupled with the low levels of transfection 
observed for the 12-3-n surfactants described above, we can conclude that the fluorescence from 
pyrene excimers is contaminating the signal from EGFP, rendering this assay useless for the py-
3-m surfactants; the pyrene excimer emission was confirmed for the surfactants alone, for the 
GP and for the GDP complexes (data not shown). As such an alternative means of determining 
transfection efficiency for the py-3-m surfactants had to be used; an ELISA assay carried out in 
collaboration with Dr. Ildiko Badea from the College of Pharmacy at the University of 
Saskatchewan.  The results of the ELISA assay will be discussed below. 
The flow cytometry transfection results for the py-3-m surfactants were not useful, 
however, the cell viability assay used was still valid. Although it is based on fluorescent 
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emission, in this case the reporting chromophore is propidium iodide (PI), which has an emission 
maximum at 630nm, well resolved from the pyrene excimer (and EGFP) fluorescence. The 
pyrenyl surfactants showed greater cell viability compared to the positive control (Lipofectamine 
2000,  
 
 
 
Figure 5.5 A) Transfection efficiency of pyrenyl gemini surfactant complexes in HEK-293 cell-
line (orange) and in MG-63 cell-line (blue) and B) cell viability (same colors) with 
Lipofectamine 2000 as the positive control 
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cell viability = 50%; see Figure 5.5) with the exception of pyrene-3-8, which was observed to be 
quite toxic (24 % viable for the GDP system and 50% for the GP system). Similar results were 
observed in the HEK-293 cells.  
The ELISA assay subsequently used to examine transfection efficiency for the py-3-m measures 
interferon-gamma protein (-IFN) expression directly and does not depend on fluorescence 
emission from EGFP. Very low transfection efficiencies (reported in terms of picogram/104 
cells) were observed for the py-3-m surfactants (Figure 5.6), with the highest transfection 
observed for the py-3-8/DOPE/plasmid complexes at a 5:1 py-3-8:DNA charge ratio after 48h 
incubation (8600 ± 2600 pg/104 cells), and at a 10:1 charge ratio after 72h incubation (15000 ± 
1500 pg/104 cells). It should be noted that these results are not directly comparable to the MG-
63 or HEK-293 cells as a COS-7 cell line was used for transfection; however the COS-7 cells 
are known to be “easily transfectable” (Dr. Ildiko Badea, private communication). These results 
for pyr-3-8 complexes are higher than those of reported Lipofectamine plus in COS-7 cell line 
(INF-γ level of expression for Lipofectamine plus after 48 h= 2000pg/2000 cells, and <2500pg/ 
2000 cells after 72 h).228, 238 The toxicity of the GDP nanoparticles prepared with the five gemini 
surfactants was evaluated in COS-7 cell line after 48 h of treatment. The cell viability of the 
pyrenyl surfactants in the COS-7 cell line were measured using an MTT-assay and are reported 
in Figure 5.7 (see also Table 5.9 in Appendix C). Cell viabilities are generally greater than 70% 
regardless of surfactant used; however both the ELISA assay and the cell viability assay lacked 
the Lipofectamine 2000 positive control and will need to be repeated in the future. 
5.4 Conclusion 
 
Overall, the 12-3-n and py-3-m surfactants were able to transfect DNA in multiple cell 
lines (for the 12-3-n surfactants); however the efficiencies observed were generally poor, and 
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certainly not at a level that could be suitable for any clinical application.  Clearly extensive 
optimization of these systems would be required before any of the potential promise as a viable 
transfection vector (indicated by the results of our Langmuir monolayer and BAM studies) could 
be realized.  The cell viabilities for the py-3-m surfactants was greater than that observed for the 
12-3-n surfactants, with reasonable viabilities in MG-63 and HEK-293 cell lines, and good 
viabilities in the COS-7 cells.  This suggests the py-3-m surfactants may have greater potential 
than the 12-3-n surfactants; however future studies are clearly required. 
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Figure 5.6 ELISA protein expression results of pyrene-based gemini surfactants complexes in 
COS-7 cell lines after two incubation times; A) 48h and B)72h with Lipofectamine plus as the 
positive control 
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Figure 5.7 Cytotoxicity produced by pyrene-based gemini surfactant complexes in COS-7 cell 
line. 
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Chapter 6: Conclusion and future studies 
 
          We have successfully synthesized and characterized pyr-3-m and 12-3-n gemini 
surfactants. Pyrene-based gemini surfactants exhibited unique aggregation properties in solution 
with much lower CMC values than their symmetric counterparts with early onset of 
micellization. This is largely attributed to the presence of the pyrene moiety in the structure of 
the molecule, increasing the hydrophobicity of the surfactants, impacting the structure of the 
aggregates formed. These aggregates ranged from vesicular to lamellar and inverted structures. 
The 12-3-n gemini surfactants exhibited much lower CMC values compared to their symmetric 
counterparts, and this is possibly due to increased dissymmetry in the structure, enhancing the 
intermolecular hydrophobic interactions between the alkyl tails of the same length, favoring the 
micellization. Both of the pyrenyl and the dissymmetric gemini surfactants have higher degrees 
of micelle ionization compared to their symmetric counterparts, and this increases with the 
increase in the alkyl tail length. The higher the α, the greater the electrostatic repulsion between 
the two head groups, rendering the micelles partially charged, which enhances the interaction 
with the negatively charged phosphate groups of DNA to reduce the electrostatic repulsion 
between the head groups when used as a transfecting agent.  
         A study of the effect of these gemini surfactants alone or complexed with DNA on model 
membrane, mimicking the cellular membranes, using two model membranes (DPPC-Chol and 
POPC-Chol monolayers) was successfully determined in Chapter IV. We have successfully 
characterized models of the endosomal membranes of normal cells (DPPC-cholesterol = 75:25 
%), and of cancer cells (POPC-Cholesterol= 75%:25%). The DPPC-Cholesterol monolayer 
showed solid phase at a surface pressure from 30 to 35 mN/m, indicating the rigidity of the 
membrane. Once the gemini surfactants were added to the DPPC-Cholesterol monolayer; 
whether those of pyrene-based surfactants, or the 12-3-n surfactants; with or without the DNA, 
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the rigidity of the membrane was substantially reduced and fluidity was induced. Pyrene-3-12 
showed unique behavior that stood apart from the rest of the pyrenyl surfactants. When added to 
the monolayer, pyr-3-12 increased the compressibility modulus of the DPPC-Chol monolayer 
and this was attributed to its structure (closer to symmetry), which makes it fit better in between 
the gaps in the monolayer, making it more rigid. This behavior changes as soon as the DNA is 
added, the DNA reorients the pyr-3-12 structure, and changes its properties. This rearrangement 
induces fluidity of the monolayer, and this is applied to all of the pyrenyl gemini surfactants once 
the DNA is added. 12-3-n gemini surfactants showed to be dramatically disruptive to the DPPC-
Chol, which was clear from the premature collapse induced by these surfactants. The POPC-
Cholesterol system was found to be much more fluid at the same surface pressures, in the LE 
phase. All of the dissymmetric gemini surfactants (pyr-3-m and 12-3-n) increase the rigidity of 
the POPC-Chol monolayer due to insertion of the surfactant into the monolayer. However 
insertion of these surfactants between the molecules of POPC-Chol may hinder the motion of 
the oleyl chain in the POPC molecules in the monolayer, giving rise to an increase in rigidity. 
The addition of DNA resulted in increased fluidity of the monolayer as it was observed in the 
DPPC-Chol monolayer, further suggesting that in the presence of DNA, the interaction(s) are 
between the monolayer and the surfactant:DNA complexes at the air/water interface.  Although 
our findings show that these gemini surfactants are expected to escape from the endosomal 
compartment, the strong interactions between the GS and the DNA may hinder the release of the 
DNA from the complex, which may result in its aggregation and clearance from the body instead 
of delivering the DNA into the nucleus. The Langmuir monolayer studies have proven the ability 
of the synthesized surfactants as part of GS-DNA complex to interact and be internalized into 
the membrane. 
           12-3-n and pyr-3-m gemini surfactants were able to transfect DNA in multiple celllines, 
however, the transfection results of 12-3-n were generally poor. Due to the spectral 
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contamination observed in the pyr-3-m transfection results, different method was used. ELISA 
assay for the transfection complexes in COS-7 were determined. In general, very little protein 
expression was observed for most of the pyrenyl surfactants, however, high protein expression 
(γ- INF) was recorded for pyr-3-8 complexes (whether after 48 h or 72 h incubation). Pyr-3-8 
gave higher protein expression than the positive control (Lipofectamine plus), regardless the 
incubation time, 239 proving to be a promising transfecting agent. These results might have been 
caused by the unique structure of the pyr-3-8, with short alkyl tail (octyl), which might have led 
to loose complexation to the DNA, possibly leading to easier release of the DNA from the 
complex. Pyr-3-m viability, whether determined by flow cytometry or MTT assay, proved that 
these surfactants are not as toxic as the 12-3-n or have higher cell viability than the positive 
control as observed for pyr-3-14 and pyr-3-16 complexes. 
This project could be expanded by looking into these surfactants using Small-angle X–ray 
scattering (SAXS), which is a more accurate method to determine the presence of high-order 
morphologies. We can investigate dissymmetric surfactants using SAXS to observe changes of 
phase behavior to confirm the packing parameter results and the results observed in the Krafft 
temperature experiments, and whether or not the formation of inverted micelles is actually 
happening  in the 12-3-n surfactants and in pyr-3-8 surfactant, and how adding the DNA can 
reorient the structures formed these surfactants in solution.240, 116 Moreover, differential scanning 
calorimetry (DSC) studies can be considered in order to observe the phase behavior (phase 
transition) as a function of temperature. 
The effect of pluronics as co-surfactants that impart no toxicity and are biocompatible on model 
membranes, together with the GS-DNA complex can be investigated. Another area for further 
study is the effect of the pH on the monolayer. This was investigated by Taksim Ahmed in our 
lab with two different surfactants, 16-7N-16 and 16-7NH-16143. The influence of pH on the 
interaction(s) of the vectors is very critical in the transfection experiments (in vitro). A better 
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understanding of the effect of pH can help us account for other possible factors that can hinder 
the passage of the vectors into the cell membrane, or even the passage through the cytosol 
without being cleared from the system. We can design the Langmuir monolayer with the 
temperature increased to 37C̊ to better mimic the conditions of the in vitro study instead of 20ºC.  
Another possibility is increasing the complexity of the model membranes to better mimic the 
real membranes. Additionally the late endosome is rich in lysobisphosphatidic acid (LBPA) or 
bis(monoacyl glycero)phosphate (BMP) and a lysosome specific lipid which is not found 
elsewhere in the cells. Thus incorporating LBPA along with cholesterol could be a good model 
membrane study for the late endosome.  
         One of the strategies to improve transfection efficiency for gene therapy is to design new, 
more efficient vectors for transgene delivery. Transfection efficiencies of dissymmetric gemini 
surfactants were tested in two cell lines, MG-63 and HEK-293 and pyrenyl surfactant complexes 
were tested in COS-7 cell line as well. Data collected for pyrenyl surfactants showed very poor 
transfection results despite the observed disruptive actions of these surfactants in Chapter IV 
with both monolayers.  12-3-n gemini surfactant complexes showed low transfection as well, 
except for 12-3-16, which showed higher transfection (10% and 14% in both cell lines), which 
is still much lower than the lipofectamine 2000 in HEK-293 cells but not the MG-63. However, 
pyr-3-8 transfection results using ELISA has proven to be quite promising.  More study and 
proper investigation of this surfactant in different celllines is required to establish its efficiency 
as a transfecting agent. Moreover, optimization of the pyrenyl surfactant complexes with and 
without DOPE can be another strategy, because these surfactants proved to be not toxic or 
possess less toxicity compared to their symmetric or dissymmetric counterparts. Further 
investigation and more optimization should be considered before concluding their inefficiency 
as transfection agents.         
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           Gene delivery abilities of these surfactants can be further investigated after applying 
structural modifications that can increase the transfection efficiency, such as, the introduction of 
tertiary or secondary amine into the spacer group.  These modified pyr-7N-m and pyr-7NH-m 
can be tested in number of cell lines (PAM 212 and COS-7). Adding targeting moieties into the 
nanoparticle formulation (e.g. α- tochopherol or folic acid) to target a specific cell line can 
improve the transfection efficiencies. Folic acid receptors are over expressed in ovarian cancer 
and this can be a strategy to increase transfection efficiency.241, 242 Moreover, the effect of 
unsaturation can be investigated (C18:1). The gene delivery assessment of these further-designed 
surfactants could be complemented by evaluation of their toxicological effects.  
        One of the options that can be explored, especially for pyr-3-8 complex, is the in vivo studies 
to see how well a non-viral vector would do when the complexity increases, and what 
optimization steps can be done to achieve a better transfection, and ultimately expression of the 
desired gene into a functioning protein. There are several in vivo studies that was done utilizing 
gemini surfactants as a non-viral vector with limited success, which means further testing and 
optimization are required to determine the full capability of gemini surfactants and other 
components of the vectors employed in each study.228 Intraperitoneal, intramuscular or 
subcutaneous methods were used for injecting the plasmid DNA or the lipoplex into animals in 
in vivo studies.243 In addition to those methods, topical DNA delivery where the formulation is 
applied to the skin with the aim of transfecting keratinocytes, dendritic cells or fibroblasts within 
the viable epidermis or dermis. Upon topical application, naked DNA or DNA encapsulated in a 
lipoplex system may be absorbed into the hair shaft and transfect the hair follicles, providing an 
opportunity for gene therapy of hair-growth disorders.228  
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Appendices 
Appendix A (Chapter III) 
1H NMR Spectra for the synthesized compounds 
Compound δ (ppm) Number of 
protons 
Group 
5-Bromohexyl-1-pyrenyl ketone 
 
8.84 1H PYR-C-H 
8.31-
8.017 
8H PYR-H 
3.45 2H CH2-Br 
3.24 2H α-CH2 
1.98-1.84 4H β & δ-CH2 
1.65-1.55 2H γ-CH2 
6-(1-Pyrenyl-bromohexane) 
 
8.27-7.83 9H PYR-H 
3.41-3.30 4H α-CH2 & Pyr-CH2 
1.90-1.81 4H β & ε-CH2 
1.51-1.48 4H γ-CH2  & δ-CH2 
Pyr-3(N-(3-dimethylaminopropyl)-N,N-dimethyl-6-(pyren-6-
yl)-hexane-1-ammonium bromide) 
 
8.20-7.80 9H PYR-H 
3.43 2H N+-CH2 
3.40-3.16 4H PYR-CH2 & CH2-
N+ 
3.05 6H N+-(CH3)2 
2.36 2H N-(CH3)2 
1.87-1.51 10H (CH2)4 & β-CH2 
Pyrene-3-12 (N1-dodecyl N1,N1,N3,N3- tetramethyl-N3-(6-
pyren-6yl)-hexyl) propane-1,3-diammonium dibromide 
8.23-7.78 9H PYR-H 
3.77-3.73 4H N+-CH2 
3.33-3.31 6H PYR-CH2 & CH2-
N+ CHAIN 
3.2 6H N+-(CH3)2-
PYRENE END 
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1.98 6H N+-(CH3)2-
DODECYL END 
1.66 2H CH2 SPACER 
1.38-1.22 28H CH2- CHAIN 
AND HEXYL 
0.87       3H C-CH3 
Pyrene-3-8 (N1-Octyl N1,N1,N3,N3- tetramethyl-N3-(6-pyren-
6yl)-hexyl) propane-1,3-diammonium dibromide 
 
8.17-7.80 9H PYR-H 
3.77-3.73 4H N+-CH2 
3.61 6H PYR-CH2 & CH2-
N+ CHAIN 
3.44 6H N+-(CH3)2-
PYRENE END 
2.73 6H N+-(CH3)2-
OCTYL END 
1.87 2H CH2 SPACER 
1.80-1.23 20H CH2- CHAIN 
AND HEXYL 
0.87 3H C-CH3 
Pyrene-3-14 (N1-tetradecyl N1,N1,N3,N3- tetramethyl-N3-(6-
pyren-6yl)-hexyl) propane-1,3-diammonium dibromide 
 
8.19-7.79  9H PYR-H 
3.72-3.57  4H N+-CH2 
3.31 6H PYR-CH2 & CH2-
N+ CHAIN 
3.11 6H N+-(CH3)2-
PYRENE END 
2.55 6H N+-(CH3)2-
TETRADECYL 
END 
2.11 2H CH2 SPACER 
1.79-1.19 32H CH2- CHAIN 
AND HEXYL 
0.87 3H C-CH3 
8.23-7.80 9H PYR-H 
3.59 4H N+-CH2 
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Pyrene-3-16 (N1-hexadecyl N1,N1,N3,N3- tetramethyl-N3-(6-
pyren-6yl)-hexyl) propane-1,3-diammonium dibromide
 
3.38-3.30 6H PYR-CH2 & CH2-
N+ CHAIN 
3.11 6H N+-(CH3)2-
PYRENE END 
2.59 6H N+-(CH3)2-
HEXADECYL 
END 
2.15 2H CH2 SPACER 
1.83-1.21 36H CH2- CHAIN 
AND HEXYL 
0.87 3H C-CH3 
Pyrene-3-18 (N1-octadecyl N1,N1,N3,N3- tetramethyl-N3-(6-
pyren-6yl)-hexyl) propane-1,3-diammonium dibromide 
 
8.23-7.80 9H PYR-H 
3.72 4H N+-CH2 
3.41-3.22 6H PYR-CH2 & CH2-
N+ CHAIN 
3.18 6H N+-(CH3)2-
PYRENE END 
2.7 6H N+-(CH3)2-
OCTADECYL 
END 
2.11 2H CH2 SPACER 
1.79-1.21 39H CH2- CHAIN 
AND HEXYL 
0.85 3H C-CH3 
12-3-14(N-dodecyl-N-tetradecyl-1, 3-propanediammonium 
dibromide) 
 
3.88-3.83 2H α-CH2 Spacer 
3.50-3.46 2H γ-CH2 Spacer 
3.38 12H N+ -(CH3)4 
3.02-2.97 4H (CH2)2 
1.82-1.78 4H (CH2)2 
1.34-1.23 42H (CH2)20  & β-CH2 
0.88-0.83 6H (CH3)2 
12-3-16(N-dodecyl-N-Hexadecyl-1, 3-propanediammonium 
dibromide) 
3.88-3.83 2H α-CH2 Spacer 
3.50-3.46 2H γ-CH2 Spacer 
3.38 12H N+ -(CH3)4 
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3.02-2.97 4H (CH2)2 
1.82-1.78 4H (CH2)2 
1.34-1.23 44H (CH2)21  & β-CH2 
0.88-0.83 6H (CH3)2 
12-3-18(N-dodecyl-N-octadecyl-1, 3-propanediammonium 
dibromide) 
 
3.88-3.83 2H α-CH2 Spacer 
3.50-3.46 2H γ-CH2 Spacer 
3.38 12H N+ -(CH3)4 
3.02-2.97 4H (CH2)2 
1.82-1.78 4H (CH2)2 
1.34-1.23 46H (CH2)22  & β-CH2 
0.88-0.83 6H (CH3)2 
 
1H NMR spectra for 5-Bromohexyl-1-pyrenyl ketone 
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1H NMR spectra for pyr-3 
 
 
 
 
 
1H NMR spectra for pyr-3-14 
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1H NMR spectra for pyr-3-16 
 
 
 
1H NMR spectra for 12-3-14 
 
 
 
 
 
179 
 
Table 3.1 Conductivity measurements of Pyrene-3-12 
# C(mM) 
Conductivity. 
(uS/cm) 
Average 
Conductivity Std. 
1 0 2.69 2.69 0.00 
  2.70   
2 0.018 7.13 7.14 0.01 
  7.15   
3 0.037 10.9 10.87 0.03 
  10.9   
4 0.055 14.7 14.74 0.00 
  14.7   
5 0.073 18.4 18.41 0.01 
  18.4   
6 0.092 21.9 21.95 0.07 
  22.0   
7 0.11 24.9 24.95 0.07 
  25.0   
8 0.128 28.3 28.40 0.14 
  28.5   
9 0.146 31.3 31.40 0.14 
  31.5   
10 0.165 34.6 34.65 0.07 
  34.7   
11 0.183 37.1 37.10 0.00 
12 0.201 39.5 39.55 0.07 
  39.6   
13 0.22 41.8 41.80 0.00 
14 0.24 43.2 43.35 0.21 
  43.5   
15 0.26 44.6 44.70 0.14 
  44.8   
16 0.28 45.9 46.00 0.14 
  46.1   
17 0.29 46.8 46.80 0.00 
18 0.31 47.9 47.95 0.07 
  48.0   
19 0.33 48.6 48.60 0.00 
20 0.35 49.5 49.50 0.00 
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Table 3.2 Surface measurement of 12-3-16 
Log C (M) Surface tension (mN/m) 
-5.14927 68.19 
-4.85029 65.77 
-4.67618 60.89 
-4.55331 56.83 
-4.45840 53.63 
-4.38132 50.9 
-4.31629 48.44 
-4.26033 45.47 
-4.21118 43.13 
-4.16732 41.08 
-4.12792 39.35 
-4.09212 37.73 
-4.05927 36.43 
-4.02907 35.36 
-4.00104 34.58 
-3.97488 33.98 
-3.9505 33.67 
-3.92758 33.21 
-3.90597 32.73 
-3.88558 32.39 
-3.86629 32.23 
-3.84796 32.21 
-3.83051 32.03 
-3.81398 32.16 
-3.79786 32.22 
-3.7827 32.14 
-3.76843 32.14 
-3.75426 32.03 
-3.74088 32.1 
-3.72790 32.01 
-3.71564 32.23 
-3.70339 32.14 
-3.69179 32.21 
-3.68080 32.18 
-3.67009 32.48 
-3.65933 32.56 
-3.64942 32.72 
-3.63944 32.93 
-3.62996 32.91 
-3.62068 32.86 
-3.61160 33.04 
-3.60297 33.00 
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-3.59450 32.89 
-3.58619 33.17 
-3.57804 33.19 
-3.57028 33.2 
-3.56266 32.88 
-3.55517 33.02 
-3.54780 32.98 
-3.54078 33.00 
-3.53388 32.92 
-3.52708 33.12 
-3.52039 33.30 
-3.51401 33.06 
-3.50772 33.13 
-3.50152 32.96 
-3.49541 33.66 
-3.48938 33.48 
-3.48363 33.17 
-3.47796 33.33 
-3.47236 33.33 
-3.46684 33.63 
-3.46156 33.28 
-3.45636 33.67 
-3.45121 33.61 
-3.44612 33.76 
-3.44110 33.56 
-3.43630 33.74 
-3.43156 33.48 
-3.42670 33.70 
-3.42224 33.70 
-3.41764 33.75 
-3.41310 33.60 
-3.40877 33.57 
-3.40449 33.71 
-3.40024 33.62 
-3.39604 33.65 
-3.39203 33.76 
-3.38791 33.76 
-3.38398 33.61 
-3.38008 33.72 
-3.37622 33.72 
-3.37255 33.60 
-3.36875 33.66 
-3.36514 33.82 
-3.36141 33.77 
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-3.35786 33.87 
-3.35434 33.81 
-3.35099 33.81 
-3.34752 33.84 
-3.34422 33.92 
-3.34095 33.93 
-3.33756 33.88 
-3.33434 33.86 
-3.33128 33.86 
-3.32810 33.88 
-3.32509 33.82 
-3.32195 33.91 
-3.31898 33.85 
-3.31603 33.89 
-3.31309 33.86 
-3.31018 33.91 
-3.30728 33.90 
-3.30454 33.89 
-3.30181 33.88 
-3.29897 33.82 
-3.29627 33.83 
-3.29360 33.85 
-3.29093 33.84 
-3.28842 33.87 
-3.28579 33.88 
-3.28330 33.88 
-3.28070 33.88 
-3.27824 33.86 
-3.27579 33.82 
-3.27336 33.80 
-3.27094 33.83 
-3.26865 33.80 
-3.26626 33.81 
-3.26388 33.80 
-3.26163 33.79 
-3.25939 33.73 
-3.25716 33.78 
-3.25495 33.76 
-3.25275 33.78 
-3.25055 33.73 
-3.24837 33.72 
-3.24632 33.72 
-3.24415 33.68 
-3.24212 33.70 
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-3.24009 33.70 
-3.23807 33.72 
-3.23606 33.73 
-3.23406 33.74 
-3.23207 33.81 
-3.23009 33.75 
-3.22812 33.68 
-3.22627 33.69 
-3.22442 33.67 
-3.22247 33.67 
-3.22064 33.66 
-3.21882 33.66 
-3.21701 33.66 
-3.21520 33.67 
-3.21340 33.65 
-3.21161 33.62 
-3.20993 33.59 
-3.20815 33.65 
-3.20648 33.66 
-3.20472 33.67 
-3.20306 33.67 
-3.20141 33.65 
-3.19977 33.63 
-3.19814 33.63 
-3.19651 33.62 
-3.19488 33.64 
-3.19327 33.65 
-3.19176 33.66 
-3.19015 33.64 
-3.18865 33.64 
-3.18706 33.69 
-3.18557 33.65 
-3.18408 33.66 
-3.18251 33.66 
-3.18103 33.67 
-3.17956 33.65 
-3.17810 33.68 
-3.17674 33.64 
-3.17528 33.65 
-3.17383 33.60 
-3.17239 33.67 
-3.17105 33.62 
-3.16961 33.64 
-3.16828 33.66 
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-3.16694 33.65 
-3.16562 33.67 
-3.16420 33.65 
-3.16288 33.69 
-3.16157 33.68 
-3.16025 33.68 
-3.15895 33.68 
-3.15774 33.63 
-3.15644 33.65 
-3.15514 33.70 
-3.15394 33.67 
-3.15265 33.63 
-3.15146 33.64 
-3.15018 33.63 
-3.14899 33.66 
-3.14781 33.65 
-3.14663 33.67 
-3.14537 33.65 
-3.14419 33.63 
-3.14302 33.61 
-3.14186 33.61 
-3.14078 33.61 
-3.13962 33.55 
-3.13846 33.58 
-3.13731 33.57 
 
Table 3.3 Surface tension measurement of Pyrene-3-16 
Log C (M) Surface tension (mN/m) 
-5.55246 69.74 
-5.25308 69.76 
-5.07864 69.77 
-4.95531 69.47 
-4.86012 69.44 
-4.78258 69.37 
-4.71709 69.38 
-4.66069 69.37 
-4.61100 69.39 
-4.56682 69.38 
-4.52709 69.37 
-4.49085 69.36 
-4.45757 69.20 
-4.42694 67.82 
-4.39860 67.21 
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-4.37213 66.01 
-4.34730 65.04 
-4.32404 64.14 
-4.30207 62.81 
-4.28127 61.47 
-4.26161 59.09 
-4.24290 57.68 
-4.22514 56.33 
-4.20809 55.01 
-4.19193 53.99 
-4.17635 53.13 
-4.16146 52.36 
-4.14715 51.46 
-4.13337 50.86 
-4.12008 50.19 
-4.10732 49.56 
-4.09500 49.00 
-4.08308 48.48 
-4.07155 48.08 
-4.06037 47.89 
-4.04960 47.52 
-4.03915 47.47 
-4.02900 47.15 
-4.01914 46.87 
-4.00955 46.52 
-4.00023 45.68 
-3.99121 44.96 
-3.98237 44.54 
-3.97376 44.20 
-3.96541 44.00 
-3.95727 43.79 
-3.94929 43.6 
-3.94154 43.58 
-3.93397 43.43 
-3.92658 43.49 
-3.91936 43.48 
-3.91225 43.34 
-3.90535 43.27 
-3.89873 43.23 
-3.89191 43.22 
-3.88561 43.27 
-3.87900 43.19 
-3.87288 43.28 
-3.86685 43.19 
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-3.86091 43.08 
-3.85504 43.03 
-3.84925 43.03 
-3.84354 43.17 
-3.83827 43.10 
-3.83270 43.30 
-3.82757 43.19 
-3.82213 43.14 
-3.81712 43.15 
-3.81217 43.20 
-3.80692 43.31 
-3.80208 43.41 
-3.79729 43.33 
-3.79255 43.71 
-3.78820 43.29 
-3.78357 43.37 
-3.77898 43.23 
-3.77444 43.38 
-3.77026 43.23 
-3.76613 43.18 
-3.76172 43.09 
-3.75766 43.15 
-3.75365 42.97 
-3.74967 42.89 
-3.74542 43.02 
-3.74151 43.07 
-3.73794 43.04 
-3.73410 42.86 
-3.73029 42.74 
-3.72652 42.72 
-3.72307 42.7 
-3.71936 42.64 
-3.71596 42.57 
-3.71231 42.41 
-3.70897 42.33 
-3.70565 42.42 
-3.70208 42.39 
-3.69882 42.35 
-3.69558 42.83 
-3.69236 42.44 
-3.68917 42.39 
-3.68600 42.29 
-3.68285 42.28 
-3.67998 42.31 
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-3.67688 42.24 
-3.67380 42.27 
-3.67099 42.25 
-3.66795 42.25 
-3.66518 42.26 
-3.66243 42.19 
-3.65945 42.15 
-3.65674 42.16 
-3.65404 42.21 
-3.65136 42.22 
-3.64869 42.18 
-3.64604 42.20 
-3.64341 42.20 
-3.64079 42.16 
-3.63819 42.29 
-3.63561 42.21 
-3.63303 42.14 
-3.63071 42.20 
-3.62817 42.25 
-3.62564 42.15 
-3.62336 42.23 
-3.62086 42.37 
-3.61860 42.94 
-3.61635 43.04 
-3.61389 43.08 
-3.61167 43.16 
-3.60946 42.86 
-3.60725 42.95 
-3.60506 43.07 
-3.60289 43.02 
-3.60072 43.22 
-3.59856 43.25 
-3.59641 43.15 
-3.59428 42.9 
-3.59215 42.87 
-3.59004 42.87 
-3.58814 42.91 
-3.58604 42.99 
-3.58396 43.07 
-3.58209 43.21 
-3.58002 43.16 
-3.57817 43.23 
-3.57612 43.33 
-3.57429 43.30 
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-3.57246 43.20 
-3.57044 43.22 
-3.56862 43.25 
-3.56682 43.27 
-3.56502 43.07 
-3.56323 42.96 
-3.56145 42.65 
-3.55948 43.10 
 
Table 3.4 Krafft temperature measurement of Pyrene-3-16 
Temp(Cᵒ) Cond. (uS/cm) Ave. Cond. (uS/cm) Std. 
10 83.2 83.20 0.00 
15 85.8 85.90 0.14 
 86.0   
20 87.3 87.35 0.07 
 87.4   
25 88.1 88.15 0.07 
 88.2   
30 88.3 88.35 0.07 
 88.4   
35 89.1 89.15 0.07 
 89.2   
40 90.1 90.15 0.07 
 90.2   
45 91.3 91.40 0.14 
 91.5   
50 92.8 92.85 0.07 
 92.9   
55 94.4 94.50 0.14 
 94.6   
60 95.9 95.95 0.07 
 96.0   
65 98.0 98.05 0.07 
 98.1   
70 100.7 100.75 0.07 
 100.8   
75 104.8 104.90 0.14 
 105.0   
80 108.8 108.90 0.14 
 109.0   
85 112.5 112.45 0.07 
 112.4   
90 116.0 116.10 0.14 
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 116.2   
95 118.6 118.60 0.00 
100 122.9 122.95 0.07 
 123.0   
105 125.0 125.00 0.00 
110 125.5 125.50 0.00 
 
Table 3.5 Packing parameter and the structure of the micelle 
 
 
 
 
 
 
 
 
 
Appendix B (Chapter IV) 
Graph 4.1 Pyrene-3-8 monolayer π-A 
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Mean molecular area (Å2)
Surface pressure isotherm of Pyrene-3-8
Pyr-3-8-2nd trial
Surfactants a˳ (Å2) V(Å3) l (Å) P 
Pyr-3-8 35 837 16.05 1.50 
Pyr-3-12 56 945 16.68 1.00 
Pyr-3-14 113 999 19.21 0.46 
Pyr-3-16 52.6 1053 21.74 0.92 
Pyr-3-18 70 1107 24.27 0.65 
12-3-14 30 756 19.21 1.30 
12-3-16 21 810 21.74 1.77 
12-3-18 19 864 24.27 1.87 
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Figure 4.2 Compressibility modulus of Pyrene-3-8 monolayer 
 
Figure 4.3 Surface pressure-area isotherm of Cholesterol monolayer 
 
Figure 4.4 Surface pressure-area isotherm of DPPC monolayer 
 
Figure 4.5 Surface pressure-area isotherm of POPC monolayer 
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Appendix C (Chapter V) 
Table 5.1 Particle size of 12-3-14 and DNA nanoparticles at different charge ratio 
C (mM) Ratio         Ave. size(nm)                 ST.D Z-Ave PDI 
0.01 0   449.33 205.82 d.nm   
0.01 0.1 177.50 3.48 303.1 0.467 
     360.2 0.385 
        684.7 0.622 
0.025 0.25 174.20 19.36 180.3 0.226 
     173.6 0.224 
        178.6 0.218 
0.05 0.5 148.10 9.10 181.2 0.664 
     178.7 0.429 
     189.5 0.551 
0.1 1 151.60 38.76 196.0 0.373 
     159.0 0.567 
     167.6 0.489 
0.2 2 192.77 4.38 160.6 0.283 
     153.8 0.249 
     161.1 0.266 
0.5 5 71.12 4.39 138.1 0.286 
     150.3 0.301 
        155.9 0.399 
1 10 38.91 2.245 77.4 0.344 
     78.7 0.347 
0 0 119.17 16.94 84.3 0.375 
     119.1 0.222 
     141.2 0.252 
     194.5 0.380 
     79.3 1.000 
     79.7 1.000 
     134.0 0.447 
     188.7 0.482 
     197.4 0.503 
     192.2 0.488 
     56.3 1.000 
     120.1 0.747 
     57.3 1.000 
     75.6 0.297 
     70.7 0.252 
     67.0 0.243 
     174.0 0.497 
     435.0 0.794 
     298.7 0.809 
     37.4 0.264 
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     37.8 0.266 
     41.5 0.365 
     135.4 0.232 
     120.5 0.252 
        101.6 0.465 
 
Table 5.2 Zeta potential of 12-3-14 
1    C (mM) Ratio ZP Ave. ZP (mV) ST.D   Mob 
0.01 0 49.10  2.26 µmcm/Vs 
0.01 0.1 -42.03 51.6 0.87 4.046 
   47.2  3.697 
     48.5  3.800 
0.025 0.25 -42.93 -41.8 7.57 -3.276 
   -43.0  -3.371 
     -41.3  -3.234 
0.05 0.5 -35.27 -44.5 0.83 -3.485 
   -34.7  -2.720 
   -49.6  -3.886 
0.1 1 -19.47 -34.6 0.49 -2.715 
   -35.0  -2.743 
   -36.2  -2.840 
0.2 2 -44.23 -18.9 0.31 -1.480 
   -19.8  -1.551 
   -19.7  -1.544 
0.5 5 29.40 -44.5 0.30 -3.488 
   -43.9  -3.442 
     -44.3  -3.469 
1 10 25.47 29.4 5.94 2.307 
   29.7  2.327 
0 0 -53.73 29.1 1.80 2.280 
   37.2  2.916 
   15.4  1.211 
   23.8  1.862 
   -55.4  -4.346 
   -51.8  -4.057 
   -54  -4.235 
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Table 5.3Transfection efficiency and cell viability of Pyrene-based and dissymmetric (12-3-n) 
gemini surfactants in MG-63 cell line. 
Transfection complexes Transfection efficiency Cell viability 
NC+PI 3.45 ± 2.14 88.65 ± 16.88 
LP+PI 5.60 ± 1.72 49.77 ± 13.55 
GDP-PY-121 17.35 ± 2.79 56.66 ± 0.73 
GP-PY-12 20.53 ± 4.45 53.58 ± 8.07 
PY-3-12 31.31 ± 1.29 65.40 ± 0.85 
PLASMID 1.67 ± 0.45 100.00 ± 1.01 
GDP-PY-14 17.79 ± 2.05 60.75 ± 6.80 
GP-PY-14 17.23 ± 0.60 77.33 ± 9.50 
PY-3-14 31.60 ± 2.38 53.65 ± 3.10 
GDP-PY-16 3.48 ± 1.25 84.76 ± 17.21 
GP-PY-16 3.91 ± 0.89 90.04 ± 3.35 
PY-3-16 4.48 ± 0.91 94.63 ± 2.08 
GDP-PY-18 13.67 ± 2.23 52.27 ± 6.51 
GP-PY-18 14.89 ± 6.89 41.10 ± 0.38 
Py-3-18 16.21 ± 2.14 30.94 ± 5.11 
GDP-PY-8 7.34 ± 4.19 24.32 ± 3.10 
GP-PY-8 17.83 ± 5.90 50.94 ± 3.50 
PY-3-8 19.11±1.54 67.85 ± 5.31 
GDP-12-3-14 0.77 ± 0.21 8.11 ± 0.46 
12-3-14P 0.38 ± 0.27 3.20 ± 1.19 
GDP-12-3-16 10.46 ± 0.88 73.84 ± 2.74 
12-3-16P 11.24 ± 3.37 76.36 ± 12.07 
GDP-12-3-18 4.62 ± 0.69 42.56 ± 8.27 
12-3-18P 4.10 ± 0.77 48.75 ± 5.30 
PGD: Plasmid+GS+DOPE, P: Plasmid, and PY1: Pyrene, LP: Lipofectamine 2000, and NC: 
negative control 
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Table 5.4 Transfection efficiency and cell viability values of pyrene-based, and 12-3-n gemini 
surfactants complexes in HEK-293 cell line 
Complexes Transfection efficiency  Cell viability 
NC+PI 2.92 ± 1.04 95.15 ± 0.67 
LP+PI 23.10 ± 7.30 66.58 ± 11.41 
GDP-PY-12 6.25 ± 2.03 51.17 ± 9.70 
GP-PYR-12 6.22 ± 1.74 56.96 ± 8.90 
PYR-3-12 1.97 ± 0.70 46.23 ± 5.11 
GDP-PY-14 2.00 ± 0.10 84.48 ± 21.27 
GP-PYR-14 2.12 ± 0.32 33.43 ± 6.00 
PYR-3-14 4.73 ± 0.71 29.69 ± 2.54 
GDP-PYR-16 2.09 ± 0.90 38.029 ± 4.16 
GP-PYR-16 1.36 ± 0.30 90.07 ± 1.41 
PYR-3-16 1.29 ± 0.15 86.03 ± 3.32 
GDP-PYR-18 24.50 ± 7.42 60.25 ± 23.98 
GP-PYR-18 24.46 ± 0.87 74.05 ± 13.34 
PYR-3-18 13.04 ± 6.64 84.63 ± 8.43 
GDP-PYR-3-8 11.06 ± 6.29 86.71 ± 0.41 
GP-PYR-3-8 12.56±0.86 84.42 ± 0.00 
PYR-3-8 12.52 ± 4.74 12.52 ± 0.00 
GDP-12-3-14 2.05 ± 1.37 5.27 ± 20 
GP-12-3-14 3.03 ± 1.77 12.27 ± 5.90 
GDP-12-3-16 14.8 ± 1.38 57.63 ± 6.38 
GP-12-3-16 13.57 ± 5.18 76.27 ± 17.34 
GDP-12-3-18 6.32 ± 1.61 13.76 ± 4.31 
GP-12-3-18 14.77 ± 0.75 39.07 ± 6.61 
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Table 5.5 MTT assay for the pyrene-based gemini surfactants complexes 
 
                                                                                   Viability % 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
A 1.718 2.202 3.014 2.425 2.976 2.526 2.682 2.132 2.765 2.351 3.911 3.473
B 2.782 2.254 2.802 2.59 2.775 2.528 2.801 2.206 2.744 2.362 4.037 3.969
C 2.782 2.321 2.873 2.568 2.757 2.479 2.835 2.298 3.061 2.352 3.9 3.715
D 2.642 2.357 2.778 2.443 3.979 2.309 2.819 2.355 3.087 2.492 3.762 3.518
E 3.504 3.993 3.864 3.703 3.736 3.889 3.767 3.286 3.349
F 3.971 3.8 3.8 3.716 3.942 2.583 3.888 2.286 3.331
G 3.53 3.921 3.81 3.633 3.709 3.674 3.202 3.503 3.163
H 3.455 3.875 3.49 2.992 3.873 2.286 3.254 3.503 2.004
Pyrene-3-8
5 1.718 2.782 2.782 2.642 53.20533 86.1567 86.1567 81.821 76.83493 13.75691
10 2.202 2.254 2.321 2.357 68.19449 69.80489 71.87984 72.99474 70.71849 1.853056
Pyrene-3-12
5 3.014 2.802 2.873 2.778 93.34159 86.77609 88.97491 86.03283 88.78136 2.846432
10 2.425 2.59 2.568 2.443 75.10065 80.21059 79.52927 75.6581 77.62465 2.266746
Pyrene-3-14
5 2.976 2.775 2.757 3.979 92.16476 85.93992 85.38247 123.227 96.67854 15.55727
10 2.526 2.528 2.479 2.309 78.22855 78.29049 76.77299 71.50821 76.20006 2.776078
Pyrene-3-16
5 2.682 2.801 2.835 2.819 83.05977 86.74512 87.79808 87.30257 86.22639 1.865806
10 2.132 2.206 2.298 2.355 66.02663 68.31836 71.16754 72.9328 69.61133 2.644605
Pyrene-3-18
5 2.765 2.744 3.061 3.087 85.63023 84.97987 94.79715 95.60235 90.2524 4.960868
10 2.351 2.362 2.352 2.492 72.80892 73.14958 72.83989 77.1756 73.9935 1.842009
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Table 5.6 Statistical analysis: one-way ANOVA test of the asymmetric 12-3-n gemini 
surfactants in MG-63 and HEK-293 cell lines 
Cell 
line 
Formulation 
Mean 
transfection 
Transfectio
n SD 
Transfectio
n SE 
Viability 
mean 
Viability 
SD 
P 
Value 
F 
valu
e 
Independent 
Variable 
MG-
63 
Asymmetric 
full 
5.284089 4.265666 1.421889 25.54921 13.54451 0.985 
0.00
8 
Transfection 
Asymmetric 
plasmid 
5.242229 5.084563 1.694854 22.83906 15.33754     
          
MG-
63 
Positive 
control 
5.606289 1.451699 0.3748271 49.76729 11.45297 0.782 
 
0.07 
8 
  
Treatment 5.263159 4.552939 1.0731381 24.19413 14.10591     
          
MG-
63 
Positive 
control 
5.606289 1.451699 0.3748271 49.76729 11.45297 
3.45E-
06 
31.7
8 
Viability 
Asymmetric 5.263159 4.552939 1.0731381 24.19413 14.10591     
          
MG-
63 
Negative 
control 
3.450393 1.810859 0.4675619 88.65382 14.27005 
4.31E-
14 
169.
1 
  
Treatment 5.263159 4.552939 1.0731381 24.19413 14.10591     
          
HEK-
293 
Asymmetric 
full 
7.724621 5.748258 1.916086 26.34086 24.26054 0.521 
0.43
1 
Transfection 
Asymmetric 
plasmid 
9.522161 5.861673 1.953891 37.82408 27.21913     
          
HEK-
293 
Positive 
control 
23.102105 6.178396 1.595255 66.57943 9.650446 
7.60E-
08 
48.8
6 
Transfection 
Treatment 8.623391 5.707341 1.345233 32.08247 
25.70079
9 
    
          
HEK-
293 
Negative 
control 
2.921962 0.881482 0.2275977 96.155 0.571 
0.0005
99 
14.6 Transfection 
Treatment 8.623391 5.707341 1.3452332 32.08247 25.70     
          
HEK-
293 
Negative 
control 
0.921962 0.881482 0.2275977 96.155 0.571 
7.87E-
11 
92.6
9 
Viability 
Treatment 8.623391 5.707341 1.3452332 32.08247 25.7     
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Table.5.7 ELISA test calculations for 48 h 
Charge ratio 
Protein 
expression    
 Pyrene-3-8    
5 1.299 1.276 2.195 1.96 
10 0.904 1.655 1.554 1.898 
 Pyrene-3-12    
5 0.312 0.23 0.417 0.326 
10 0.202 0.41 0.374 0.231 
 Pyrene-3-14    
5 0.403 0.361 0.267 0.105 
10 0.345 0.367 0.218 0.388 
 Pyrene-3-16    
5 0.267 0.306 0.318 0.277 
10 0.187 0.192 0.268 0.163 
 Pyrene-3-18    
5 0.594 0.279 0.312 0.245 
10 0.195 0.183 0.241 0.459 
Lipofectamine 3.79 3.408 3.502 3.102 
NT 0.112 0.098 0.092 0.09 
 
Table.5.8 ELISA test calculations for 72 h 
 
 
Charge ratio 
Protein 
expression    
 Pyrene-3-8    
5 0.993 0.86 1.66 1.492 
10 1.983 1.86 2.334 2.038 
 Pyrene-3-12    
5 0.353 0.187 0.259 0.293 
10 0.273 0.382 0.303 0.207 
 Pyrene-3-14    
5 0.425 0.597 0.409 0.099 
10 0.24 0.234 0.273 0.582 
 Pyrene-3-16    
5 0.239 0.353 0.242 0.218 
10 0.171 0.242 0.301 0.15 
 Pyrene-3-18    
5 0.485 0.428 0.56 0.387 
10 0.195 0.202 0.246 0.536 
lipofectamine  3.598 3.224 3.126 3.6 
Non treated 0.099 0.097 0.096 0.094 
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Table 5.9 Protein expression of γ-INF-GFP after 48h and 72h incubation period for Pyrene-
based gemini surfactants formulation (GDP) 
48H Protein expression average  
 5 10 
Pyrene-3-8 8589.43 ± 2527.13 7615.02 ± 2301.03 
Pyrene-3-12 1210.22 ± 415.24 1118.06 ± 558.72 
Pyrene-3-14 1008.29 ± 716.57 1254.94 ± 414.04 
Pyrene-3-16 1051.66 ± 129.88 566.48 ± 246.46 
Pyrene-3-18 1406.73 ± 867.46 929.69 ± 689.12 
 
72H Protein expression average  
 5 10 
Pyrene-3-8 8613.53 ± 2874.87 14603.87 ± 1501.19 
Pyrene-3-12 1311.28 ± 517.02 1447.51 ± 541.80 
Pyrene-3-14 2128.65 ± 1547.24 1753.56 ± 1249.43 
Pyrene-3-16 1236.64 ± 452.9 885.80 ± 515.03 
Pyrene-3-18 2744.48 ± 559.9 1473.64 ± 1212.32 
   
 
 Table 5.10 Toxicity of Pyrene-based gemini surfactants-DNA-DOPE complex in COS-7 cell 
line 
Formulation 1:5 ratio 1:10 ratio 
Pyrene-3-8DP 76.83 ± 13.76 70.72 ± 1.85 
Pyrene-3-12DP 88.78 ± 2.84 77.62 ± 2.27 
Pyrene-3-14DP 96.68 ± 15.56 76.20 ± 2.80 
Pyrene-3-16DP 86.23 ± 1.86 69.61 ± 2.64 
Pyrene-3-18DP 90.25 ± 4.96 73.99 ± 1.84 
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